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The continuous growth in the incidence and prevalence of chronic (non-communicable) 
diseases, mainly fuelled by an ageing population, has led to an increasing use of multiple 
medications. In line with this, studies examining medication appropriateness and regimen 
complexity have been at the forefront of research in recent years, especially in high-risk 
patients, such as the elderly and those with chronic kidney disease (CKD). CKD is a growing 
public health problem that affects around 8-16% of the adult population worldwide. It is 
characterised by a substantial burden of multimorbidity and disease complications leading to 
the use of multiple medications. This, in turn, poses potential concerns regarding medication 
appropriateness, regimen feasibility, and adherence. However, despite the high medication 
burden in patients with CKD, previous studies have mainly focussed on evaluating the dosage 
appropriateness of renally-cleared and/or nephrotoxic medications. Further, little is published 
on clinical outcomes associated with medication-related factors in these patients. Therefore, 
investigating medication-related problems and understanding their determinants in patients 
with CKD is important in building an evidence base to inform future interventions and practice. 
The overarching aim of this thesis was, therefore, to examine medication-related issues and 
associated outcomes in patients with CKD considering prescriber, regimen, healthcare 
environment, and patient factors. The specific objectives of the thesis were to: (i) summarise 
the evidence on the prevalence of inappropriate prescribing, associated clinical outcomes and 
the potential impact of interventions in CKD; (ii) measure the magnitude of, and evaluate the 
impact of hospitalisation on, medication inappropriateness in older patients with CKD; (iii) 
investigate the associations between medication-related factors, including regimen complexity, 
and risk of hospital readmission in older patients with CKD; (iv) investigate the associations 
between medication adherence and burden, and health-related quality of life (HRQOL) in 
adults with advanced pre-dialysis CKD; and (v) evaluate the influence of pharmacist-led 
medication review on medication appropriateness in older adults with CKD.  
To address these objectives, two cohorts including adults with CKD (estimated glomerular 
filtration rate [eGFR] < 60 mL/min/1.73m2) not receiving renal replacement therapy were 
examined using retrospective and prospective study designs. The first was a retrospective 
cohort of older adults (≥ 65 years) with CKD  (eGFR 15-60 mL/min/1.73m2) hospitalised in a 




cohort included a prospective cohort of adults with advanced pre-dialysis CKD (eGFR < 30 
mL/min/1.73m2) living in the community (n = 101).  
A systematic review of the literature was conducted to summarise the magnitude of 
inappropriate prescribing, associated outcomes and the impact of interventions in patients with 
CKD. Based on this review of 49 studies, widespread prevalence of potentially inappropriate 
medications (PIMs) use was observed across a spectrum of the care continuum. The prevalence 
of PIMs use was 9.4%-81.1% for hospital settings, 13%-80.5% in ambulatory care settings and 
16%-38% for long-term care facilities. A small number of studies reported an association 
between PIMs use and poor clinical outcomes, including prolonged hospitalisation and 
mortality. Although the heterogeneity between studies precluded a meta-analysis, the number 
of medications, comorbidities, and age were consistently identified as predictors of PIMs use. 
This review showed that, despite the regimen complexity in this patient group, previous studies 
were largely focused on assessing the appropriateness of renally-cleared and/or nephrotoxic 
medications, rather than more patient-centred outcomes, such as adherence.  
Capitalising on the gaps identified in this review, a study was conducted to comprehensively 
assess medication appropriateness in older patients with CKD recruited via Tasmania’s 
principal tertiary care hospital. The Medication Appropriateness Index (MAI), an implicit set 
of criteria, was used to assess medication appropriateness, with higher scores on this index 
corresponding with higher medication inappropriateness. The 2015 Beers criteria, a list of 
medications recommended to be avoided in older adults or under certain conditions, was also 
applied to identify PIMs use. Overall, 204 older patients with CKD with a median age of 83 
years (IQR 76-87 years) were included. This study revealed that most patients had some level 
of medication inappropriateness based on MAI (89%), while more than half of them (55%) 
were taking at least one medication from Beers criteria at hospital admission. A higher number 
of medications (β 0.72; 95% CI 0.56 to 0.88)  and lower eGFR (β 0.11; 95% CI -0.18 to -0.04) 
were significantly associated with a higher level of medication inappropriateness. 
Hospitalisation was associated with a small but significant improvement in medication 
appropriateness in these patients, as shown by a decrease of MAI from admission to discharge 
(median [IQR]: 6 [3–12] to 5 [2–9]; p<0.01]). The number of patients with at least one PIM 
from Beers criteria also declined from 55% to 48% during hospitalisation. These findings 
indicate that, despite an improvement in medication appropriateness during hospitalisation, 




In the subsequent two studies, the association between medication-related factors (including 
medication appropriateness, regimen complexity and the use of selected medications) at 
hospital discharge and hospital readmission was explored. Overall, people who were 
readmitted within 30 and 90 days of discharge had a higher level of medication 
inappropriateness (MAI) compared with their non-readmitted counterparts. Those with higher 
MAI scores were also likely to be readmitted to hospital relatively sooner within 90 days of 
discharge. However, after statistical modelling, medication inappropriateness was not 
independently associated with the occurrence of 30-day (adjusted OR 1.03; 95% CI 0.97-1.09) 
or 90-day readmissions (adjusted OR 1.06; 95% CI 1.00-1.12). Similarly, regimen complexity 
(MRCI) was not independently associated with 30-day (adjusted OR 1.27; 95% CI 0.94-1.73) 
or 90-day readmissions (adjusted OR 1.31; 95% CI 0.99-1.72). However, higher medication 
regimen complexity (MRCI) was associated with a shorter time to readmission within one year 
of discharge (HR 1.18 95% CI 1.01-1.36). In contrast, use of renin-angiotensin system blocking 
drugs was associated with a lower occurrence of 30-day (OR 0.39; 95% CI 0.19-0.79) and 90-
day readmissions (OR 0.45; 95% CI 0.24-0.84), and longer time to 90-day readmission (HR 
0.52; 95% CI 0.33-0.83). 
In the fourth study, the relationships between medication adherence and burden, and HRQOL 
was assessed using 101 adults with advanced pre-dialysis CKD (eGFR <30mL/min/1.73m2). 
The findings of this study showed that medication non-adherence was reported by 43% and 60% 
of participants using two different self-report adherence measures (Morisky-Green-Levine 
Scale and the Tool for Adherence Behaviour Screening). Perceived medication burden, but not 
actual burden, was the main driver of medication non-adherence (adjusted OR 4.89; 95% CI 
1.02-23.5). Further, poorer kidney disease-related and generic HRQOL measures were 
associated with higher regimen complexity (MRCI) and medication non-adherence was 
associated with a decline in physical HRQOL over time. 
In the final study, the effect of hospital pharmacist-led medication review on medication 
appropriateness was retrospectively assessed in older adults with CKD. Medication 
appropriateness was evaluated before and after medication review and after acceptance/non-
acceptance by physicians of pharmacist recommendations. Of 204 eligible patients, medication 
review was conducted in 95 (46%). Medication review by pharmacists improved medication 
appropriateness significantly, as shown by a median MAI reduction from 7 [3-12] to 5 [2-10]; 
p<0.001. More importantly, medication appropriateness showed greater improvement upon 




from 7 to 3; p<0.05). Of note, medication appropriateness also improved in patients with no 
medication review by pharmacists, indicating hospitalisation alone improved medication 
appropriateness in these patients. However, the overall trend was indicative of greater 
improvement in medication appropriateness with pharmacist-led medication review, 
particularly when the recommendations were acted upon by physicians. 
In conclusion, this thesis presents a series of interconnected studies that thoroughly examined 
medication-related factors and their consequences in adults living with CKD. Generally, the 
studies revealed that these patients are prone to high levels of medication regimen complexity 
and inappropriateness. People who were readmitted within 30 and 90 days had higher levels of 
medication inappropriateness and regimen complexity, albeit these variables did not 
independently predict readmissions within these periods. Further, patients with more complex 
regimens were more likely to be readmitted relatively sooner within 12 months of discharge. 
The findings, overall, suggest that these medication-related variables may be important proxy 
measures of overall health status in this patient group. Also, these findings imply that 
medication inappropriateness and regimen complexity can be used to prioritise patients who 
can benefit from optimisation of medication regimens. This is potentially important in contexts 
like community pharmacies, where there is limited clinical information available for decision-
making. The association between renin-angiotensin system blockers use and lowered 
readmission risk indicates the importance of assessing for ongoing need or potential 
underprescribing of important medications.  
The thesis also identified medication burden, both perceived and actual, to be associated with 
patient-centred outcomes, including medication non-adherence and health-related quality of 
life. This finding highlights the importance of assessing and incorporating patient-reported 
medication experiences and perceptions, along with routine medication review, with the goal 
of improving medication adherence. Healthcare professionals should actively engage patients 
in conversations concerning their medications to identify difficulties associated with 
medication management and adherence. Reiterating the importance of medication adherence 
in improving the quality of life and slowing disease progression  is also instrumental to promote 
optimal medication use.  
Another important finding was the effect of pharmacists’ involvement in CKD care. The 
greater improvement in medication appropriateness after implementation of hospital 




multidisciplinary approach in CKD care. However, despite pharmacists’ valuable input in 
optimising medication in these patients, medication review was completed in less than half of 
included patients. This indicates a need to upscale the role of pharmacists by implementing a 
standard clinical pharmacy service in all hospitalised patients with CKD. Improved detection 
of medication-medication and medication-disease interactions and medication non-adherence 
by pharmacists can be particularly useful to ensure quality use of medicines in this highly 
vulnerable patient group. Further research is needed to confirm if this is translated into 
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1. CHAPTER ONE: Introduction  
1.1. Background 
The burden of chronic non-communicable diseases has shown an alarming increase in recent 
decades mainly due to an ageing population across the globe.1 Chronic diseases are not only 
becoming increasingly prevalent but they are now the leading causes of morbidity and 
mortality, contributing to nearly 70% of all deaths worldwide.2 The economic consequences of 
chronic diseases are also enormous due to the combined costs of healthcare and loss of 
productivity because of illness and premature deaths.3 Conditions, such as cardiovascular 
diseases, chronic kidney disease (CKD), cancer and diabetes, are among the leading 
noncommunicable diseases that put significant burden on global health.4 The estimated global 
cost associated with managing cardiovascular diseases, according to a report by World 
Economic Forum, was USD 863 billion in 2010 and it is projected to rise to USD 1,044 billion 
in 2030, an increase of 22% after accounting for changing age demographics.5   
Medicines are the most common form of interventions used for the prevention and treatment 
of noncommunicable chronic diseases.3,6 Over the last several decades, the use of multiple 
medications has shown a significant increase.4,6 This has been mainly fuelled by the growing 
need to use multiple medications to treat medical conditions, such as cardiovascular diseases 
and diabetes mellitus, and to prevent future diseases by managing risk factors.4,6 The ageing 
population in different parts of the world is also associated with multiple comorbidities, that 
require the concomitant use of several medications.4 Despite the importance of using 
medications to prevent or delay disease onset, control of diseases and relief of pain, the 
continual increase in the number of medicines also poses challenges for the patient, healthcare 
professionals and the healthcare system at large.7,8  
The use of multiple medications increases the likelihood of adverse drug events, medication-
medication and medication-disease interactions, poor medication adherence and preventable 
medication-related hospitalisations.9,10 When left unoptimised, medications have also been 
associated with medication-related morbidity and mortality that is worth more than half a 
trillion American dollars per annum.8 Therefore, optimisation of medication therapy, in the 
milieu of multimorbidity and polypharmacy, is a challenge with an impact on health outcomes 
and healthcare expenditure.8 As such, researchers in recent years have put greater emphasis on 
evaluating medication appropriateness and its health consequences, particularly focusing on 
the older population.  
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Patients with CKD are among patient groups with one of the highest medication burdens.11 
This is because of the various treatment goals aimed at preserving renal function (or slowing 
disease progression), treating multiple comorbidities, and managing disease-related 
complications.11 The high number of comorbidities and associated use of multiple medications 
in patients with CKD, in turn, predisposes patients to different medication-related harms.12 The 
primary concern in patients with CKD is that many medications rely on the renal route for 
clearance from the body.13 Therefore, upon renal impairment, patients will have a reduced 
ability to eliminate these medications, leading to plasma accumulation and possibly associated 
toxicity.14,15  
The altered pharmacokinetic and pharmacodynamic profiles in patients with CKD make dose 
adjustment and/or avoidance of most renally-cleared medications necessary.15 Accordingly, 
studies have widely examined inappropriate prescribing of renally-cleared medications across 
a spectrum of patients with CKD in different health settings.16,17 However, the quality use of 
medicines in patients with CKD is multi-faceted; it encompasses underuse of recommended 
preventive therapies, as well as dosage adjustments and avoiding potentially inappropriate 
medications (PIMs) use.13 Therefore, evaluation of medication appropriateness that transcends 
the mere checking of dosage appropriateness of renally-cleared medications can be useful in 
identifying areas of improvement.  
The second concern in CKD management relates to the complex regimens used by most 
patients. In addition to the number of medications, other medication characteristics like the 
dosage form, dosing frequency and additional medication instructions involved can also 
contribute to regimen complexity.18 Evidence suggests that medication regimen complexity, 
quantified considering these variables, may have an impact on health outcomes in older 
adults.19,20 Therefore, understanding the association between medication regimen complexity 
and different health outcomes in patients with CKD is important to identify patients who can 
benefit from regimen simplification strategies.  
In addition to medication appropriateness and regimen complexity, another important 
consideration in chronic disease prevention and management is medication adherence.21 
Medication adherence is defined by the World Health Organization (WHO) as ‘the extent to 
which an individual complies with agreed recommendations from healthcare providers about 
their medications.’11 However, despite the importance of medication adherence in improving 
health outcomes, the prevalence of non-adherence among patients receiving medications for 
CHAPTER ONE: Introduction 
3 
 
chronic diseases ranges between 43% and 78%.22 Similarly, suboptimal medication adherence 
is commonly reported in patients with CKD, although previous studies were highly focussed 
on people with end-stage kidney disease (ESKD).23  
Factors affecting medication adherence are broadly categorised into five domains: patient, 
therapy, socioeconomic, healthcare system, and condition factors.24 These factors are also 
relevant in predicting medication adherence in patients with CKD.23 Studies showed that 
therapy-related factors, such as regimen complexity and perceived medication burden, have 
been linked with adherence in patients with CKD, albeit inconsistently.23,25 Identifying 
therapy-related factors affecting adherence in patients with CKD is important to propose a 
multifaceted intervention that integrates these factors with other patient and system-based 
factors to improve adherence. Understanding the interplay among medication burden, 
adherence and patient-centred outcomes in patients with CKD is also in line with a call for a 
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1.2. Literature review  
1.2.1. Medication utilisation patterns and trends 
In Australia, medication use has increased enormously in recent decades.6,26 The National 
Health Survey of 1995 revealed that 10.7 million people reported having used one or more 
medications, comprising more than half of the population at the time (59%).27 Another study 
conducted 15 years later between 2009-2010, surveying 4,500 Australians aged 50 years and 
above showed a much higher proportion of medication use, as reported by 87% of the 
participants.6 The combined Pharmaceutical Benefits Scheme (PBS) and Repatriation 
Pharmaceutical Benefits Scheme (RPBS) prescription counts have also shown a 63% increase 
from 133,568,781 prescriptions in 1997 to 217,220,377 in 2015.26 This is to be compared with 
a population growth of nearly 28% over the same period. The rise in the use of medications is 
mainly driven by the increasingly ageing population, the growing prevalence in chronic 
diseases, and decreasing mortality rates.28,29 For instance, the National Health Survey of 
Australia reported an increase in the proportion of people with at least one chronic condition 
from 42.2% to 47.3% between 2007-08 and 2017-18.29 
Cardiovascular agents constitute the major class of medications that has shown a remarkable 
growth in volume in recent decades in Australia (Figure 1.1.).28 In particular, as shown in the 
Figure 1.1., a steep increase in medication use was observed between the late 1990s and early 
2000s.  Medications acting on the nervous system and anti-infectives for systemic use were 









Figure 1.1. Medication volume (services) for various medications dispensed in Australia 
between 1992-2009 (total of PBS and RPBS)28  
The use of prescription medicines has also shown an increasing trend for over half a century in 
the Unites States (US).4  Between 1988-1994 to 2007-2010, while the number of people (of all 
ages) who did not take any regular medication(s) has decreased from almost 61% to 52.5%, 
the percentage of those on polypharmacy (defined as taking five or more prescription 
medications) increased from 4% to 10% (Figure 1.2.). This equates to half of all Americans 
with at least one prescription medication.4 Further, another study in the US also reported an 
increase in the use of prescription medications from 51% to 59% of adults between 1999-2000 
and 2011-2012, with a corresponding increase in the prevalence of polypharmacy from 8.2% 
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Figure 1.2. The use of prescription medications, by the number of drugs taken and age: 
United States, 1988-1994 to 2007-20104 
The increase in the use of prescription medications is mainly driven by an ageing population 
across the globe, the rise in incidence and prevalence of chronic diseases and the development 
of various disease-specific clinical practice guidelines.3,4,31 Medication research targeted at 
better treatment and management of risk factors for chronic conditions, including hypertension, 
congestive heart failure, high cholesterol and diabetes also led to increased medication use.4 
However, this increase could also be attributed to other factors, such as the development of 
newer medications for the treatment of communicable and non-communicable diseases, the 
widespread availability of medications and the growth of marketing strategies by the 
pharmaceutical companies.4,32 Compared to communicable diseases, chronic non-
communicable diseases have been associated with a significant increase in the use of multiple 
medications.4 Diseases, such as cancer, cardiovascular conditions (e.g. hypertension, heart 
failure and dyslipidaemia), kidney diseases, diabetes and depression are among those in which 
medication use has shown an increasing pattern. (Figure 1.3.)  
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Figure 1.3. Prescription medication use in the past 30 days among adults aged 18 and over, 
by age and selected drug class: United States, 1988–1994 and 2007–20104 
1.2.2. Medication appropriateness  
1.2.2.1. Definition of medication appropriateness 
The use of multiple prescription medications, although quintessential in the management of 
chronic diseases, can potentially lead to detrimental outcomes, especially if left unoptimised.8 
Medication-related problems (MRPs) is an umbrella term used to describe problems that occur 
due to the use of medications. The concept of MRP originates after the idea of pharmaceutical 
care came to the fore at the beginning of the 1990s.33 Pharmaceutical care, according to Helper 
and Strand, ‘…is a quality improvement process in which the professional improves the 
outcomes of pharmacotherapy.’34 This quality improvement process encompasses the 
identification of the causes that potentially lead to the problem and addressing it.33 The 
philosophy of pharmaceutical care, in turn, leads to the concept of MRPs.33 As such, MRP was 
first defined by Strand et al as ‘an undesirable patient experience that involves medication 
therapy and that actually or potentially interferes with patient outcome.’35 This definition 
contains eight conceptual categories that healthcare professionals can use to identify or 
characterise MRPs. These include the presence of an indication that requires a medication, 
appropriateness of the medication for the given indication, under- and over-dosing of 
medications, presence of a medical condition resulting from an adverse drug reaction of 
medications, presence of drug-drug, drug-food and drug-laboratory interactions, presence of a 
medical condition not receiving the recommended prescribed medication, and having a 
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medication with no valid indication.35 These MRPs are important not only in terms of 
standardising the clinical care that patients receive, but also because they are potentially 
modifiable through detection, treatment and, most importantly, prevention by healthcare 
practitioners. 
The Pharmaceutical Care Network Europe also defined MRPs almost similarly as: ‘event(s) or 
circumstance(s) involving drug therapy that actually or potentially interferes with desired 
health outcomes.’33 This classification has a broad category of domains consisting of problems, 
causes and interventions. A problem is defined as ‘the expected or unexpected event or 
circumstance that is, or might be wrong, in therapy with medicines.’ The ‘cause’ part assesses 
the action, or lack thereof, that leads to the occurrence of potential problems. This could relate 
to medication selection, the patient’s proper use of medication, lack or misinterpretation of 
information, personality of the patient or logistics of prescribing/dispensing. The ‘intervention’ 
section looks at the different measures taken to correct the causes of MRPs. Each of these 
categories has sub-domains that enable evaluators to capture problems at patient, medication 
and prescriber levels.33  
Although several other criteria and definitions of MRPs have emerged from different research 
groups, none of these tools could be easily implemented in clinical practice.36 However, in an 
effort to easily integrate prescribing quality assessment in routine practice, especially in the 
older population, several criteria have been developed. These criteria are broadly classified into 
implicit and explicit measures. The implicit criteria are patient-specific approaches that require 
access to an array of medical and laboratory information to assess the appropriateness of 
individual medications.37 The focus of explicit criteria is to identify PIMs whose risk outweigh 
the benefit and, therefore, are best to be avoided in older adults or under certain disease 
conditions.37 Although the development of these criteria simplified the evaluation of 
medication inappropriateness in older adults, the time they take and the lack of a gold-standard 
measure of medication appropriateness have made their integration into clinical practice 
challenging.  
The Medication Appropriateness Index (MAI),38 commonly used implicit criteria, was initially 
developed in 1992 to measure the quality of care in healthcare services and to assess changes 
in prescribing over time.38 Subsequent research has shown that this tool has an acceptable intra- 
and inter-rater reliability, and predictive validity in older populations in different health 
contexts.39 This tool consists of 10 pharmacotherapeutic components: indication, effectiveness, 
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dosage, directions for use and practicality of the directions, drug-drug and drug-disease 
interactions, the relative expense of medications, duplication of therapy and duration of 
treatment. Each criterion has rating instructions to assess its appropriateness. For items rated 
as inappropriate, weighted scores ranging between 1 and 3 (e.g. 3 for “indication”, 2 for “drug 
interactions” and 1 for “therapeutic duplication”) are used to calculate the MAI score for 
medications. The MAI scores per patient are then obtained based on the summation of the MAI 
scores of individual medications. The MAI scores for each medication range between 0 and 18, 
with higher MAI scores corresponding with a higher level of medication inappropriateness. 
However, the need for detailed clinical data and the time it takes to assess individual 
medications limits the applicability of implicit tools such as the MAI in practical settings. 
Therefore, researchers have developed explicit and easy-to-use approaches to capture 
prescribing quality in the older population, which require less time and medication information.  
Several explicit measures have been developed to identify PIMs use in older adults.40 Explicit 
tools comprise a list of medications that are recommended to be avoided in older people or 
under certain conditions because the risk associated with the use of these medications generally 
outweighs their benefit. The American Geriatrics Society was a pioneer in developing the first 
explicit measure of inappropriate medication use in 1991 and, given its relevance and 
application for research and clinical practice, it has been updated numerous times since.41-45 
Following the development of the first Beers criteria, several explicit measures were developed 
aiming to improve the identification of PIMs use in the older population.46-54 Of these tools, 
the screening tool of older people’s prescriptions (STOPP) and screening tool to alert to right 
treatment (START) criteria were the most notable and widely accepted in research.47 This is 
mainly because, in addition to medications to be avoided, the STOPP-START criteria also 
consider potential prescription omissions in medication assessment. The Beers criteria were 
also updated in 2015 and 2019 considering newer evidence emerging from the latest 
literature.45,54 However, the explicit criteria available are somewhat limited because of their 
lack of depth in terms of assessing medication appropriateness using detailed laboratory and 
clinical information. This is because these tools often categorically identify medications to be 
avoided in older adults, rather than considering other relevant individual pharmacotherapeutic 
aspects, such as dosage appropriateness, concomitant conditions, indication, drug-drug, drug-
laboratory and drug-disease interactions and duplication of therapy, among others. 
Australian-specific prescribing quality indicators have also been developed for use in older 
adults.50,55,56 The original tool that was developed by Basger et al contains 48 prescribing 
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indicators based on medications and health conditions that are common in Australian settings.56 
This tool mainly consists of explicit indicators (45 out of 48 items) that are used to assess 
under- and over-treatment in older adults.55 However, despite the relevance of having a setting-
specific tool to identify PIMs use, most of the limitations of explicit criteria mentioned above 
are more or less applicable to these Australian tools alike.  
1.2.2.2. Extent of medication inappropriateness  
Medication inappropriateness, and its association with different clinical and patient outcomes, 
has been targeted by several studies. A systematic review by Morin et al reported that the 
prevalence of PIMs use has significantly increased from 30.3% in studies conducted between 
1990-1999 to 49.8% in those conducted after the year 2005 (p<0.01).57 Another study 
corroborates this evidence showing that the odds of exposure to PIMs showed an average 11% 
per year increase between 2005 and 2015.58 Furthermore, a significant proportion of people in 
residential care homes receive PIMs (overall weighted point prevalence: 43%), with the 
prevalence showing an increasing trend over time.57,58 
The review by Morin et al also indicated that the prescribing of PIMs in European nursing 
homes was relatively higher than that from the North American and other countries.57 In 
comparison, an Australian study that targeted 2,345 aged care residents reported that about 35% 
of them were receiving at least one PIM as defined by the Beers criteria.59 A comparable 
prevalence of 30% was reported in a study specifically targeting older Australians with 
dementia residing in residential aged care facilities.60  
Several studies have assessed medication inappropriateness in a hospital setting.61-63 A study 
consisting of 195 older adults from the United Kingdom reported a PIMs prevalence of 26.7% 
upon patients’ hospital admission.61 On the other hand, various ranges of PIMs use were 
reported in a study performed in six countries across Europe.64 The prevalence in these 
countries varied depending on the tool used to assess medication inappropriateness. For 
example, while the prevalence of PIMs use ranged between 34.7% in Prague to 77.3% in 
Geneva when the STOPP criteria were applied, the prevalence varied from 22.7% to 43.3% 
when Beers criteria were applied.64 Other studies from Australia reported that more than 52% 
and 55% of the targeted patients were receiving at least one PIM based on the STOPP criteria 
at hospital admission.63 A recent study from the US also reported a relatively higher level of 
PIMs use at hospital admission, which varied depending on the tool applied – 62.3% based on 
Beers criteria and 43.4% using STOPP criteria.62  
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Based on  a systematic review of studies from eleven countries, the prevalence of PIMs use in 
primary care is generally lower than that in hospital and residential care settings, and widely 
varies between 2.9 and 38.5%.65 Similarly, another systematic review targeting community-
dwelling older adults in European countries reported an overall weighted prevalence of PIMs 
use of 22%, which is lower than for people in residential care facilities.66 On the other hand, 
studies from the US and Canada reported a prevalence of 29% and 31% in community-dwelling 
older adults, respectively.67 
1.2.2.3. Outcomes associated with medication inappropriateness 
Medication inappropriateness is not only an indicator of poor prescribing practice, but it has 
the potential to lead to detrimental clinical and patient outcomes. However, despite the 
increasing number of publications focusing on the evaluation of medication (in)appropriateness 
in the older population using different criteria, limited data is available on clinical outcomes 
attributed to PIMs use. Of these, a study conducted in Australia revealed that exposure to PIMs 
from Beers criteria was associated with frequent unplanned hospitalisations in older adults.68,69 
Further, people prescribed with multiple PIMs (≥ two) were more likely to experience other 
negative outcomes, including longer hospitalisations and higher hospital costs than those with 
one PIM.70 Similarly, in older community-dwelling patients, the use of two or more PIMs 
(defined based on the STOPP criteria) was associated with poorer HRQOL and increased 
emergency visits over a two-year period.71 Another study targeting people discharged from 
hospital indicated that inappropriate prescribing, as defined based on Beers criteria, was 
associated with poor medication adherence after hospital discharge.72 A review of the economic 
impact of PIMs use in older adults showed that the use of PIMs was associated with higher 
health care utilisation and increased healthcare expenditure compared with no use of PIMs.73 
Moreover, the estimated annual cost of morbidity and mortality due to nonoptimised 
medication therapy in the US is reported to exceed half a trillion dollars.8 
1.2.2.4. Determinants of medication inappropriateness 
In addition to reporting the prevalence of medication inappropriateness, several studies have 
identified factors associated with the use of PIMs. A higher number of medications, living in 
residential care homes, advanced age, female gender, presence of depression, low functional 
status and low socioeconomic status were among the factors associated with PIMs use.57,66 
Particularly, medication-related factors, such as the number of medications and regimen 
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complexity, are modifiable factors that are consistently and independently associated with the 
use of PIMs in older people.57,66  
1.2.2.5. The role of interventions in optimising medications 
The high prevalence of PIMs reported by different studies, along with associated clinical 
consequences, have prompted the implementation of different interventions. These include 
manual interventions (mostly involving pharmacist-led medication reviews) and integration of 
computerised decision support systems into the usual clinical care.74 The paradigm shift in 
pharmacy practice in recent decades, from the old product-oriented to a more patient-oriented 
program, has provided pharmacists with the opportunity to improve inpatient care.75 The 
unique training pharmacists now receive about pharmacotherapy has equipped them with the 
necessary training to be involved in therapeutic decision-making.75 The involvement of 
pharmacists in the primary care setting has also led to improved and cost-effective services.76  
Owing to these developments, the scope of pharmacy training in different parts of the world is 
expanding in ways that foster collaborations between pharmacists and physicians across the 
care continuum.77,78 This ranges from involving pharmacists in collaborative medication 
management in the US to the implementation of independent pharmacist prescribing models in 
the United Kingdom.77-79 The staggering economic burden associated with nonoptimised 
medications also increases the pivotal role pharmacists will have in the foreseeable future.8 
Medication reconciliation is one of the well-established roles of clinical pharmacists that is 
implemented in different health settings. This involves querying patients about the medications 
they take to obtain an accurate and updated list of medications and has become part of clinical 
care in most hospitals and across the care continuum since its introduction. Improved detection 
of medication discrepancies is observed with pharmacist-led medication reconciliation when 
compared with usual care.80 Further, medication reconciliation by pharmacists is associated 
with improved healthcare utilisation after hospital discharge.81 
Another important role of pharmacists as part of clinical pharmacy services is medication 
review and therapy management to ensure the appropriateness and safety of medications. In 
line with this, the impact of pharmacist-led medication review in optimising older peoples’ 
medications has been explored across different settings.82,83 Studies reported that involving 
pharmacists in a multidisciplinary team in primary and secondary geriatric care can improve 
medication appropriateness in older people.82,83 These interventions involving pharmacists are 
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more beneficial to patients with complex disease status and medication regimens, including 
patients with CKD.84 However, a recent review by Rankin et al showed that while 
pharmaceutical care was relevant in slightly reducing prescription omissions, it had little effect 
in reducing negative outcomes, such as hospital admissions and quality of life.74  
Rankin et al assessed the impact of pharmaceutical care in the form of medication reviews by 
different healthcare professionals, including general physicians, pharmacists and 
geriatricians.74 The results revealed that pharmaceutical care did not result in a significant 
improvement in medication appropriateness, measured via both implicit and explicit criteria.74 
The review showed that interventions that involved multidisciplinary and clinical decision 
support system components were relatively effective.74 However, the review is generally 
limited for including studies that were of relatively poor quality. 
1.2.3. Chronic kidney disease (CKD) and its management 
1.2.3.1. Definition and classification of CKD 
The Kidney Disease Improving Global Outcomes (KDIGO) and Kidney Health Australia’s 
Caring for Australasians with Renal Impairment (KHA-CARI) define CKD based on 
abnormalities of kidney structure or function lasting for at least three months, with implications 
for health.85,86 The diagnosis of CKD relies on the presence of at least one of the following 
criteria for at least three months: a decreased glomerular filtration rate (GFR)  of < 60 
mL/min/1.73m2 and/or having indicators of kidney damage (based on albumin-creatinine ratio 
(ACR) ≥ 30 mg/g and albumin excretion ratio of ≥ 30 mg/24h).86,87 The GFR cut-off value of 
60 mL/min/1.73m2 is used to define CKD because this value is considered to be less than half 
of the normal renal filtration rate in young adult men and women (~125 mL/min/1.73m2). An 
ACR of 30 mg/g is also three times greater than the normal value in healthy adults and is thus 
used as a reference value.85  
CKD is traditionally classified into five stages based on GFR (often estimated GFR; eGFR). In 
this classification, people with eGFR < 90 mL/min/1.73m2 are considered to have some form 
of renal impairment.85 However, due to the association of lower eGFR and higher albuminuria 
values with increased cardiovascular events, acute kidney injury, disease progression, and 
mortality, both of these criteria have become an integral part of CKD staging.85,88 As such, the 
classification of CKD based on disease cause, eGFR and albuminuria categories provides a 
more accurate classification and has greater prognostic value.88 Based on these considerations 
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the staging of CKD is modified into six eGFR (G) and three albuminuria (A) categories, as 









Figure 1.4. Staging of chronic kidney disease (CKD) based on glomerular filtration rate and 
albuminuria85  
1.2.3.2. Epidemiology of CKD 
CKD is a growing public health problem that affects 8-16% of the adult population 
worldwide.89 The global mean prevalence of CKD is estimated at 13.4%, with stage three CKD 
(eGFR: 30-59 mL/min/1.73m2) contributing to the majority (80-90%) of the reported cases.89,90 
High-income countries, including the US, Canada, and Australia, are more affected by CKD 
than developing nations.90 The prevalence (in adults) in these countries is reported to be around 
11%.91 Moreover, the epidemiology of CKD also varies depending on ethnicity and social class 
within these countries.91 This is shown by a significantly higher CKD prevalence in people in 
the lowest socioeconomic quartile (compared to the highest), ethnic minorities in the UK 
(African and Asian people) and the US (Hispanics), and Indigenous people in Australia, New 
Zealand and Canada.91 Although the burden of CKD is more pronounced in developed regions 
of the world, it is expected to become a substantial burden in developing and developed nations 
alike.89,90 This is mainly due to the expanding older population in countries like China and 
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India.89 The incidence of end-stage kidney disease (ESKD) is similarly rising in different parts 
of the world.89 Although most patients (>80%) receiving treatment for ESKD are from highly-
developed countries, the incidence of ESKD is also showing a disproportionate increase in 
developing countries.92  
1.2.3.3. Causes and risk factors of CKD 
The main causes of CKD in developed countries and most developing countries are diabetes 
and hypertension.89 Glomerulonephritis is the third most common cause of CKD, especially in 
Asian and sub-Saharan countries.89 In Australia, diabetes, glomerulonephritis, and 
hypertension are the three most common causes of kidney diseases.93 In addition to the 
continuously rising burden of non-communicable diseases, the increasing number of people 
living to old age also leads to an increased prevalence of CKD.94 (Figure 1.5.)  
In contrast, infectious diseases, environmental pollution by heavy metals, pesticides, abuse of 
analgesics and unregulated food additives are among other causes of CKD in developing 
settings.89 Human Immunodeficiency Virus is an infectious cause of CKD in sub-Saharan 
Africa.91 The double-burden of infections and chronic noncommunicable diseases is, therefore, 
believed to bring future challenge in developing settings.89 Herbal medicines, often common 
in rural populations of Africa and Asia, can also have nephrotoxic effects leading to CKD, 
acute kidney injury (AKI) and electrolyte disturbances.89,91 Low birthweight and 
poststreptococcal glomerulonephritis are identified as indicators of kidney disease in remote-
living Aboriginal people.95 Genetic causes of CKD involving single or multiple genes have 
also been identified.91 These include congenital anomalies since birth or childhood or 
autosomal dominant polycystic kidney disease, which occurs later in life.91,96 Polycystic kidney 
disease currently affects more than half a million people in the US and is responsible for nearly 
5% of all ESKD cases.96 
 




Figure 1.5. The worldwide distribution of causes of chronic kidney disease89 
(CGN, chronic glomerulonephritis; HT, hypertensive nephrosclerosis; CIN, chronic interstitial nephritis; 
RVD, renovascular disease.) 
In addition to the causes of CKD mentioned above, various risk factors (both modifiable and 
non-modifiable) are associated with an increased risk of developing CKD. These factors can 
be broadly categorised into clinical and sociodemographic risk factors. Diabetes, hypertension, 
autoimmune diseases, obesity, tobacco smoking, family history of CKD, neoplasm, AKI, 
infection and low birth weight are among some of the clinical factors that increase the risk of 
developing CKD.59,95,97 On the other hand, older age, ethnicity (African American, American 
Indian, Hispanic, Asian or Pacific Islander) and low socioeconomic status are among the 
sociodemographic factors that contribute to increased risk of CKD.89 Gender differences have 
been observed in CKD epidemiology; while women are generally more affected by CKD (pre-
dialysis) than men, the incidence of RRT is higher in men.98 These disparities could be partly 
due to longer life expectancy in women, hormonal differences, faster disease progression in 
men, differences in access to care and preference (women have reduced access to kidney donors 
and greater tendency to choose conservative care).98 
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1.2.3.4. Medications as causes of CKD 
Another important and, in most cases, modifiable cause of kidney diseases is exposure to 
nephrotoxic medications.99 Prolonged exposure to non-steroidal anti-inflammatory 
medications is among the most common medication causes of CKD.99  Other medications, 
including aminoglycosides antibiotics (especially when their doses are unadjusted), lithium and 
radiographic contrast materials, are among those with nephrotoxic effects.99  The use of 
nephrotoxic medications is particularly common in hospitalised patients.99 Exposure to 
nephrotoxic medications is associated with increased risk AKI, irreversible loss of renal 
function and other costly adverse drug events.100 Figure 1.6. shows a list of medications with 
nephrotoxic effects. Of note, this figure contains a list of nephrotoxic medications based on an 
American study101 and is not an exhaustive list of all nephrotoxic medications. 
 
Figure 1.6. List of nephrotoxic medications101  
 
1.2.3.5. Consequences of CKD 
CKD is associated with a substantial increased risk of morbidity and mortality. According to 
the Global Burden of Disease study, the absolute number of deaths due to CKD rose by  
34% (from 920, 000 to 1, 230, 000) from 2007 to 2017.1 However, the age-standardised annual 
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death rates remained relatively stable, showing an increase of 1.5%.1 Further, the same dataset 
shows a rise in disability-adjusted life years of 52.6% in patients with CKD (from 1, 269, 049 
to 1, 935, 954) and an increase in death due to CKD of 58.3% (from 52, 127 to 82, 539) between 
2002 and 2016.102 Patients with CKD also have comparably higher rates of hospitalisation and 
hospital readmission compared with people with no CKD.103 In the US, the rate of 
hospitalisation in CKD in 2012 was 1.73 per patient year, with 35.2% of people on dialysis 
readmitted to hospital within 30 days of discharge.103  
CKD imposes a tremendous economic burden on healthcare expenditure. High-income 
countries spend a disproportionate 2-3% of their annual healthcare budget for the treatment of 
ESKD, despite this patient group representing only less than 0.3% of their total population.89 
The cost of treating pre-ESKD patients is even higher than that for ESKD treatment. For 
example, in 2015, the US government spent USD 64 billion for the treatment of general CKD 
compared with USD 34 billion for ESKD treatment.104 Similarly, in the United Kingdom, the 
National Health Service estimated that CKD was responsible for the 1.3% of total healthcare 
spending in the year 2009-10.89 Additionally, CKD contributes to the increased healthcare 
spending in diabetes and hypertension patients.104 
1.2.3.6. CKD in the Australian context: epidemiology and consequences  
The burden of CKD has been growing in the Australian context over the last decades and has 
now become the 10th leading cause of death.93,105 It was estimated that around 1.7 million 
Australian adults (1 in 10) have some biomedical signs of CKD, whereas 1 in 3 is at increased 
risk of eventually developing it.106 The prevalence is even higher in older adults (with the risk 
nearly quadrupled in those aged 75 years or older), men, and in those with low socioeconomic 
status.107 Further, Indigenous Australians have double the risk of their non-Indigenous 
counterparts in terms of showing the biomedical signs of CKD.17 (Figure 1.7.) 
The incidence and prevalence of ESKD patients on renal replacement therapy (RRT) has also 
markedly increased in Australia since its implementation in the 1960s (Figure 1.8.).108 There 
were 3,056 new cases of RRT patients in 2017 (overall incidence rate of 124 per million 
population), showing a 70% increase from the 1,723 cases reported in 2000 (90 per million 
population).108 Similarly, in 2017, a total of 24,738 people (i.e. 1006 per million population) 
were receiving RRT.108 The incidence of RRT in Australia was projected to grow by 60% (from 
19,780 to 31,589) between 2011 and 2020, and is expected to double in those aged ≥75 years.109 
The incidence has also shown a disparity in trend based on patient and equity status. Males (1.5 
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times as high compared with females), people living in remote and very remote areas (twice as 
high compared to major cities) and those with low socio-economic status (1.6 times as high in 
the lowest compared with the highest socioeconomic group) being at a higher risk of 
developing ESKD.109  
Figure 1.7. The number (proportion) of people living with biomedical signs of CKD in 
Australia, by indigenous status and geographical location (2013)110 
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Figure 1.8. The number of new patients on renal replacement therapy and the change over the 
last 30 years108 
CKD is a cause of significant morbidity and mortality in Australia, especially in older adults. 
For example, a total of 43,600 hospitalisations (excluding regular dialysis episodes) had CKD 
as the principal diagnosis from 2015-2016.11 This represented 16% of overall hospitalisations 
in Australia during this time and an increase of 51% since the year 2005-2006.107 The age-
standardised hospitalisation rate, over the same period, had also increased by 22% from 138 to 
169 per 100,000 population.107 (Figure 1.9.) Hospitalisation due to CKD is five times higher in 
Indigenous Australians than for non-Indigenous Australians.107   
Figure 1.9. Trends of hospitalisation in Australia with CKD as a principal diagnosis 
(excluding dialysis) between 2005-06 to 2015-16, by gender107 
CKD was responsible for 11% of all deaths in Australia in the year 2015, representing nearly 
17,000 deaths.107 The rates of death due to CKD, as an underlying and/or associated cause, has 
remained relatively stable between the year 1997 and 2015, and was responsible for almost 
13,000 deaths per year during this time frame.107 The extent of the problem can also be 
illustrated through the higher number of lives that CKD claims each year than prostate cancer, 
breast cancer, or traffic accidents.97 Of note, CKD-related deaths are more common among 
males (1.5 times higher than females) and older people (4 times higher in those aged 75-84 
years).107 In Indigenous Australians, CKD contributes to 16% of all deaths. This is equivalent 
to 3.9 times higher risk in Indigenous females and 2.6% times higher rate for Indigenous males 
as compared with non-Indigenous Australians.111 
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CKD places a significant burden on the Australian economy.112 Patients with CKD incur 
significantly higher total costs, including healthcare and non-healthcare costs, and 
governmental social benefits (excluding age-related pension), compared with age-matched 
Australians without CKD.112 Further, the cumulative cost of treating existing and emerging 
cases of ESKD is estimated to be around AUD 12 billion for the period 2009-2020.97  
1.2.3.7. Comorbidities and disease-related complications in CKD 
Diabetes mellitus, hypertension, and other cardiovascular diseases are the most common 
comorbidities in patients with CKD. While more than 70% of patients with CKD have 
coexisting hypertension, nearly 40% have diabetes mellitus as a comorbidity.113 Cardiovascular 
diseases are primarily responsible for the morbidity and mortality in these patients.89,114 For 
example, patients with CKD are 20 times more likely to die from cardiovascular conditions 
than those without CKD.109 Further, Australian data show that 51% of patients with CKD have 
cardiovascular diseases and/or diabetes as comorbidities.109 This burden increases with age, 
with people aged 65 years or older being 16-45 times as likely to have concomitant 
cardiovascular disease, diabetes and/or CKD, compared with younger people.109 (Figure 1.10.) 
CKD is also associated with various complications that often manifest in the later phase of the 
disease. Anaemia and iron deficiency are among the most common complications of CKD. 
Anaemia in these patients occurs due to the reduction in erythropoietin production by the 
kidney due to the loss of renal mass and shortened red blood cell survival. The risk of 
developing anaemia increases with declining GFR, with around 67% of people with ESKD 
affected.115  
Metabolic acidosis is another complication that is more prevalent in people with a severe form 
of CKD. Acidosis occurs mainly because of an increased tendency for hydrogen ion retention 
in patients with CKD. This complication can lead to an increased risk of proteinuria, dissolution 
of bone, disease progression and mortality.116 Hyperuricaemia, fluid and electrolyte 
imbalances, mineral and bone disorders (primarily hyperphosphataemia), hypertension, 
dyslipidaemia, and sexual dysfunction are among other disease complications that occur in 
patients with CKD.  





Figure 1.10. Prevalence of cardiovascular diseases (CVD), diabetes, CKD, and their 
comorbidity, among persons aged 18 and over in Australia, 2011–12109 
1.2.3.8. Medication use considerations in CKD 
1.2.3.8.1. Medication dosing 
The renal system is responsible for the excretion of waste products, including drug metabolites 
and toxins, to maintain the extracellular environment for cell functioning. It is also responsible 
for maintenance of fluid and electrolyte balance in the body and secretion of various hormones 
that are involved in hemodynamic regulation. Therefore, in the event of renal impairment, some 
of these functions will be impaired or lost, resulting in harmful outcomes. This includes a build-
up of renally-cleared medications and their metabolites when given at standard dose, leading 
to potential toxicity.117  
In line with this, guidelines have proposed renal dosage adjustment recommendations based on 
the level of kidney function of patients. For this purpose, GFR is the primary marker used to 
assess the level of kidney functioning. This can be measured in patients using urine collection 
or can be estimated using the GFR equations as described in section 1.2.3.8.2. However, given 
that creatinine clearance calculated based on a 24-hour urine collection is not a better indicator 
of kidney function than estimated GFR (eGFR) values, different equations have been 
developed for routine laboratory and research purposes.118 
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1.2.3.8.2. Renal function estimation  
For routine CKD staging and dosage recommendations, renal function is more easily estimated 
using equations than measured. The Cockcroft-Gault (CG) equation was the first equation  
developed and widely accepted estimation of renal function. It was developed in 1976 using 
249 men with creatinine clearance (CLcr) ranging between 30 and 130 mL/min.119 This 
equation uses serum creatinine for CLcr estimation considering factors like age, gender, and 
weight.119 However, this equation has certain limitations. The use of an unstandardised 
creatinine assay from 1976 that cannot be traced to its origin is the main drawback of this 
equation, that limits its application for use in defining and staging kidney disease.120 The other 
limitation with the use of the CG equation is the confusion regarding the varied use of actual, 
ideal or adjusted body weight, depending on the body mass of the individual.120 Guidelines are 
also not consistent in the use of actual, adjusted or ideal body weight in drug dosing 
recommendations.120  
The Modification of Diet in Renal Disease (MDRD) equation was developed to rectify some 
of the limitations of the CG formula.121 This equation was developed using 1600 subjects and 
has improved accuracy and less bias compared with the CG equation in detecting kidney 
disease. Although most of the limitations of the MDRD are applicable to any creatinine-based 
equation, its inaccuracy at higher GFR values is its main downside.122 This led to the 
development of another equation, the CKD Epidemiology Collaboration (CKD-EPI).122 
Although the CKD-EPI and MDRD equations were equally accurate in people with eGFR less 
than 60 mL/min/1.73m2, the former is more applicable in diverse population groups and 
relatively accurate at higher eGFR values (> 60 mL/min/1.73m2).122 As such, the KDIGO 
guideline currently recommends the use of the CKD-EPI for diagnosis and classification of 
kidney disease unless there is a more preferable locally-validated version of this equation.87 
Both the MDRD and CKD-EPI equations report eGFR that is normalised to body surface area. 
Concerns related to the varying accuracy of these equations in the detection of CKD are also 
applicable when used in terms of renal drug dosing.123 Various guidelines have recommended 
dosage adjustment for medications based on CLcr, as compared to eGFR, because most 
published pharmacokinetic studies relied on CLcr in estimating renal function. However, a 
study by Stevens et al in 2009 concluded that, after comparing with the CG equation (using 
both actual and ideal body weight), the MDRD equation can be used for both pharmacokinetic 
studies and dosage adjustments.124 The CKD-EPI, on the other hand, is currently used to report 
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renal function by most laboratories given its advantage over the MDRD at higher GFR values 
and in diverse population groups.122 The National Kidney Disease Education Program 
(NKDEP)118 suggests that unless it is for medications with a narrow therapeutic window, the 
interchangeable use of the CLcr or eGFR estimation equations for dosing has little difference 
for most patients and medications. 
1.2.3.8.3. Medication regimen complexity and its sources in CKD 
Patients with CKD have one of the highest medication burdens compared with most chronic 
diseases.11 Pharmacotherapy approaches in patients with CKD are directed at achieving one of 
the following objectives: treating causes of the disease (focussing on reversible targets), 
preventing or slowing disease progression, and managing the CKD-related complications.11 
(Table 1). These diverse goals inevitably cause the use of multiple medications, leading to high 
medication regimen complexity.  Dosage forms, dosing frequency and additional instructions 
are other attributes of medications that can complicate medication regimens in these patients. 
Medication regimen complexity may not be a problem in and of itself, as the use of complex 
regimens could be unavoidably important in some patients. However, there are instances where 
regimens could be inappropriately complex and thus can be targeted via interventions. This 
could include: the use of frequently administered medications despite the presence of long-
acting alternatives; the use of parenteral dosage forms instead of orally taken medications; or 
instruction to break tablets while there are lower strengths. Higher medication regimen 
complexity quantified in consideration of these attributes has been associated with outcomes, 
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 Table 1. Major therapeutic goals and associated considerations for the most prevalent 





Therapy goals Recommendations 
Slowing disease progression  
Hypertension    Individualise blood pressure target based on albuminuria 
 Use of renin-angiotensin system (RAS) blockers in diabetic and 
nondiabetic adults with micro or macro albuminuria 
Albuminuria   Use of RAS blockers  
Glycaemic control   Use of RAS blockers, statins, and antiplatelet therapy, where 
clinically indicated 
 Use of sodium-glucose cotransporter 2 inhibitors  
Management of complications 
Anaemia   Use of iron supplements (depending on therapeutic goal and use 
of iron/erythropoietin stimulating agents) 
 Use of erythropoietin stimulating agents (after addressing all 
correctable causes of anaemia) 
Metabolic acidosis   Use of oral serum bicarbonate when serum bicarbonate 
concentration is <22 mmol/L 
Bone and mineral 
disorders 
 Use of vitamin D supplementation if there is documented 
deficiency  
 Use of bisphosphonates and phosphate binders  
Management of cardiovascular conditions 
Heart failure   Use of RAS blockers, beta-blockers, and diuretics, as required  
Acute coronary 
syndrome 
 Antiplatelets, anticoagulants, beta-blockers and RAS blockers as 
per the general population 
Chronic coronary 
artery disease  
 Antiplatelets, anticoagulants, beta-blockers and RAS blockers as 
per the general population 
 Use of single antiplatelet can be used without an increased 
bleeding risk 
 Risk of bleeding should be seen considering eGFR values 
Lipid management   Use a statin for adults aged ≥50 years if eGFR > 
60mL/min/1.73m2 
 Use a statin/ezetimibe for adults  aged ≥50 years if eGFR < 
60mL/min/1.73m2 
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Cardiovascular and metabolic diseases are the main causes of morbidity and mortality in 
patients with CKD that require the use of highly complex medication regimens. This is because 
strict blood pressure and glycaemic control are important treatment objectives to improve renal 
and cardiovascular outcomes in these patients.85 Greater control of blood pressure (below 
130/80 mmHg), for example, is associated with maintenance of residual renal function in 
patients with CKD.125 The use of renin-angiotensin system (RAS) blockers is especially 
beneficial in this regard, as they reduce proteinuria in both diabetic and nondiabetic patients 
with CKD and, therefore, slow disease progression.85,126 Calcium channel blockers and 
mineralocorticoid antagonists are among other antihypertensive medications widely used in 
CKD with an effect on proteinuria.126 The benefit of antihypertensive medications in 
decreasing proteinuria generally lies in their ability to reduce blood pressure. However, 
medications like RAS blockers and calcium channel blockers are thought to have an additional 
mechanism to reduce proteinuria, which is independent of the reduction in blood pressure.127  
Management of hyperglycaemia and diabetes is another important treatment target in patients 
with CKD. According to the KDIGO, diabetes care should aim to achieve a haemoglobin A1c 
level of ~7% to prevent disease complications in these patients.85 This and other main clinical 
targets that should be aimed to delay disease progression in patients with CKD are highlighted 
below in Table 2. 
Table 2. Important laboratory targets in CKD management (based on the KDIGO 2012 
guideline)106  
 
In addition to treating the different comorbidities mentioned above, the management of CKD-
related complications also contributes to the use of multiple medications with a variety of 
Condition  Target values 
Glycaemic control   Haemoglobin A1c (HbA1c) ~ 7% to prevent or delay 
progression of the microvascular complications of 
diabetes, with higher targets for people with limited life 
expectancy, comorbidity or a higher hypoglycaemia risk. 
Blood pressure   CKD without albuminuria: ≤140/90 mm Hg 
 CKD with albuminuria (≥30 mg/24h): ≤130/80mm Hg 
Haemoglobin    In non-dialysis CKD: 10-11.5 g/dL (≥100 g/L) 
Metabolic acidosis   Treatment should start when serum bicarbonate falls 
below 22mmol/L, although specific target is often unclear 
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dosage forms and complex instructions. These complications become more prevalent as the 
disease advances in stage.85 The use of erythropoietin agonists, sodium bicarbonate, phosphate 
binders, lipid-lowering agents, and diuretics are among medications used to treat complications 
like anaemia, metabolic acidosis, bone and mineral density disorders, volume overload, 
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1.3. Thesis rationale 
Several studies have assessed the prevalence of PIMs use and identified the type of medications 
commonly involved in patients with CKD.17 Most of these studies defined medication 
(in)appropriateness based on a discrepancy between guideline recommendations and the actual 
clinical practice in relation to renally-cleared and/or nephrotoxic medications. However, 
patients with CKD typically have complex medication regimens that require the use of a 
comprehensive assessment of appropriateness considering all medications and the patient’s 
specific characteristics. Understanding factors associated with medication inappropriateness is 
especially important to identify areas of medication prescribing that might need improvement.  
Although CKD is characterised by the presence of multimorbidity and complex regimens, 
limited studies have evaluated the clinical outcomes associated with medication-related factors. 
For example, CKD is characterised by remarkably high rates of hospitalisation and hospital 
readmission—usually higher than the general population.103 However, limited data is available 
on the association between medication-related factors and clinical outcomes in patients with 
CKD, with published works mainly focussed on those with ESKD.12,128,129 Therefore, there is 
a paucity of evidence on medication-related outcomes in patients with CKD in general and in 
those at earlier stages of the disease in particular.  
Patient-centred outcomes record patients’ perceptions of their own wellbeing and functionality 
and are becoming increasingly relevant in outcome research and clinical practice.130 These 
perceptions can take the form of views to general health status or they could relate to specific 
disease conditions.130 For example, in pre-dialysis patients with CKD, these outcome measures 
can be important tools for prognostic assessment that inform future treatment modalities.131 
However, despite the increased recognition of patient-centred outcomes in patients with CKD, 
little is known about these outcome measures in pre-dialysis CKD.131,132 Medication-related 
variables, such as medication count, regimen complexity and total pill burden, would be 
anticipated to affect patient-centred outcomes in patients with CKD. In particular, the 
relationship between medication-related factors and health-related quality of life (HRQOL) is 
relatively under-examined, with the data available limited to patients with ESKD.23  
Finally, evaluation of the effect of the healthcare environment and the associated care in 
improving the quality use of medicines in patients with CKD is another area that has received 
little attention in the past. For example, hospitalisation presents an opportunity for healthcare 
professionals to re-evaluate the complex regimens in patients with CKD and rectify identified 
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problems. It is also an important opportunity to re-assess new risk factors in patients whose 
conditions have changed. Particularly, considering the now-established clinically-oriented role 
of pharmacists, hospitalisation provides pharmacists with an opportunity to review patients’ 
medication regimens. However, little is known about the impact of the health care received 
during hospitalisation, including medication review by pharmacists, on the quality use of 
medicines in patients with CKD.  
1.4. Aim and specific objectives of the thesis 
The overarching aim of this thesis was to examine medication-related factors and associated 
outcomes in patients with CKD, considering prescriber, regimen, environmental and patient 
factors.  
Specifically, the objectives of the thesis were to: 
I. Summarise the evidence on the prevalence of inappropriate prescribing, associated 
clinical outcomes and the potential impact of interventions in CKD; 
II. Measure the magnitude, and evaluate the impact of hospitalisation, on medication 
appropriateness in older adults with CKD; 
III. Investigate the associations between medication-related factors, including regimen 
complexity, and hospital readmission in older adults with CKD; 
IV. Investigate the associations between medication adherence and burden, and HRQOL in 
adults with advanced CKD not receiving RRT; and  
V. Evaluate the role of pharmacist-led medication review on medication appropriateness 
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1.5. Theoretical framework and thesis layout  
Figure 1.11. illustrates the theoretical framework of this thesis. At the inception, the author 
hypothesised that different medication-related problems could occur at or be influenced by 
prescriber-, regimen-, environmental- or patient-level factors. The magnitude of these 
problems and factors driving them are explored applying retrospective and prospective study 
designs. The potential interaction between factors, such as medication appropriateness, 
regimen complexity and adherence, and health outcomes (hospital readmission and HRQOL) 
was explored. Finally, the effect of the healthcare service provided during hospitalisation, 
including medication review performed by clinical pharmacists, was explored in view of 
improving the quality use of medicines.   
These concepts are discussed in detail in nine consecutive chapters. Chapter One presents the 
introduction of the thesis, containing the general thesis background, literature review and 
objectives of the thesis. Chapter Two presents a systematic review of inappropriate prescribing 
in patients with CKD across the care continuum, associated clinical outcomes and the impact 
of interventions. Chapter Three describes the findings of a retrospective study on the effect of 
hospitalisation on medication inappropriateness and factors associated with medication 
inappropriateness at hospital admission. Subsequently, Chapter Four and Five report results 
from two consecutive retrospective studies examining the association between medication-
related factors, including regimen complexity, and hospital readmission in patients with CKD. 
Chapter Six describes the relationship among medication burden, adherence and HRQOL using 
a prospective cohort study. In Chapter Seven, the study reports findings of the effect of 
pharmacist-led medication review on medication appropriateness in hospitalised older patients 
with CKD. Chapter Eight, discusses the overall findings of the studies included in the thesis, 
followed by research limitations, practical implications and future directions. Finally, the 
conclusions and recommendations based on the studies is presented in Chapter Nine.





















Figure 1.11. Thesis conceptual framework  
(Objectives: I, Summarise the prevalence of inappropriate prescribing in CKD; II, Measure the magnitude, and evaluate the impact of hospitalisation, on medication 
appropriateness in CKD; III, Investigate the associations between medication-related factors and hospital readmission in CKD; IV, Investigate the interplay among medication 
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2. CHAPTER TWO: Inappropriate prescribing in chronic kidney disease: A
systematic review of prevalence, associated clinical outcomes and impact of
interventions
Overview
This chapter presents a study that addresses the first objective of the thesis. It summarises
the prevalence of inappropriate prescribing in patients with CKD, identifies factors and
clinical outcomes associated with inappropriate prescribing and examines the effect of
interventions in reducing inappropriate prescribing.
This work is a reproduction of the following publication. 
Wubshet Hailu Tesfaye1, Ronald L. Castelino2, Barbara C. Wimmer1 and Syed Tabish R. 
Zaidi.1  
1Pharmacy, School of Medicine, College of Health and Medicine, University of Tasmania, 
Australia.  
2Sydney Nursing School, The University of Sydney, New South Wales, Australia. 
Int J Clin Pract. 2017; 71:e12960 doi: 10.1111/ijcp.12960. 
(https://onlinelibrary.wiley.com/doi/full/10.1111/ijcp.12960). 
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Summary 
The key finding from the systematic review above was that inappropriate use of medications 
was common and widespread depending on the healthcare setting and stages of disease. Further, 
the focus of the included studies was medications that are renally-cleared and/or nephrotoxic 
and, thus, should be adjusted or avoided in the event of renal impairment. However, the 
complex regimen used in CKD management necessitates the evaluation of medication 
appropriateness using robust techniques that transcend the mere checking of dosage adjustment 
of renally-cleared medications. Another important observation was that some medications, for 
example angiotensin converting enzyme inhibitors (ACEIs) and metformin, were not 
necessarily dose-adjusted based on renal impairment but clinical outcomes. Based on these 
observations, the following study was conducted to evaluate medication (in)appropriateness 
using a more comprehensive approach and to identify the medications involved. 
CHAPTER THREE: The effect of hospitalisation on potentially inappropriate medication use in older 
adults with chronic kidney disease 
3. CHAPTER THREE: The effect of hospitalisation on potentially inappropriate
medication use in older adults with chronic kidney disease
Overview 
This chapter presents a study addressing the second objective of the thesis. It is an 
evaluation of medication (in)appropriateness in older patients with CKD using the MAI 
and Beers criteria. These criteria are applicable in older people. Additionally, Chapter 
Three explores the impact of hospitalisation and the care involved on medication 
appropriateness in patients with CKD. 
This chapter is a reproduction of the following publication. 
Wubshet H. Tesfayea, Barbara C. Wimmera, Gregory M. Petersona,b, Ronald L. Castelinoc, 
Matthew D. Josea,d,e, Charlotte McKercherd and Syed Tabish R. Zaidia,f 
aDepartment of Pharmacy, School of Medicine, College of Health and Medicine, University 
of Tasmania, Tasmania, Australia;  
bUnit for Medication Outcomes Research and Education, University of Tasmania, 
Tasmania, Australia;  
cSydney Nursing School, The University of Sydney, Sydney, Australia;  
dMenzies Institute for Medical Research, University of Tasmania, Tasmania, Australia;  
eRoyal Hobart Hospital, Tasmania, Australia;  
fSchool of Healthcare, University of Leeds, Leeds, UK.  
Curr Med Res Opin. 2019; 35(6) doi: 10.1080/03007995.2018.1560193 
(https://www.tandfonline.com/doi/full/10.1080/03007995.2018.1560193). 
Chapter 3 has been removed for copyright or
proprietary reasons.
It has been published as:Tesfaye, WH, Wimmer, BC, Peterson, GM, Castelino, 
RL, Jose, MD, McKercher, C, Zaidi, STR, 2019. The effect of hospitalization on 
potentially inappropriate medication use in older adults with chronic kidney 
disease,  Curr Med Res Opin. 2019; 35(6), 1119-1126 50 
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Summary 
The above study evaluated medication inappropriateness and how that is impacted by the 
healthcare environment. Results revealed that various medication classes, both renally-cleared 
and those that are excreted via other routes, are potentially prescribed inappropriately. 
Although hospitalisation resulted in a significant decline in medication inappropriateness, there 
was still space for improvement.  
Interestingly, medications, such as metformin and spironolactone, are commonly prescribed 
inappropriately in mild to moderate stages of CKD. This could be because, as discussed in 
Chapter Two, clinicians use objective clinical targets (for example potassium levels) for 
discontinuation and/or adjustment of medications rather than solely relying on guidelines. This 
leads to the importance of the next chapter, which looks at the clinical outcomes associated 
with medication-related factors in older adults with CKD. 
It is important to note here that while using the MAI in the evaluation of medication 
appropriateness, two components, feasibility of directions and relative expense, were removed. 
This was done mainly due to the difficulty involved in obtaining the necessary data to 
accurately assess these components. Previous research has used the same approach in using 
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4. CHAPTER FOUR: Medication-Related Factors and Hospital Readmission in 
Older Adults with Chronic Kidney Disease 
 
Overview 
This chapter presents a study addressing the third objective of the thesis. In this work, the 
association between medication-related factors, such medication (in)appropriateness, 
regimen complexity and the use of selected medication classes, and 30-day and 90-day 
hospital readmission are examined targeting older adults with CKD.  
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Abstract: This study aimed to examine the association between medication-related factors and
risk of hospital readmission in older patients with chronic kidney disease (CKD). A retrospective
analysis was conducted targeting older CKD (n = 204) patients admitted to an Australian
hospital. Medication appropriateness (Medication Appropriateness Index; MAI), medication regimen
complexity (number of medications and Medication Regimen Complexity Index; MRCI) and use
of selected medication classes were exposure variables. Outcomes were occurrence of readmission
within 30 and 90 days, and time to readmission within 90 days. Logistic and Cox hazards regression
were used to identify factors associated with readmission. Overall, 50 patients (24%) were readmitted
within 30 days, while 81 (40%) were readmitted within 90 days. Mean time to readmission within
90 days was 66 (SD 34) days. Medication appropriateness and regimen complexity were not
independently associated with 30- or 90-day hospital readmissions in older adults with CKD, whereas
use of renin-angiotensin blockers was associated with reduced occurrence of 30-day (adjusted OR
0.39; 95% CI 0.19–0.79) and 90-day readmissions (adjusted OR 0.45; 95% CI 0.24–0.84) and longer
time to readmission within 90 days (adjusted HR 0.52; 95% CI 0.33–0.83). This finding highlights the
importance of considering the potential benefits of individual medications during medication review
in older CKD patients.
Keywords: chronic kidney disease; medication appropriateness index; medication regimen
complexity index; the elderly
1. Introduction
Chronic kidney disease (CKD) is associated with a substantial risk of cardiovascular-related
morbidity and mortality [1]. Conversely, cardiovascular diseases are also among the primary causes of
morbidity and mortality in patients with CKD [2]. Therefore, pharmacological treatment in patients
with CKD is largely directed at preventing and managing these cardiovascular problems. In addition
to these comorbidities, CKD-related complications, such as anaemia and bone and mineral disorders,
further complicate pharmacological approaches when treating these patients.
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Multimorbidity in CKD is associated with higher medication burden and poorer survival [3].
Due to comorbidities and disease complications, the use of multiple medications in patients with CKD
is often unavoidable, increasing the risk of exposure to medication-related problems that can lead to
adverse drug events [4]. Medication-related problems are common causes of hospitalisation, mortality,
and poorer quality of life in people with CKD [4,5]. Conversely, a number of medications, including
sodium bicarbonate, erythropoiesis-stimulating agents, urate-lowering therapy, renin-angiotensin
system (RAS) blockers, statins, and mineralocorticoid antagonists, are associated with improved
outcomes in patients with CKD [6–8]. Therefore, the suboptimal and/or inappropriate use of such
medications could potentially lead to poor patient and clinical outcomes.
Most studies examining medication use and outcomes in individuals with CKD have focussed
on those with end-stage kidney disease (ESKD) [5,9–11], with a lack of studies targeting patients in
earlier stages of the disease. Also, while previous studies have frequently reported the prevalence
and type of inappropriate medications in CKD, evidence associating medication-related factors with
risk of hospitalisation remains limited [12–14]. Finally, despite the reported clinical benefit of certain
classes of medications in this patient group [6], there is inadequate information on the clinical impact
of using preventive medications in older adults with CKD. Therefore, we aimed to investigate the
association between medication-related factors (medication appropriateness, regimen complexity and
the use of selected medications) and the occurrence of hospital readmission and time to readmission in
hospitalised older patients with CKD.
2. Materials and Methods
2.1. Study Design, Participants and Data Collection
A retrospective study targeting 204 older adults ( 65 years) with CKD, consecutively admitted
to a tertiary care hospital in Tasmania for any cause between 1 January and 30 June 2015 [15],
was conducted. Out of the 1472 eligible older adults with an estimated glomerular filtration rate
(eGFR) <60 mL/min/1.73 m2, we included 204 patients who fulfilled the inclusion criteria, i.e.,
had a documented diagnosis of CKD or repeated eGFR values between 15–60 mL/min/1.73 m2
reported for at least three months prior to admission and had not received any form of renal
replacement therapy [16]. The eGFR values were estimated using the CKD Epidemiology Collaboration
(CKD-EPI) [17] and are automatically reported along with requests for serum creatinine. Patients who
stayed in hospital briefly (<24 h), with incomplete medical records and/or with acute kidney injury
(AKI), alone or superimposed on CKD, were excluded. AKI was identified based on documentation
(as noted in medical progress notes or discharge summaries) or a marked increase in serum
creatinine ( 1.5 times the baseline value) [18]. People who were critically ill or died during the
index hospitalisation were also excluded (Figure 1).
Demographic, laboratory, and clinical information for each patient was extracted using a
state-wide digital medical record (DMR). Medications being used on a long-term basis, administered
both regularly or as required, were recorded and coded using the Anatomical Therapeutic Classification
(ATC) classification system of the World Health Organization [19]. Patient comorbidities and causes for
the index admission and subsequent hospitalisations were coded using the International Classification of
Diseases, 10th edition (ICD-10) [20].
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2.2. Exposure Variables
Main exposure variables were medication-related factors, including medication regimen
complexity (measured using the validated Medication Regimen Complexity Index (MRCI) [21]
and the number of regularly taken medications), medication appropriateness (evaluated via the
Medication Appropriateness Index; MAI) [22], and the use of selected medications at hospital discharge.
The MRCI is a tool that measures an individual’s regimen complexity by taking into an account the
dosage form, dosing frequency, and additional instructions. The MAI is an implicit measure of
medication appropriateness containing 10 pharmacotherapeutic aspects: indication, effectiveness,
dosage, directions and their feasibility, drug-drug and drug-disease interactions, duration, duplication
and expense of medications. For practical reasons, we excluded two components of the MAI during
the evaluation: the feasibility of directions and relative expense of medications [15,23]. Patient MAI
scores were the summation of that of the individual medications, with higher scores reflecting a higher
level of medication inappropriateness.
Given their benefit to CKD patients in general [24,25], the use of statins or RAS blockers at the
index hospital discharge was included as an exposure variable in this study. Additionally, based on
previous studies [6,11], the use of calcium channel blockers, beta blockers, diuretics, mineralocorticoid
antagonists, and anticoagulants was also assessed during the analyses.
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2.3. Outcome Variables
Outcomes of interest were (i) the occurrence of hospital readmission within 30 and 90 days of
discharge and (ii) time to readmission in a 90-day follow-up period. These relatively short periods
were chosen to minimise the possibility of significant changes in medication regimens of patients
following their index hospitalisation.
2.4. Covariates
Renal function was measured using eGFR and serum creatinine values reported at the index
hospital admission (at points closest to the date of admission). Comorbidity status was assessed
at baseline using the original version of Charlson’s Comorbidity Index (CCI) [26], Given the
well-established link between previous hospitalisations and hospital readmission [27], the number
of hospitalisations in the six months preceding the index admission was also recorded as a
covariate. Socioeconomic status of patients was calculated using the Index for Relative Socioeconomic
Disadvantage [28], This index considers different variables to indicate the relative disadvantage of
areas, with lower scores on this index reflecting a higher proportion of relatively disadvantaged people
in an area.
2.5. Analyses
Descriptive statistics were reported using means (SD) or medians (IQR) depending on the
normality of data distribution, which was assessed via visual inspection of histograms. Patient,
laboratory, and clinical variables were compared in patients with or without readmission during the
follow-up periods. For these comparisons, chi-square tests were used to examine the differences in
categorical variables between these groups. Independent samples t-tests and Mann-Whitney U tests
were applied to compare continuous variables, depending on the fulfilment of the assumption of
normality of distribution.
To assess the association between medication-related variables at hospital discharge and 30- and
90-day readmissions, binary logistic regression was used, with effect sizes reported as odds ratios
(ORs) and 95% confidence intervals (CIs). To determine the association between the medication-related
factors and time to 90-day readmission, Cox proportional hazards regression was utilised, with effect
sizes reported as hazard ratios (HRs) and 95% CIs. We employed two models in the Cox regression
analysis: one partially adjusted for age, gender, and CCI (Model 1) and another one fully adjusted
for the factors in Model 1 plus eGFR, the number of prior hospitalisations and discharge destinations
(home versus residential care). Variables were included in the multivariate models based on either
a p < 0.1 result on unadjusted analysis or a priori based on their relevance in predicting similar
outcomes in previous studies [1,11,29]. For this analysis, the end of follow-up was set at 90 days after
hospital discharge or date of death, whichever occurred first. Kaplan–Meier plots were also used for
visual depiction of the difference in readmission risks within 90 days based on different MAI scores
(categorised into quartiles as follows: 0–2; 3–5; 6–9 and 10–29) and the use of RAS blockers. Finally,
to understand if people with multiple hospitalisations were medically more complex, we examined the
relationship between the number of prior hospitalisations and medication-related variables at hospital
admission, with results reported using Spearman’s coefficient. Analyses were performed using STATA,
version 15.1 (StataCorp LLC, College Station, TX, USA). The study was conducted in accordance with
the Declaration of Helsinki, and the Tasmanian Human Research Ethics Committee granted ethical
approval for this study (H0016044).
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3. Results
Overall, 204 older CKD patients (61% males) were included for analysis (Figure 1). Of these,
50 (24.5%) and 81 (40%) patients were readmitted at least once within 30 and 90 days of discharge
from the index hospitalisation, respectively. The mean number of days to 90-day readmission was
66 (SD 34). Table 1 shows the baseline characteristics of participants. Additional laboratory and clinical
information of the included patients are also presented in the attached Supplementary Material.
The most common causes of index hospitalisation were diseases of the circulatory system (41%),
external causes of morbidity and mortality (e.g., fall-related) (14%) and infections (8%). Diseases of
the circulatory system also contributed to more than one-third of readmissions within 30 (36%) and
90 days (36%). (Figure 2) Half of the included patients were prescribed RAS blockers (51%), with
an almost equivalent number taking statins (49.5%). Similarly, while half of the patients were on
diuretics, nearly a third of them were prescribed calcium channel blockers (28%) and mineralocorticoid
antagonists (25%).
Patients taking RAS blockers were relatively younger (mean [SD]: 80 [8] vs. 83 [7] years; p < 0.01)
and had diabetes as a comorbidity (63% vs. 46%; p = 0.02) compared to those not on these medications.
Additionally, most patients on RAS blockers had no hospitalisation record in the six months preceding
the index admission (65%), with only 8.5% of them having three or more prior hospitalisations.
However, users of RAS blockers were not significantly different in terms of gender (male: 52% vs. 48%),
CCI (median [IQR]: 4 [2–5] vs. 4 [3–5]) and eGFR (mean [SD]: 36 [11] vs. 38 [9] mL/min/1.73 m2).
Table 1 shows that there was no significant difference in most of the medication-related variables
among patients with or without hospital readmission within 30 days. MAI and MRCI were not
significantly associated with the occurrence of readmission within 30 and 90 days on adjusted
analyses (Table 2). However, the number of prior hospitalisations (in the six months before the
index admission) significantly increased the risk of 30-day (OR 1.41 95% CI 1.05–1.90) and 90-day
(OR 1.54 95% CI 1.15–2.10) readmissions after adjusting for age, gender, eGFR, CCI and the number
of medications. The use of RAS blockers was associated with a reduced occurrence of readmission
within both 30 (OR 0.39; 95% CI 0.19–0.79) and 90 days (OR 0.45 95% CI 0.24–0.84) after adjusting for
the same variables.
Similarly, MAI and MRCI were not associated with time to 90-day readmission on fully adjusted
models (Table 3). After adjusting for age, gender, CCI, eGFR and discharge destination, the number of
prior hospitalisations was predictive of the timing of readmission within 90 days (HR 1.44; 95% CI
1.19–1.73). The Kaplan-Meier plots (Figure 3) illustrate that people in the highest quartile of the
MAI had a relatively shorter time to readmission within 90 days compared to people in the lowest
quartile (60 vs. 72 days; p < 0.05). The use of RAS blockers was associated with longer time to
readmission within 90 days in both partially (HR 0.52 95% CI 0.33–0.83) and fully adjusted (HR 0.49;
95% CI 0.30–0.78) models (Table 3). The use of calcium channel blockers, beta blockers, diuretics,
mineralocorticoid antagonists, and anticoagulants was not associated with hospital readmission in this
patient group.
Finally, the number of prior hospitalisations was significantly associated with MRCI at the index
hospital admission (Spearman’s r = 0.20; p = 0.02). However, it was not significantly associated with
the number of medications (r = 0.14; p = 0.05) or the MAI (r = 0.10; p = 0.32) at the index admission.
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Table 1. Patient characteristics by 30- and 90-day readmissions.
Characteristics Total (n = 204)
30-Day Readmission 90-Day Readmission
Yes (n = 50) No (n = 154) p Yes (n = 81) No (n = 123) p
Age (years), mean (SD) 82 (7.6) 81 (7.3) 82 (7.7) 0.61 81 (7.4) 82 (7.8) 0.37
Male gender, n (%) 125 (61) 36 (72) 89 (58) 0.07 54 (67) 71 (58) 0.20
SBP (>140 mm Hg), n (%) 84 (41) 20 (40) 64 (42) 0.85 36 (44) 48 (39) 0.44
Serum creatinine (µmol/L), median (IQR) 134 (113–162) 142 (119–183) 134 (110–162) 0.11 128 (115–164) 138 (113–162) 0.16
eGFR (mL/min/1.73 m2), mean (SD) 37 (10) 36 (12) 37 (9.6) 0.16 37 (9) 37 (11) 0.77
CCI, median (IQR) 4 (3–5) 4 (3–5) 4 (2–5) 0.35 4 (2–5) 4 (2–5) 0.17
CCI (>3), n (%) 157 (77) 41 (82) 116 (75) 0.33 68 (84) 89 (72) 0.05
No. of medications at admission, median (IQR) 10 (7–13) 10 (6–13) 10 (7–12) 0.32 10 (7–12) 9 (6–13) 0.18
No. of medications at discharge, median (IQR) 10 (7–13) 10 (7–13) 10 (7–13) 0.24 11 (7–13) 9 (6–12) 0.02
MRCI at admission, median (IQR) 25 (17–33) 28 (21–34) 24 (16–33) 0.09 27 (20–34) 23 (15–32) 0.04
MRCI at discharge, median (IQR) 27 (20–35) 30 (21–36) 26 (18–34) 0.12 30 (22–37) 26 (17–34) 0.01
MAI at admission, median (IQR) 6 (3–12) 6 (4–13) 6 (3–11) 0.49 7 (4–12) 6 (3–11) 0.08
MAI at discharge, median (IQR) 5 (2–9) 6 (3–10.5) 4.5 (2–9) 0.23 7 (2.5–12) 4 (2–8) 0.03
Use of different medications, n (%)
RAS blockers 105 (51) 18 (36) 87 (56) 0.01 35 (43) 70 (57) 0.05
Statins 101 (49.5) 26 (52) 75 (49) 0.68 38 (47) 63 (51) 0.55
Calcium channel blockers 58 (28) 14 (28) 44 (29) 0.93 23 (28) 35 (28) 0.99
Beta blockers 94 (46) 23 (46) 71 (46) 0.99 39 (48) 55 (45) 0.63
Diuretics 104 (51) 26 (52) 78 (51) 0.87 44 (54) 60 (48) 0.44
Anticoagulants 53 (26) 11 (22) 42 (27) 0.46 18 (22) 35 (28) 0.32
Aldosterone antagonist 32 (16) 10 (20) 22 (14) 0.33 15 (18) 17 (14) 0.37
Primary cause of hospitalisation, n (%) 0.71
0.63
Cardiovascular 80 (39.2) 22 (44) 58 (38) 35 (43) 45 (37)
Infection 25 (12.2) 6 (12) 19 (12) 9 (11) 16 (13)
Other 99 (48.5) 22 (44) 77 (50) 37 (46) 62 (50)
Prior admission(s) in six months before, n (%) 101 (49.5) 27 (54) 74 (48) 0.46 49 (60) 52 (42) 0.01
Discharge destination, n (%) 0.18
0.09Home 162 (79.4) 43 (86) 119 (77) 69 (43) 93 (57)
Residential care 42 (20.1) 7 (14) 35 (23) 12 (29) 30 (71)
IRSD (lowest quartile) 51 (12) 14 (28) 37 (24) 0.59 22 (27) 29 (23.5) 0.68
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CCI, Charlson’s comorbidity index; eGFR, estimated glomerular filtration rate;
IQR, interquartile range; IRSD, index of relative socioeconomic disadvantage; IU, international unit; MAI, Medication Appropriateness Index; MRCI, medication regimen complexity
index; RAS, renin angiotensin system; SBP, systolic blood pressure; SD, standard deviation.
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Table 2. Logistic regression for medication-related factors and occurrence of readmission within
30 and 90 days.
a Readmission within 30 Days
Unadjusted ORs (95% CIs) Adjusted ORs (95% CIs) ¶
MAI 1.03 (0.97–1.09) 1.01 (0.94–1.07)
MRCI 1.21 (0.94–1.55) 1.24 (0.95–1.63)
Use of RAS blockers 0.43 (0.22–0.84) (0.19–0.79)
b Readmission within 90 Days
MAI 1.07 (1.01–1.12) 1.06 (1.00–1.12)
MRCI 1.33 (1.06–1.68) 1.31 (0.99–1.72)
Use of RAS blockers 0.58 (0.33–1.01) 0.45 (0.24–0.84)
Abbreviations: MAI, Medication Appropriateness Index; MRCI, medication regimen complexity index; ORs, odds
ratios; RAS, renin-angiotensin system ¶ Analysis adjusted for age, gender, eGFR, Charlson’s Comorbidity Index,
prior admissions and the number of medications.
Table 3. Cox proportional hazards regression for medication-related factors and time to readmission
within 90 days.
Unadjusted HRs (95% CIs) Adjusted HRs (95% CIs)
Model 1
MAI 1.04 (1.01–1.08) 1.04 (1.01–1.08)
MRCI 1.18 (1.01–1.39) 1.23 (1.03–1.47)
Use of RAS blockers 0.57 (0.38–0.89) 0.52 (0.33–0.83)
Model 2
MAI 1.04 (1.01–1.08) 1.03 (0.99–1.08)
MRCI 1.18 (1.01–1.39) 1.16 (0.96–1.39)
Use of RAS blockers 0.57 (0.38–0.89) 0.49 (0.30–0.78)
Abbreviations: HRs, hazard ratios; MAI, Medication Appropriateness Index; MRCI, medication regimen complexity
index; RAS, renin-angiotensin system. Model 1: Analyses adjusted for age, gender and Charlson’s Comorbidity
Index. Model 2: Analyses adjusted for factors in Model 1 plus eGFR, prior admissions and discharge destination.
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Figure 2. Causes for the index hospital admission and subsequent readmissions within 30 and 90 days,
by ICD-10 classification (in frequencies).
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independently associated with readmission, were likely to reflect poorer health and multimorbidity,
which may have contributed to the overall readmission rate in these patients.
Previous studies have reported conflicting results regarding the relationship between medication
appropriateness and hospital readmission. For example, studies reported that a greater number of
medications, but not inappropriate medication use, was associated with elevated risk of hospitalisation
and death [12,30], with no differences observed in people with or without CKD [12]. Furthermore, a
randomised trial aimed at improving medication therapy management in CKD patients (stage 3–5;
not on dialysis) after hospital discharge did not translate to a reduced occurrence of readmission
within 90 days [31]. In contrast, another study targeting general older adults showed that the use of
inappropriate medications (measured using explicit measures) at hospital discharge was significantly
associated with repeated hospital readmissions [32].
The number of hospitalisations in the six months prior to the index admission was strongly
associated with hospital readmission within 30 and 90 days. Prior hospitalisation increased the odds
of 30- and 90-day readmissions by 43% and 54%, respectively, and resulted in a significantly shorter
time to readmission within 90 days. The association between previous hospitalisations and risks of
subsequent readmission in older adults has previously been reported [14,27,33]. It would be anticipated
that people with repeated hospitalisations are likely to be sicker and medically more complex than
those with less frequent hospitalisations. This probably explains the significant correlation between
the number of prior hospitalisations and medication regimen complexity at hospital admission in
our study. Additionally, given that each hospital admission has the potential of causing a substantial
change in the medication regimen [34], multiple hospitalisations are bound to result in frequent
medication regimen changes in these patients. This, in turn, may affect medication management and
adherence, especially in older adults with lower cognitive functioning or social support.
An important finding from this study was the association between the use of RAS blockers and
lower risk of readmission, both within 30 and 90 days. This is interesting because these medications
are the first-line treatment for hypertension in diabetic and nondiabetic CKD patients, especially
those with proteinuria [25,35]. These medications are also an important part of pharmacotherapy
in different cardiovascular conditions and their use is associated with lower cardiovascular events
in people with CKD [36,37]. It is worth noting that the main reasons for index hospitalisation and
hospital readmissions in our study were cardiovascular in nature. Therefore, in addition to their role
in maintaining residual renal function [38], the cardioprotective effect of these medications appears to
be of great importance in terms of reducing potential cardiovascular-related admissions. Consistent
with our report, a longitudinal study that followed older adults with ESKD for up to three years
reported an association between use of RAS blockers and lower risk of hospitalisation [11]. However,
another study targeting a small number of older patients with stage 4 and 5 CKD (mean eGFR
of 16.38 mL/min/1.73 m2) reported that the discontinuation of RAS blockers was associated with
improved outcome [39]. Another large study targeting people with AKI also showed that the use
of RAS blockers was linked to lower mortality but a higher risk of hospitalisation for renal causes,
especially acute renal failure and hyperkalemia [40]. Of note, we found higher use of RAS blockers in
the relatively younger and in those with no hospitalisation history, suggesting that these medications
tended to be prescribed more commonly to relatively healthier individuals. This could be because
frail individuals, such as those with frequent hospitalisations, may have a lower tolerance to the
potential adverse effects of these medications, including worsening renal function, hyperkalaemia, and
hypotension. While available data generally indicate the benefit of these medications in older CKD
patients, the presence of proteinuria as well as the risk of progression and overall health should be
considered when initiating RAS blockers [41].
Our study has some strengths and limitations. Access to data from the state-wide DMR has
enabled us to accurately track patients’ hospitalisation records. Admission data in this study are
therefore likely to be accurate and complete. The use of validated tools to evaluate medication
appropriateness and regimen complexity is another strength of the study. We evaluated the association
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between medication-related factors at one point (discharge) and readmission after up to three months
of follow-up. Our analysis, therefore, did not consider changes in medication regimens during the
follow-up period. Finally, although we assessed the impact of medication-related factors, due to the
retrospective nature of the study, we were not able to assess the level of medication adherence or
ascertain the causality of the observed associations.
5. Conclusions
Medication appropriateness and regimen complexity were not independently associated with
30- and 90-day hospital readmissions in older adults with CKD. While there is a clear need for a larger
prospective study, the significant association between the use of RAS blockers and reduced risk of
30- and 90-day readmissions suggests that these medications could be particularly beneficial in older
adults with CKD.
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Summary 
The above study indicated that, despite the medical complexity in this patient group, 
medication regimen complexity and inappropriateness were not predictors of hospital 
readmission in older adults with CKD. However, the use of RAS blockers appeared to be 
associated with a lower risk of readmission within 30 and 90 days, highlighting the need to 
thoroughly assess patients’ regimen considering the benefit and risk associated with individual 
medications. Although there was no significant association between medication-related 
problems and hospital readmission within 30 and 90 days, the author did not consider a change 
in medication regimen due to hospitalisation in the analyses.  
It is important to consider that people could be readmitted due to a lack of communication 
during transition and lack of proper follow-up in a primary care setting. Therefore, adequate 
follow-up of patients after hospital discharge and performing medication reconciliation at each 
point across the care continuum have the potential to reduce hospital readmissions.  
Following this, a subsequent study focusing on the association between medication regimen 
complexity and risk of readmission was assessed. This is relevant given its implication for 
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5. CHAPTER FIVE: Medication Regimen Complexity and Hospital 
Readmission in Older Adults with Chronic Kidney Disease 
 
Overview 
This chapter expands on Chapter Four addressing the third objective of the thesis, with 
special focus on medication regimen complexity. It therefore examines the association 
between medication regimen complexity and hospital readmissions within a year of follow-
up.  
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Medication-related problems are important causes of 
adverse health outcomes, including hospitalizations and 
readmissions.1,2 Hospital readmission is considered a ser-
vice quality metric that may indicate poor inpatient care.3 
Although the estimates vary considerably, studies have 
found that hospital readmissions related to medications are 
common, and many of these readmissions are considered 
preventable.4 Medication regimen complexity is a modifi-
able risk factor that is associated with poor adherence and 
hospital readmissions in older adults.5-10 Despite this, evi-
dence on the association between medication regimen com-
plexity and clinical outcomes is equivocal.8 The multiple 
changes that occur during hospitalization have been associ-
ated with increased medication regimen complexity.11 It has 
also been reported that when hospitalization-led medication 
changes are followed by inadequate medication reconcilia-
tion and follow-up, they can increase patients’ risk of hospi-
tal readmission.12-14
Older adults with chronic kidney disease (CKD) are 
among patient groups with highly complex drug regimens 
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Abstract
Background: Chronic kidney disease (CKD) is characterized by high rates of hospital admissions and readmissions. 
However, there is a scarcity of research into medication-related factors predicting such outcomes in this patient group. 
Objective: To evaluate the effect of medication regimen complexity at hospital discharge on subsequent readmissions 
and their timing in older adults with CKD. Methods: This was a 12-month retrospective cohort study of 204 older (⩾65 
years) CKD patients in an Australian tertiary care hospital. Medication regimen complexity was quantified using the 65-
item medication regimen complexity index (MRCI). The outcomes were the occurrence of readmission in 30 days and 
time to readmission within 12 months. Logistic regression was used to identify factors predicting 30-day readmission, and 
a competing risks proportional subdistribution hazard model, accounting for deaths, was used for factors predicting time to 
readmission. Results: Overall, 50 (24%) patients, predominantly men (72%), were readmitted within 30 days of follow-up. 
MRCI was not significantly associated with 30-day readmission (odds ratio [OR] = 1.27; 95% CI = 0.94-1.73). The median 
(interquartile range) time to readmission within 12 months was 145 (31-365) days. On a multivariate analysis, a 10-unit 
increase in MRCI was associated with a shorter time to readmission within 12 months (subdistribution HR = 1.18; 95% CI 
= 1.01-1.36). Conclusion and Relevance: Medication regimen complexity was not significantly associated with 30-day 
readmission; however, it was associated with a significantly shorter time to 12-month readmission in older CKD patients. 
This finding highlights the importance of medication regimen complexity as a potential target for medical interventions to 
reduce readmission risks.
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and, therefore, potentially at increased risk of medication-
related hospitalizations.2 CKD patients also have higher 
rates of hospitalizations and hospital readmissions than 
those without CKD,12,15 although research into the modifi-
able causes of hospitalizations in these patients remains 
scant.12 Identifying modifiable risk factors that can be used 
clinically in identifying patients at risk of future readmis-
sions is imperative in designing and implementing prag-
matic preventive strategies.
Despite CKD patients’ greater risk of hospital admis-
sions and readmissions, the role that medication regimen 
complexity plays in predicting such outcomes has not been 
investigated. Furthermore, there is a relative paucity of 
medication-related outcome data in people with CKD. 
Therefore, we aimed to examine the association between 
medication regimen complexity at hospital discharge and 
readmission within 30 days in older CKD patients. 
Moreover, we aimed to determine the association between 
medication regimen complexity and time to hospital read-
mission in a 12-month follow-up period.
Methodology
Study Design and Participants
This was a 12-month retrospective cohort study conducted 
in a 500-bed tertiary care hospital in Tasmania, Australia. 
Older patients (aged ⩾65 years) with CKD (estimated glo-
merular filtration rate [eGFR] of 15-60 mL/min/1.73m2), 
estimated via the CKD epidemiology collaboration (CKD-
EPI) equation,16 at a point closest to discharge and who 
were hospitalized between January and June 2015 were eli-
gible for inclusion. Of 1472 older adults with at least 1 low 
eGFR value reported and who were hospitalized during the 
study period, 204 met the inclusion criteria. Patients were 
excluded for one of the following reasons: (1) stayed for a 
period shorter than 24 hours (n = 505), (2) had acute kidney 
injury (n = 387), (3) were critically ill/died during admis-
sion (n = 42), (4) had no repeated measures of eGFR over 
a period longer than 3 months to confirm CKD (n = 118), 
(5) receiving renal replacement therapy (n = 36), (6) had 
anomalies (n = 8), and (7) had incomplete records (n = 
172). The study was approved by the Tasmanian Human 
Research Ethics Committee (H0016044).
Data Collection
Demographic, laboratory, and medical information for par-
ticipants was extracted from their medical records. The 
Anatomical Therapeutic Chemical classification system17 
was used to record and classify medications, whereas the 
International Classification of Diseases (ICD-10)18 was 
used to code the reasons for hospital readmission. A list of 
patients with low eGFR (<60 mL/min/1.73m2) values 
reported between January and June 2015 were electroni-
cally extracted using patient identifiers from Royal Hobart 
Hospital Pathology. Using the digital medical record (DMR) 
of the Department of Health and Human Services, each 
patient was evaluated for inclusion based on the predefined 
criteria. The discharge summaries of patients who met the 
inclusion criteria were thoroughly reviewed by the principal 
investigator (WHT) to retrieve drug information, including 
dosage form, dosing frequency, and additional instructions, 
which formed the basis to calculate the discharge medica-
tion regimen complexity.
Measures
Medication regimen complexity was the main exposure 
variable and was quantified using the 65-item medication 
regimen complexity index (MRCI).19 The MRCI comprises 
dosage forms, dosing frequency, and additional directions, 
with each component assigned different weights. The total 
MRCI is the sum of the scores for the 3 sections, and higher 
scores reflect more complex medication regimens. This 
score has no upper limit because there is no limit to the num-
ber of medications that could be prescribed to a patient or 
additional directions given.19 Typically, a medication that 
has to be administered twice daily receives a higher score 
than once-daily dosing. Parenteral and inhalational dosage 
forms receive higher scores than orally administered medi-
cations. In computing the MRCI, both regular and “as 
needed” medications and supplements were considered. 
Medications used only for a short period, including oral anti-
biotics and analgesics prescribed during a patient’s hospital 
stay, were excluded from the calculation. The number of 
medications comprised the total sum of individual medica-
tions and supplements taken by an individual. Combination 
medications were counted as single medications for comput-
ing both the MRCI and number of medications.
Outcomes of interest were (1) hospital readmission in a 
30-day period of discharge from the index hospitalization 
and (2) time to hospital readmission within 12 months. The 
index hospitalization was set as the first hospital admission 
during the study period (between January 1, 2015, and June 
30, 2015) and the follow-up time of patients determined 
individually based on their respective discharge dates. The 
admission and discharge dates for the index hospitalization, 
readmissions during the follow-up periods, and time to the 
first readmission were extracted from the DMR. The fol-
low-up data were included for people who were readmitted 
to the same tertiary care hospital, which is the only one in 
the region.
Covariates
Age, gender, the source of index hospitalization (home or 
residential care), the presence of hospitalizations within a 
77
Tesfaye et al 3
year prior to the index hospitalization, dose administration 
aids (DAAs) use (mainly dosette boxes and blister packs), 
and discharge destination were recorded. Length of hospi-
talization for the index admission was computed using the 
days between initial admission and discharge. The Charlson 
comorbidity index (CCI)20 was used to determine comor-
bidity. We also included an examination of anticholinergic 
drug use, given consistent reports of an association between 
anticholinergic burden and both hospitalization and falls in 
older individuals.21 The use of anticholinergic drugs at dis-
charge was determined based on the use of any drug from 
the modified Anticholinergic Risk Scale (mARS).22 The 
mARS ranks medications with anticholinergic property 
using a 3-point scale. The mARS score for a patient is the 
sum of each medication with anticholinergic effect. 
Socioeconomic status was determined using the Index of 
Relative Socioeconomic Disadvantage (IRSD) from the 
Socio-Economic Indexes for Areas (SEIFA 2011).23 Using 
the postcode of residence, this index measures the relative 
level of socioeconomic disadvantage based on a range of 
census characteristics that reflect disadvantage, such as low 
income, low educational attainment, high unemployment, 
and jobs in relatively unskilled occupations.
Statistical Analyses
Demographics, comorbidity, and eGFR for patients with 
and without readmission were compared descriptively. 
Continuous outcomes were reported as means (SD) for nor-
mally distributed variables and medians (interquartile range 
[IQR]) for nonnormally distributed variables. Categorical 
variables were compared between readmission and non-
readmission groups using χ2 tests; independent-samples 
t-tests were used for normally distributed continuous vari-
ables and Mann-Whitney U tests for nonnormally distrib-
uted continuous variables.
To evaluate factors associated with hospital readmission 
in a 30-day follow-up period, unadjusted and adjusted odds 
ratios (ORs) with 95% CIs were estimated using logistic 
regression. For these analyses, the number of medications 
and MRCI were dealt with separately because of the high 
correlation between the 2 variables.7 The MRCI score was 
used in the analysis in tenth units (total MRCI divided by 
10) because a 10-unit increase was deemed more clinically 
relevant and meaningful.24 For factors associated with time 
to readmission in a 12-month period, a competing risks 
proportional subdistribution hazards model was applied to 
report unadjusted and adjusted subdistribution hazard 
ratios (HRs) and 95% CIs, as proposed by Fine and Gray.25 
We used this model because death, as a competing risk, can 
hinder the occurrence of readmission and, therefore, affect 
the relationship between MRCI and readmission. In both 
models, factors with a P value <0.20 in univariate analyses 
were included in the multivariate analyses. The 
significance level for all analyses was set at a P value 
<0.05, and data were analyzed using STATA, version 15 
(StataCorp LLC, TX).
Results
A total of 204 older adults with CKD (eGFR = 15-60 mL/
min/1.73 m2) met the inclusion criteria. Their baseline char-
acteristics are presented in Table 1. Overall, 2056 medica-
tions were prescribed at the discharge of the index 
hospitalization; most of these medications were orally 
administered (tablet and capsules; 86%) followed by inha-
lational (6.1%) and parenteral (4.1%) dosage forms. 
Paracetamol (6.3%), furosemide (5%), acetylsalicylic acid 
(4.7%), cholecalciferol (4.1%), and esomeprazole (3.1%) 
constituted the most frequently prescribed individual medi-
cations at discharge. A total of 76 (37%) patients were tak-
ing drugs with anticholinergic activity, with 26 (13%) on at 
least 1 very strong anticholinergic drug (mARS ⩾ 3).
The median (IQR) MRCI score at discharge from index 
hospitalization was 27 (20-35), and the mean (SD) number 
of medications was 10 (4). Overall, looking at individual 
components of the MRCI, dosing frequency contributed to 
nearly half (46%) of the overall MRCI score, with a median 
(IQR) value of 12.4 (8-16.5).
Almost a quarter of the patients (50; 24.5%) were read-
mitted in the 30-day follow-up, whereas almost two-thirds 
of the patients (127; 62.3%) had a readmission in the 
12-month period. Of included patients, 50 of them, predom-
inantly male (68%), died before the end of the 12-month 
follow-up. The main reasons for readmission in the 30-day 
follow-up (Table 2) included cardiovascular conditions 
(34%), falls (10%), and infections (10%). Additionally, 
although 14% of the readmissions in this period were 
recorded as being drug induced, all patients readmitted 
because of falls were also taking at least 1 medication that 
could cause a fall. The common causes for readmission 
within a 12-month period were very similar to those for 
readmission within 30 days: cardiovascular causes (31.5%), 
followed by infections (14.2%) and falls (12%).
Factors Associated With Hospital Readmissions
There was no significant difference in the demographic or 
clinical characteristics of patients with or without readmis-
sion in the 30-day follow-up (Table 1). The number of 
medications (OR = 1.03; 95% CI = 0.94-1.12) and MRCI 
(OR = 1.16; 95% CI = 0.86-1.57) were not associated 
with a 30-day hospital readmission on multivariate logistic 
regression (Table 3).
The median (IQR) time to first hospital readmission 
was 145 days (31-365). On univariate analysis, MRCI 
was significantly associated with time to readmission in 
12 months (subdistribution HR = 1.21; 95% CI 
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= 1.07-1.37). Similarly, after adjusting for age, serum 
creatinine, CCI, anticholinergic drug use, discharge des-
tination, IRSD, the use of DAAs, and previous admis-
sions, higher MRCI score was associated with a shorter 
time to readmission (subdistribution HR = 1.18; 95% CI 
= 1.01-1.36). Adjusting for similar covariates, the num-
ber of medications was not associated with time to read-
mission in this period (subdistribution HR = 1.04; 95% 
CI = 0.99-1.08). On the other hand, having multiple 
admissions in the 12 months prior to the index hospital-
ization was associated with a shorter time to readmission 
within 12 months (adjusted subdistribution HR = 2.24, 
95% CI = 1.48-3.40; Table 4). Finally, the serum 
 creatinine of patients was weakly associated with time to 
readmission (adjusted subdistribution HR = 1.003; 95% 
CI = 1.00-1.01).




Readmission Within 30 days
Yes (n = 50) No (n = 154) Significance
Age (years) 83 (76-87) 83 (77-86) 83 (76-87) 0.69
Male gender 125 (61) 36 (72) 89 (58) 0.09
Serum creatinine (µmol/L) 129 (108-162) 133 (113-174) 127 (106-127) 0.13
eGFR (mL/min/1.73 m2) 38 (11) 38 (12) 39 (11) 0.55
Hemoglobin (g/L) 118 (106-134) 118 (103-133) 119 (108-134) 0.55
CCI 4 (3-5) 4 (3-5) 4 (3-5) 0.17
DAA 76 (37) 18 (36) 58 (38) 0.87
Length of hospitalization (days) 4 (2-8) 4 (2-8) 4 (3-8) 0.37
Regular medications 9 (4) 9 (4) 9 (4) 0.28
Total medications 10 (4) 11 (4) 10 (4) 0.27
MRCI 27 (20-35) 30 (21-37) 27 (18-34) 0.12
Anticholinergic use (⩾1 drug with mARS ⩾1) 76 (37) 23 (46) 53 (34) 0.09
Admitted from home 185 (91) 47 (94) 138 (90) 0.42
Discharged home 162 (79) 43 (86) 119 (77) 0.23
Prior admissions in 12 months (⩾2) 93 (46) 27 (54) 66 (43) 0.19
Living alone 54 (26) 12 (24) 42 (27) 0.71
IRSD (highest quartile) 46 (23) 8 (16) 38 (25) 0.59
Abbreviations: CCI, Charlson comorbidity index; DAA, dose administration aid; eGFR, estimated glomerular filtration rate; IRSD, index of relative 
socioeconomic disadvantage; mARS, the modified Anticholinergic Risk Scale; MRCI, medication regimen complexity index.
aResults are given as median (interquartile range), mean (SD), or number (percentage).
Table 2. Reasons for Hospital Readmission in 30-Day and 12-Month Follow-up Periods.
Readmission Causes ICD-10 Codes 30 Days, n (%)a 12 Months, n (%)b
Cardiovascular BA5Z, I20.0, I21.0, I20.8, I20.9, 
I25.3, I35.0, I42.0, I48.1, I49, I50.0, 
I50.1, I51.9, I95.2, R06.0, R55
17 (34) 41 (32.2)
Fall related S00.0, S40.0, S82.0, S17.8, W01, 
W05, W06, W08, W13, W19
5 (10) 15 (12)
Infections A09.0, A41.9, J13, J22, L03, I69.0, 
J00, K57.9, K61.3, N39.0, T81.4
5 (10) 18 (14.2)
Gastrointestinal A01, K57, K61.3, K92.2, K40, 
K40.1, K45, K56.6, R10.1
3 (6) 9 (7.1)
Drug induced E16.0, G50.8, R00.1, K92.2, W18 7 (14) 8 (6.3)
Miscellaneous D01.5, E61.1, F00.9, F05.9, G41.0, 
H25, J44, K56.6, K81.1, K85.9, 
L03.1, M54.9, M86, N17.9, R10.1, 
R30, R10.0, H81.4, X84
13 (26) 36 (28.3)
aThe denominator is the number of patients hospitalized within 30 days (n = 50).
bThe denominator is the number of patients hospitalized within 12 months (n = 127).
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Discussion
This is the first study to evaluate the association between 
medication regimen complexity and hospital readmission in 
older CKD patients. The main findings indicate that in this 
study, increased medication regimen complexity was asso-
ciated with a significantly shorter time to 12-month read-
mission. Increased medication regimen complexity was 
also associated with an increase in the odds for 30-day read-
mission; however, this was not statistically significant.
Although medication regimen complexity and the num-
ber of medications were not associated with readmission 
within 30 days, up to 14% of these readmissions were 
recorded as drug induced. Furthermore, all patients who 
were readmitted because of a fall within this period were 
taking at least 1 medication that increases the risk of falls. 
This result suggests that individual medications are impor-
tant contributors to readmission, irrespective of medication 
regimen complexity. This is supported by previous research 
indicating that taking certain drugs could predispose 
patients to higher risks of hospitalization, rather than the 
presence of polypharmacy.26
The association between medication regimen complex-
ity and readmission is important because this variable has 
been suggested for use to target individuals at high risk of 
hospitalization.27 Previous studies reported that medication 
regimen complexity was associated with hospital admis-
sions and readmissions.5-7,10 However, in most of these 
studies, medication regimen complexity was not identified 
to be a better predictor of hospitalization than the number of 
medications. In contrast, in our study, medication regimen 
complexity, but not the number of medications, was associ-
ated with time to readmission. This could be because CKD 
is typically characterized by the use of medications with 
complex instructions for treating various comorbidities and 
disease complications.2 Nevertheless, compared with sim-
ply using the number of medications, computing MRCI for 
an individual patient is difficult to implement in routine 
clinical practice. However, a study showed that MRCI 
scores can be automatically computed and integrated into 
electronic health records for easier clinical decision 
making.28
The effect of medication regimen complexity on read-
mission has an important clinical implication because this 
variable, unlike simple medication count, has different 
components that can be targeted during medication review 
to optimize medication adherence. In particular, given that 
dosing frequency contributed the most to the overall MRCI 
score of patients in this study, health professionals should 
Table 3. Factors Associated With Hospital Readmission Within 30 Days After Discharge for the Index Hospitalization.
Variables Unadjusted OR (95% CI) Adjusted OR (95% CI)
MRCI 1.21 (0.94-1.55) 1.16 (0.86-1.57)
Male gender 1.88 (0.94-3.76) 1.76 (0.85-3.62)
Serum creatinine 0.99 (0.96-1.02) 0.98 (0.95-1.01)
CCI 1.25 (0.63-2.51) 1.08 (0.90-1.30)
Anticholinergic use 1.62 (0.85-3.10) 1.06 (0.83-1.36)
Prior admissions in 12 months (⩾2) 1.89 (0.92-3.87) 1.79 (0.84-3.80)
Abbreviations: CCI, Charlson comorbidity index; MRCI, medication regimen complexity index (analyzed using the tenth of the original score); OR, 
odds ratio.
Table 4. Factors Associated With Time to Readmission Within 12 Months.a
Variables Unadjusted HRs (95% CIs) Adjusted HRs (95% CIs)
MRCI 1.21 (1.07-1.37) 1.18 (1.01-1.36)
Age (years) 0.98 (0.96-1.00) 1.00 (0.97-1.03)
CCI 1.06 (0.98-1.14) 1.02 (0.93-1.11)
DAAs use 1.28 (0.90-1.81) 1.08 (0.73-1.60)
Discharged home 1.56 (0.95-2.55) 1.54 (0.89-2.68)
IRSD (highest quartile) 0.72 (0.44-1.17) 0.82 (0.49-1.39)
Anticholinergic use 1.09 (0.97-1.23) 1.00 (0.88-1.14)
Prior admissions in 12 months (⩾2) 2.49 (1.67-3.71) 2.24 (1.48-3.40)
Serum creatinine 1.00 (0.99-1.01) 1.003 (1.00-1.01)
Abbreviations: CCI, Charlson comorbidity index; DAAs, dose administration aids; HR, hazard ratio; IRSD, index of relative socioeconomic 
disadvantage; MRCI, medication regimen complexity index (analyzed using the tenth of the original score).
aFine and Gray’s competing risks regression model was used to compute the subdistribution HRs and 95% CIs for factors associated with readmission 
accounting for death as a competing factor.
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consider this factor during prescribing for older adults with 
CKD. The use of longer-acting medications is one of the 
suggested strategies to reduce dosing frequency and, there-
fore, simplify patients’ regimens.27 This finding is particu-
larly relevant for people who are discharged home, have 
lower cognitive functioning, and have little support in med-
ication management.
Patient factors, comorbidity, number of prior hospital-
izations, and length of hospitalization were some of the fac-
tors that previously predicted hospital readmission in people 
with CKD.12,29 In our study, patients readmitted in 30 days 
were not significantly different in terms of age, comorbid-
ity, and length of hospital stay as compared with those who 
were not readmitted in this period. However, although the 
difference was not statistically significant, patients with a 
30-day readmission were more likely to be men (72%). This 
corresponds with the report by the Australian Institute of 
Health and Welfare that male CKD patients have higher 
hospitalization rates than female patients.30 On the other 
hand, having multiple prior hospitalizations in the year pre-
ceding the index hospitalization was associated with a 
shorter time to readmission in the subsequent 12 months.
The use of a validated measure to compute medication 
regimen complexity is one strength of the study. This tool 
comprises important components such as dosage form, the 
frequency of administration, and additional instructions 
provided to patients. The study is limited by a relatively 
small sample size from a single hospital. Despite the inclu-
sion of several factors in our analyses, we may have also 
missed important contributors given the complexity sur-
rounding causes of hospital readmission. Another potential 
limitation was that we examined the association between 
medication regimen complexity at only one point and the 
risk of readmissions in up to 12 months of follow-up. 
However, the care patients receive from multiple health 
care providers during the follow-up period may result in 
changes in medication regimen complexity. Because of the 
retrospective nature of the study, we were unable to assess 
adherence to medications. The appropriateness of individ-
ual medications was also not assessed in this study; how-
ever, we have included the use of anticholinergics in our 
analyses, given their contribution to hospitalization in older 
people.21
Conclusion and Relevance
This study demonstrated that medication regimen complex-
ity was not significantly associated with hospital readmis-
sion within 30 days in older patients with CKD; however, it 
was associated with a significantly shorter time to 12-month 
readmission. Although there is a need for large-scale studies 
to determine the relationship between medication regimen 
complexity and clinical outcomes in these patients, the 
finding highlights the importance of considering regimen 
complexity during medication review at hospital discharge 
to reduce the risk of readmission. Future studies should 
examine the relationship between changes in medication 
regimen complexity during hospitalization and risks of hos-
pital readmissions.
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Summary 
The study above indicates that medication regimen complexity is potentially relevant in 
predicting long-term clinical outcomes. This reaffirms the assertion in Chapter Five that 
medication regimen complexity is likely an indirect measure of overall health and morbidity 
status in older patients with CKD. 
In the next chapter, the relevance of medication-related factors in CKD is further assessed using 
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6. CHAPTER SIX: Medication adherence, burden and health-related quality of 




This study addresses the fourth objective of this thesis. It is a prospective cohort study 
examining the relationships between medication burden and adherence, and HRQOL in 
adults with advanced CKD not receiving renal replacement therapy. Participants were 
interviewed at two points to assess the change in HRQOL over time and how medication 
(non)-adherence relates to such change. 
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Medication adherence, burden and health-related quality of life in adults with pre-
dialysis chronic kidney disease: a prospective cohort study 
Abstract 
Objective: To examine the associations between medication adherence and burden, and health-
related quality of life in adults with pre-dialysis chronic kidney disease (CKD). 
Methods: A prospective study targeting adults (≥18 years) with advanced CKD (estimated 
glomerular filtration rate (eGFR) <30 mL/min/1.73m2) and not receiving renal replacement 
therapy was conducted in Tasmania, Australia. Actual medication burden was assessed using 
the 65-item Medication Regimen Complexity Index and a medication count, whereas perceived 
burden was self-reported using a brief validated questionnaire. Medication adherence was 
assessed using the 4-item Morisky-Green-Levine Scale (MGLS) and the Tool for Adherence 
Behaviour Screening (TABS). The Kidney Disease and Quality of Life Short-Form, which 
contains kidney disease-targeted and generic components, was used to assess health-related 
quality of life. Activities of daily living, cognitive functioning and autonomy preference (in 
decision-making and information-seeking) were among covariates assessed. 
Results: Of 464 eligible adults identified and invited, 101 participated in the baseline interview 
and 63 completed a follow-up interview at around 14 months. Participants were predominantly 
men (67%), with a mean age of 72 (SD 11) years and eGFR of 21 (SD 6) mL/min/1.73m2. 
While the mean number of medications was 8.5 (SD 3.7), medication non-adherence was 
reported in 43% and 60% of participants based on MGLS and TABS, respectively. Higher 
perceived medication burden (OR 4.89; 95% CI 1.02-23.5) and desire for decision-making (OR 
4.56 95% CI 1.68-12.35) were associated with non-adherent behaviour. Poorer health-related 
quality of life was associated with higher regimen complexity, whereas medication non-
adherence was associated with a decline in physical health-related quality of life over time. 
Conclusion: Medication non-adherence, influenced by perceived medication burden, is 
prevalent in this pre-dialysis CKD cohort, and is associated with a significant decline in 
physical health-related quality of life even over a short time period.  
Key words: Chronic kidney disease; medication adherence; health-related quality of life; 
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Introduction  
Medication adherence is the primary determinant of treatment success, yet nearly half of people 
with chronic conditions do not take their medications as prescribed.21 The reported prevalence 
of medication non-adherence in chronic kidney disease (CKD) varies considerably; 12%-53% 
in stage 3 to 4 CKD and 21%-74% in end-stage kidney disease (ESKD).134-136 Medication 
adherence is particularly relevant in people with CKD given its potential importance in slowing 
disease progression and thus improving health outcomes. Poor adherence to antihypertensive 
medications in CKD, reported in nearly one-third of patients, is associated with uncontrolled 
hypertension.137,138 Research also indicates that non-adherence to cardiovascular medications 
at the pre-dialysis stage is an independent predictor of post-dialysis mortality in people with 
advanced CKD.139 
Patient-centred outcomes, such as health-related quality of life (HRQOL), are important 
measures that capture patients’ perspectives and experiences about their functionality and 
wellbeing.130 These outcome measures are particularly relevant in patients with advanced CKD 
as they inform treatment goals and modalities.131 Nevertheless, there is limited data on patient-
centred outcomes in people with advanced CKD,25,131,140 particularly in those not receiving 
renal replacement therapy.132 More importantly, the relationship between HRQOL and 
medication-related factors, such as medication burden and adherence, is relatively under-
examined in this patient group.141  
Actual and perceived medication burden can be assessed in different ways including the 
complexity of medication regimens and the number of medications used. Medication regimen 
complexity and the number of medications would be expected to influence adherence, although 
findings on this subject are not consistent.20 In patients with CKD, the association between 
medication regimen complexity and adherence is inconclusive.25,140 Moreover, despite the high 
medication burden in patients with advanced CKD, evidence is lacking on the association 
between medication-related factors and patient-centred outcomes in pre-dialysis CKD.  
This study aimed to (i) identify factors associated with medication burden (perceived and 
actual), (ii) examine the association between medication burden (actual and perceived) and 
adherence in adults with pre-dialysis CKD, (iii) examine the association between HRQOL and 
actual medication burden, and (iv) evaluate the relationship between medication adherence and 
a change in HRQOL over time. 
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Materials and Methods 
Study design and population 
This analysis utilised data from the Tasmanian CKD study, a prospective cohort of adults aged 
≥18 years with advanced CKD (based on a single estimated glomerular filtration rate (eGFR) 
reading of <30mL/min/1.73m2 in the 3 months prior to recruitment) and not receiving renal 
replacement therapy. A detailed description of the rationale, design and results of the pilot 
study have been published previously.142 Participants were recruited and attended a baseline 
clinic between February 2016 and September 2018. Individuals with at least one medication 
and who agreed to participate in an additional medication interview were included in the 
current analysis.  
At baseline, participants attended a study clinic where a range of sociodemographic, clinical, 
and HRQOL information was collected. Consenting participants were then contacted by a 
research pharmacist (WHT) to arrange an additional interview regarding participants’ 
medications and medication-taking behaviour. At follow-up (at least a year after the baseline 
assessment), participants attended a clinic for an additional interview (between August 2017 
and October 2018). This study was approved by the Tasmanian Health and Medical Human 
Research Ethics Committee (H0015099). 
Measures 
Medication-related factors 
Medication-related information collected from participants during the baseline interview was 
verified using electronic health records. To determine actual medication burden, the validated 
65-item medication regimen complexity index (MRCI)18 and simple medication count were 
used. Perceived burden of medication (PBM), a tool previously developed and validated in 
adults with ESKD, was used to assess participants’ perceived burden of their medication 
regimens.25 This tool consists of six Likert-scale questions asking if patients feel bothered by 
the number of medications they take, size of pills, adverse effects of medications, the dosing 
frequency, the need to take medications at work or in social contexts, and the need to drink 
fluid to take medications.  
Medication adherence was self-reported by participants at baseline using the Morisky-Green-
Levine Scale (MGLS).143 This scale consists of four questions with ‘yes/no’ answers, with 
patients deemed non-adherent if they respond ‘yes’ on at least one of the questions. The Tool 
for Adherence Behaviour Screening (TABS), a questionnaire developed in Australia to assess 
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adherence behaviour in adults taking chronic medications,144 was also used during the 
interview. This tool has two subcomponents, one for ‘adherence’ and one for ‘nonadherence.’ 
The subcomponents have four items each and a differential score (i.e. total for ‘adherence’ 
minus total for ‘nonadherence’) of ≥15 reflects good adherence and a score of ≤14 indicates 
suboptimal adherence.145 These adherence measures were chosen in this study because they 
address both intentional and unintentional non-adherence behaviour. 
Covariates  
Patient characteristics, including age, gender, marital status, level of education and means of 
income, and smoking history (current/former vs never), were recorded at baseline. Index of 
Socioeconomic Disadvantage was retrieved using the postcode of participants from the Socio-
Economic Indexes for Areas of the Australian Bureau of Statistics.146 The modified Charlson’s 
Comorbidity Index (CCI),147 calculated using medical conditions as reported by the 
participant’s treating physician, was used to determine the medical comorbidities. Baseline 
laboratory values, including haemoglobin, eGFR, and serum creatinine, were extracted using 
electronic records. eGFR was calculated using the CKD Epidemiology Collaboration (CKD-
EPI) equation.122 
Participants self-reported their level of functionality using the basic Activities of Daily Living 
(ADL)148 and Instrumental Activities of Daily Living (IADL) scale.149 The ADL assesses the 
ability to perform six basic self-care tasks independently, with scores ranging between 0 and 6 
for low to high level of functioning. The IADL assesses functionality to deal with more 
complex tasks, including handling of finance and managing medications. This tool contains 
eight items ranging from 0 for highly dependent individuals to 8 for those who are increasingly 
independent. Treating physicians also rated the functionality of the participants using the 
Karnofsky Performance Scale.150 Scores range between 0 and 100, with higher scores 
corresponding to greater performance. Participants self-reported their desire for autonomy 
using the Autonomy Preference Indexes. This tool includes an eight-item decision-making 
scale (preference to be involved in decision-making) and a six-item information-seeking scale 
(desire to be informed) scales. Each of these scales were then standardised into scores ranging 
between 0 and 100.151 Zero indicates low preference for autonomy (i.e. delegating to healthcare 
professionals), with 100 indicating a high preference and 50, a neutral attitude.151,152 Cognitive 
functioning was objectively measured using the Montreal Cognitive Assessment (MOCA), 
with those scoring 26 or above deemed to have good cognitive functioning.153 The Patient 
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Health Questionnaire, a 9-item diagnostic and assessment tool, was used to assess the presence 
and severity of depression.154 
HRQOL was self-reported by participants at baseline and at follow-up using the Kidney 
Disease Quality of Life Short-Form health survey (KDQOL-36).155 This tool consists of a 
combination of kidney disease-targeted items and generic items. The disease-specific part 
consists of eleven domains including two dialysis related domains. Therefore, nine domains 
assessing symptoms, effects, burden, work status, cognitive function, social interaction, sexual 
function, sleep, social support were applicable to this cohort. Participants responses were 
transformed into a 100-point scale, with higher scores reflecting better health. The short form 
(SF-36) is a 36-item questionnaire that assesses eight generic health domains, including 
comprising physical functioning, physical role limitations, pain, general health, vitality, social 
functioning and mental health. These domains are then aggregated into two component 
summary scores; physical health (PCS) and mental health component summaries (MCS), with 
higher scores reflecting greater self-reported HRQOL. Change in HRQOL was examined using 
the difference between baseline and follow-up MCS and PCS scores, with score differences of 
≥ 5 considered clinically significant.132 
Statistical analyses  
Variables were checked for normality of distribution via visual inspection of histograms. 
Normally distributed continuous variables were reported as mean ± standard deviation (SD), 
and non-normally distributed variables were reported as median (interquartile range [IQR]). 
Frequency (percentage) was used to report proportions and categorical variables.  
Participants characteristics were compared with respect to medication adherence (yes/no). 
Student’s t-test was used to compare continuous variables with a normal distribution, while 
Mann Whitney-U test was applied for non-normally distributed variables. Chi-square test was 
used for comparison of categorical variables. Factors associated with medication non-
adherence were examined using binary logistic regression, with effect sizes reported using odds 
ratios (ORs) and 95% confidence intervals (CIs). Factors were included in the final model 
based on a p-value <0.1 on univariate analyses or set a priori based on clinical importance and 
previous research.25,132,134 The decision-making and information-seeking scales were treated in 
these analyses both as continuous and categorical variables. A cut-off point of 50 was used for 
categorising decision-making and information-seeking scales, as this score is considered to 
show neutrality in terms of increased preference for participation in one’s care or delegating it 
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to healthcare professionals.151 To identify factors associated with actual (MRCI) and perceived 
(PBM) medication burden, linear regression models were utilised, with associations reported 
using coefficients (β) and 95% CIs.  
Finally, changes in different disease-targeted and generic HQROL measures at baseline and 
follow-up were compared using a paired t-test. Associations between medication non-
adherence (MGLS) and changes in disease-targeted and generic HRQOL measures were 
performed using linear regression models, with analysis adjusted for age, gender, and baseline 
eGFR. Clinically significant changes in physical (PCS) and mental (MCS) quality of life 
measures was compared by adherence status using a Chi-square test. The median (IQR) 
changes in PCS and MCS over the follow-up period are illustrated using boxplots. A p <0.05 
was set to determine statistical significance. STATA version 15.1 software (StataCorp LLC, 
TX) was used for analysis. 
Results 
Four hundred and sixty-four eligible individuals were invited to participate in the study (Figure 
6.1.). Of these, 132 (28%) attended a baseline study clinic appointment and 101 (21%) 
participated in an additional medication interview. Subsequently, 63 (62%) of these 
participants have completed the follow-up interview. Participants at baseline were 
predominantly men (67%), with a mean age of 72 (SD 11) years and a mean eGFR of 21 (SD 
6) mL/min/1.73m2. Participants were not different from non-participants in terms of age and 
Index of Socioeconomic Disadvantage (p > 0.05). However, a higher proportion of non-
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Figure 6.1. Flow diagram of the recruitment process   
At baseline, 79% (80/101) of the participants were taking ≥ 5 medications and 43% (43/101) 
were taking ≥ 9 medications. Based on the MGLS, about 43% (43/101) of the participants were 
considered non-adherent, while 60% (61/100) reported suboptimal adherence based on TABS. 
API scores revealed that while most participants were interested in having more information 
(mean API information-seeking; 82 ± 11), they preferred healthcare professionals to make 
decisions for them (mean API decision-making; 45 ± 17). The baseline characteristics of 
participants by medication adherence are described in Table 3. 
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Table 3. Characteristics of participants by medication adherence (n=101) 
  Adherence (MGLS) Adherence (TABS) 
Variables  Total (n=101) Yes (n=58) No (n=43)  P Yes  (n=40) No (n=61) P 
Sociodemographic  
Age (years) 72 (11) 73 (11) 70 (11) 0.12 74 (11) 70 (11) 0.06 
Male gender, n (%)  68 (67) 36 (53) 32 (47) 0.19 31 (46) 37 (54) 0.08 
Level of education (year 12 or less), n (%) 63 (62) 38 (60) 25 (40) 0.45 26 (41) 37 (59) 0.66 
Married/de facto, n (%) 65 (49) 36 (55) 29 (45) 0.58 27 (41) 38 (59) 0.59 
Government pension, n (%) 64 (63) 37 (58) 27 (42) 0.60 27 (42) 37 (58) 0.67 
Index of Disadvantage (highest quartile) 33 (33) 19 (58) 14 (42) 0.30 11 (33) 22 (67) 0.47 
























Karnofsky performance scale 87 (10) 86 (8) 88 (12) 0.54 87 (9) 86 (12) 0.65 
Major depression (PHQ-9 score ≥ 10) 12 (12) 5 (42) 7 (58) 0.24 6 (50) 6 (50) 0.61 
Clinical  
Smoking (former/current), n (%) 51 (50) 29 (57) 22 (43) 0.91 23 (45) 28 (55) 0.25 
Comorbidity index, median (IQR) 3 (1-4) 3 (1-5) 2 (1-3) 0.38 3 (2-4) 2 (1-3) 0.04 




Congestive heart failure 



















































Body mass index, kg/m2 30 (6) 31 (6) 30 (5) 0.67 28 (26-31) 32 (27-35) 0.02 
ADL 5.8 (0.4) 5.9 (0.3) 5.7 (0.5) 0.10 5.8 (0.4) 5.8 (0.4) 0.36 
IADL 5.5 (1.4) 5.5 (1.4) 5.2 (1.1) 0.06 5.4 (1.4) 5.6 (1.5) 0.34 
Cognitive impairment (MOCA<26), n (%) 65 (67) 41 (72) 24 (60) 0.22 23 (35) 42 (65) 0.17 
Laboratory  
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Abbreviations: ADL, activities of daily living; BMI, body mass index; CCI, Charlson’s comorbidity index; eGFR, estimated glomerular filtration rate; IADL, 
instrumental activities of daily living; IQR, interquartile range; MCS, mental component summary; MGLS, Morisky Green Levine Scale; MOCA, Montreal cognitive 
assessment; PBM, perceived burden of medication; PCS, physical component summary; PHQ-9, 9-item patient health questionnaire; SD, standard deviation; TABS, 
Tool for Adherence Behaviour Screening. 
Results are presented in mean (SD) unless described otherwise.
Haemoglobin (g/L) 119 (18) 117 (15) 121 (22) 0.30 119 (20) 119 (17) 0.99 
Serum creatinine (μmol/L) 265 (112) 249 (101) 288 (122) 0.03 266 (101) 265 (119) 0.97 
eGFR (mL/min/1.73m2) 21 (7) 22 (6) 21 (7) 0.51 21 (7) 21 (6.5) 0.89 
Medical  
No. of medications, median (IQR) 8 (6-11) 8 (6-11) 8 (6-11) 0.73 8 (5-11) 8 (6-10) 0.73 
MRCI, median (IQR) 19 (14-27) 20 (9-28) 17 (14-27) 0.41 19 (17-27) 19 (14-27) 0.76 
PBM, median (IQR) 1.17 (1-1.33) 1 (1-1.33) 1.33 (1-1.33) 0.01 1 (1-1.33) 1.33 (1-1.33) 0.04 
HRQOL (SF-36) 
PCS  39 (10) 39 (10) 39 (10) 0.65 39 (10) 39 (10) 0.96 
MCS  51 (10) 51 (9) 50 (11) 0.62 51 (10) 51 (10) 0.96 
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Factors associated with medication non-adherence  
Table 4a shows the effect of medication burden and other factors significantly associated with 
medication non-adherence (measured using the MGLS). People who reported non-adherence 
were more likely to report higher perceived medication burden (PBM) (OR 4.89; 95% CI 1.02-
23.5; p=0.02) after adjusting for age, gender, eGFR, comorbidity and IADL. Actual medication 
burden (the number of medications and MRCI) were not associated with non-adherence. People 
with high desire for decision-making were 4.6 times more likely to report non-adherence 
compared with those who prefer to delegate decisions to healthcare professionals (adjusted OR 
4.56 95% CI 1.68-12.35). Participants with diabetes were more likely to self-report being 
adherent (adjusted OR 0.36; 95% CI 0.14-0.89).  
We also examined factors associated with suboptimal medication adherence assessed by the 
TABS (Table 4b). Both actual and perceived medication burden were not related to TABS 
adherence measurement. However, participants with high BMI (≥30 kg/m2) were more likely 
to be non-adherent compared with those with normal BMI after adjusting for age, gender, CCI 
and eGFR (OR 3.81; 95% CI 1.01-14.5).  
Table 4. Correlates of medication non-adherence  
API, Autonomy preference index; Cat., categorical; CIs, confidence intervals; Cont., continuous; MGLS, 
Morisky Green Levine Scale; PBM, Perceived burden of medications; ORs, odds ratios. 




a. Non-adherence (MGLS) Unadjusted ORs (95% CIs) Adjusted ORs (95% CIs)* 
No. of medications 0.97 (0.87-1.08) 0.96 (0.85-1.07) 
MRCI (cont.) 0.83 (0.55-1.26) 0.89 (0.56-1.44) 
PBM (cont.)  4.02 (1.03-16) 4.89 (1.02-23.5) 
Having diabetes  0.37 (0.15-0.91) 0.36 (0.14-0.89) 
Decision making (cont.) 1.11 (1.001-1.23) 1.15 (1.02-1.29) 
Decision-making (cat; score >50) 3.29 (1.41-7.69) 4.56 (1.68-12.35) 
b. Non-adherence (TABS) Unadjusted ORs (95% CIs) Adjusted ORs (95% CIs) 
No. of medications 1.02 (0.91-1.13) 1.04 (0.92-1.18) 
MRCI (cont.) 1.003 (0.96-1.05) 1.01 (0.96-1.06) 
PBM (cont.) 3.67 (0.84-16.1) 2.78 (0.53-14.5) 
BMI (≥30 kg/m2) 2.85 (0.21-2.6) 3.81 (1.01-14.5) 
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Factors associated with perceived and actual medication burden  
Given the strong association between perceived medication burden and medication non-
adherence, we further explored factors associated with PBM (Table 5a). Higher number of 
medications (β 0.02; 95% CI 0.01 to 0.04) and MRCI scores (β 0.10; 95% CI 0.03 to 0.15) 
predicted higher perceived medication burden. Additionally, more frequent dosing intervals 
were also associated with higher perceived burden on adjusted analysis (β 0.02; 95% CI 0.01 
to 0.03). After adjustment for gender, eGFR, CCI and IADL, advanced age was associated with 
lower perceived burden from medications (β -0.01; 95% CI -0.014 to -0.004). An increased 
desire for decision-making (β 0.02; 95% CI 0.01 to 0.03) and a higher desire for information 
(β 0.02; 95% CI 0.01 to 0.04) were also associated with higher perceived burden.  
To examine if factors associated with perceived medication burden were different from those 
affecting actual medication burden (measured via MRCI), we investigated the correlates of 
MRCI (Table 5b). As expected, patients with diabetes had more complex medication regimens 
(β 7.54; 95% CI 3.43 to 11.6). Lower physical (SF36-PCS) (β -0.43; 95% CI -0.62 to -0.26) 
and mental HRQOL (SF36-MCS) (β -0.21; 95% CI -0.43 to -0.01) at baseline were associated 
with higher actual medication burden (MRCI). Participants with lower scores on kidney 
disease-targeted HRQOL measures, such as symptoms, effects and burden of kidney disease, 
and work status, had a higher actual medication burden. Of note, lower scores on these disease-
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Table 5. Correlates of perceived and actual medication burden 
API, autonomy preference index; Cont., continuous; MRCI, medication regimen complexity index; MCS, mental 
component summary; PCS, physical component summary; SF-36, 36-item short form survey. 
Analysis adjusted for age, gender, Charlson’s comorbidity index, activities of daily living (IADL) and cognitive 
functioning (MOCA). 
 
Changes in HRQOL and its association with medication non-adherence (MGLS) 
The mean ± SD follow-up time for participants who completed the second interview was 433 
± 82 days (~14 months), with no difference in follow-up duration observed between adherent 
vs non-adherent groups (436 ± 88 vs 430 ± 77 days; p=0.76) 
The changes in different components of HRQOL, both kidney disease-targeted and generic SF-
36 scales, are presented in the Appendix D attached. Follow-up data were completed by 63 and 
a. Perceived medication burden (PBM) – continuous 
Variables Unadjusted β (95% CIs) Adjusted β (95% CIs) 
No. of medications 0.02 (0.01, 0.04) 0.02 (0.01, 0.04) 
MRCI (cont.) 
            Dosage form  
            Dosing frequency 
            Additional instructions 
0.08 (0.02, 0.14) 
0.023 (-0.001, 0.05) 
0.02 (0.01, 0.03) 
0.01 (-0.01, 0.02) 
0.10 (0.03, 0.15) 
0.024 (-0.001, 0.05) 
0.02 (0.01, 0.03) 
0.01 (-0.01, 0.03) 
Age (cont.) -0.01 (-0.014, -0.004) -0.01 (-0.015, -0.005) 
API Decision-making (cont.) 0.02 (0.01, 0.03) 0.02 (0.01, 0.03) 
API Information-seeking (cont.) 0.02 (0.01, 0.04) 0.02 (0.01, 0.04) 
b. Actual medication burden (MRCI) – continuous 
Variables Unadjusted β (95% CIs) Adjusted β (95% CIs) 
No. of medications 2.44 (2.26, 2.63) 2.49 (2.31, 2.67) 
Having diabetes 7.31 (3.57, 11.1) 7.54 (3.43, 11.6 ) 
Kidney disease-targeted scales    
Symptom -0.26 (-0.38, -0.15) -0.25 (-0.37, -0.17) 
Effects of kidney disease -0.19 (-0.34, -0.06) -0.23 (-0.39, -0.08) 
Burden of kidney disease -0.12 (-0.19, -0.04) -1.64 (-0.25, -0.08) 
Work status -0.09 (-0.15, -0.04) -0.09 (-0.14, -0.03) 
SF-36 generic scales   
MCS  -0.15 (-0.35, 0.04) -0.21 (-0.43, -0.01) 
PCS  -0.43 (-0.61, -0.26) -0.44 (-0.62, -0.26) 
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60 participants for kidney-disease targeted scales and generic SF-36 scales, respectively. Out 
of the disease-targeted components, only the burden of kidney disease has shown a significant 
change at follow-up (mean ± SD score declined from 77 ± 25 to 70 ± 31; p=0.01). Overall, 
there was no association between medication adherence and changes in kidney disease-targeted 
scales over time. 
Of 60 participants with completed generic HRQOL data (SF-36), a decline of any magnitude 
in physical and mental HRQOL was observed in 58% of them at around 14 months of follow-
up. A clinically significant decline in physical HRQOL(change in SF36-PCS≤5) was observed 
in 35% of participants overall, representing 26% of adherent and 45% of non-adherent 
participants (p=0.20). A significant reduction in mental HRQOL was also observed in 35% of 
participants overall, which represented 42% of adherent and 28% of non-adherent individuals 
(p=0.16).  
As illustrated in Figure 6.2., the physical HRQOL was improved over time in adherent 
individuals compared with a decline in their non-adherent counterparts (a median [IQR] change 
in PCS of 1.5 [-5.3 to 7.6] vs -3.4 [-9.1 to 0.9]; p=0.06). Further, medication non-adherence 
has shown a significant negative association with a change in physical HRQOL after adjusting 
for age, gender, and baseline eGFR (β -4.64; 95% CI -9.10 to –0.17). There was no association 
between medication non-adherence and a change in mental HRQOL before or after adjustment 
for the same variables. Table 6  
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Figure 6.2. Changes in physical (SF36-PCS) and mental (SF36-MCS) health-related quality 
of life over 14-months by adherence status (MGLS).  
Table 6. The association between medication non-adherence (MGLS) and changes in physical 
and mental health-related quality of life health over time 
     *analyses adjusted for age, gender and baseline eGFR 
Abbreviations: CIs, confidence intervals; MGLS, Morisky Green Levine Scale; SF36-PCS, short form 











 Unadjusted β (95% CIs) Adjusted β (95% CIs)* 
SF36-PCS   
Non-adherence  -3.99 (-8.29, 0.31) -4.64 (-9.10, -0.17) 
SF36-MCS   
Non-adherence  1.82 (-3.12, 6.78) 2.03 (-2.99, 7.05) 
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Discussion  
This study indicates that a considerable proportion of adults with pre-dialysis CKD are non-
adherent to their medications. The 43% medication non-adherence (MGLS) was lower than 
that reported by an Australian study on dialysis patients that used the same questionnaire, where 
57% of participants were non-adherent.140 This is understandable given the relatively higher 
medical complexity in dialysis patients than at earlier stages of CKD.140,156 Of note, a greater 
proportion of suboptimal adherence (60%) was identified via the TABS questionnaire. This 
could relate to the differences in the constructs of the two questionionnaires.18,143 In addition 
to medication adherence, the TABS, for example, also captures patients’ experiences and 
behaviour concerning disease management.144 This shows that medication non-adherence is 
multidimensional in nature and needs different strategies to detect in patients with pre-dialysis 
CKD.  
Importantly, perceived burden (PBM) of medications, not the actual burden, was associated 
with medication non-adherence. The association between PBM and non-adherence is in 
contrast with a prior Australian study that showed no relationship between these factors.140 A 
study from Italy showed that perceived burden can modulate the relationship between 
medication regimen complexity and adherence in dialysis patients.25 In this study, Neri et al 
found that each pill that was added to a regimen of a patient with low PBM was associated with 
a 5% increase in the odds of non-adherence.25 This was not the case in those with high PBM, 
where regimen complexity was not associated with non-adherence.25 The findings highlight 
the need to evaluate the perceived burden, alongside actual medication burden, to optimise 
adherence. Also, simplifying a medication regimen may not effectively improve adherence 
unless patients’ perceptions are concomitantly addressed.25  
Another interesting result from this study was that people with an increased desire for 
autonomous decision-making were more likely to be non-adherent. This corresponds with a 
finding from a study on patients with asthma that applied the same set of questionnaires.157 The 
relationship between desire for decision-making and non-adherence could relate to intentional 
non-adherence, where patients make a conscious decision to skip medications. This 
phenomenon has been explained by a qualitative review that identified ‘rationalised non-
adherence’ as a mechanism used by patients to avoid treatment disruptions of their daily 
routine.158 A similar finding was reported in dialysis recipients where people tended to 
consciously overlook treatments, which the authors termed ‘active non-adherence.’159 This is 
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particularly common with medications they considered less important or less easy to adhere 
to.159 Therefore, there is a need to foster optimal patient-centred care to actively engage patients 
in conversations that enable them to acknowledge medication-related difficulties in view of 
improving adherence.158 Reiterating the importance of medications in slowing disease 
progression at point of care could also help improve adherence. Finally, obese participants 
(BMI ≥30kg/m2) were more likely to be non-adherent than people with normal BMI based on 
the TABS. The relationship between higher BMI and poor adherence has been reported in older 
men previously.160 This association could be because non-adherence in these individuals might 
also extend to exercise or dietary restrictions.160 
Highly complex regimens and more frequent dosing were associated with higher perceived 
medication burden, while older age was associated with feeling lower burden. The association 
of regimen complexity and more frequent dosing with perceived treatment burden has been 
reported.161,162 These factors are important given their practical relevance and relative ease to 
be targeted by interventions seeking to reduce medication burden.161 For instance, the use of 
long-acting alternatives instead of repeated use of immediate-release medications is one 
strategy that can be used to reduce the dosing frequency. Nevertheless, it is important to 
understand that even less complex regimens could prove burdensome in some patients.162 
Particularly, patients with limited cognitive functionality or with little support could be affected 
in this regard. The association between older age and lower perceived treatment burden is in 
line with prior studies.25,161,162 This may be associated with older people’s adaptation to 
medications after long-term use.161 Older adults may also consider their medications more a 
matter of necessity rather than a burden.161  
Lower HRQOL (kidney disease-targeted and generic scales) were predictive of actual 
medication burden (MRCI). The association between HRQOL measures and regimen 
complexity was independent of Charlson’s comorbidity score, suggesting that regimen 
complexity may capture additional information on the overall disease status of patients.156 This 
may also strengthen our prior hypothesis than regimen complexity could serve as a proxy 
measure of overall health in patients with CKD.163 Also, an inverse relationship between 
medication burden and HRQOL has been previously reported in pre-dialysis patients with 
CKD.141  
Medication non-adherence was not associated with baseline HRQOL; however, it was 
associated with a significant decline in physical, but not mental, HRQOL (SF36-PCS) even 
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over a short follow-up time. This finding was despite the significant decline in mental HRQOL 
during follow-up for all participants. A study from the AusDiab cohort previously reported that 
a physical decline in HRQOL is dependent on baseline eGFR values.132 However, we found 
no statistically significant association between baseline eGFR and changes in HRQOL over 
time.  
This study has some strengths and weaknesses. Examining people with advanced CKD not 
receiving renal replacement therapy adds a new perspective to the literature, as patient-reported 
medication experiences in this patient group are currently lacking. This is also the first study 
to examine the association between medication non-adherence and a change in HRQOL over 
time in patients with CKD. The inclusion of in-depth patient, clinical, medication and social 
factors is another strength of this study. The relatively small number of participants included 
may limit the generalisability of the study; however, recruiting people with relatively poorer 
health and lower functional status is difficult.142 The use of self-report, but not objective 
measures, to assess adherence is another limitation of the study, as non-adherent behaviour is 
often under-reported due to social desirability bias. However, self-reported adherence measures 
have an advantage in terms of ease of implementation in real practice. In addition, the self-
report measures applied in this study capture both intentional and unintentional adherence.  
Conclusion 
This study indicates that medication non-adherence is common in adults with pre-dialysis 
CKD. Perceived medication burden was a predictor of non-adherence, highlighting the need to 
incorporate patient-reported medication experiences in routine CKD care. Further, while 
medication regimen complexity was negatively associated with both physical and mental 
HRQOL at baseline, non-adherence was associated with a decline in physical HRQOL over 
time. This finding suggests the potential role of medication-related factors in modifying 
patient-centred outcomes and the need for further research to better understand this 
relationship.  
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Summary 
The study above shows that medication adherence and burden are important medication-related 
factors that are associated with patient-centred outcomes. In the next chapter the role of 
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7. CHAPTER SEVEN: Effect of pharmacist-led medication review on
medication appropriateness in older adults with chronic kidney disease
Overview 
This chapter presents a study addressing the fifth objective of the thesis. In this work, the 
effect of medication review conducted by pharmacists on medication appropriateness in 
older patients with CKD is explored targeting a tertiary care public hospital in Tasmania. 
This work is a reproduction of the following publication. 
Wubshet H. Tesfaye, MSc1, Barbara C. Wimmer1, Gregory M. Peterson, PhD1, Ronald L. 
Castelino, PhD2, Charlotte McKercher, PhD3, Matthew Jose, MBBS, PhD3,4 and Syed 
Tabish R. Zaidi, BCPS, PhD5 
1Pharmacy, School of Medicine, College of Health and Medicine, University of Tasmania, 
Hobart, Australia 
2Sydney Nursing School, The University of Sydney, Sydney, Australia 
3Menzies Institute for Medical Research, Hobart, Australia 
4Renal Unit, Royal Hobart Hospital, Hobart, Australia 
5School of Healthcare, University of Leeds, Leeds, UK 
J. Pharm. Pract. and Res. 2019; doi: 10.1002/jppr.1539
(https://onlinelibrary.wiley.com/doi/full/10.1002/jppr.1539). 
Chapter 7 has been removed for copyright 
or proprietary reasons.
It has been published as: Tesfaye, W. H., Wimmer, B. C., Peterson, 
G. M., Castelino, R. L., Jose, M., McKercher, C., Zaidi, S. T. R., 
2019. Effect of pharmacist‐led medication review on medication 
appropriateness in older adults with chronic kidney disease, Journal 
of pharmacy practice and research, 49(5), 471-476
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Summary 
This chapter examined the role of routine medication review by clinical pharmacists on 
medication appropriateness in older adults with CKD. The results show that collaborative 
efforts by clinical pharmacists and physicians can lead to a significant improvement of 
medication appropriateness in older adults with CKD. The lack of medication review in more 
than half of the patients included also revealed the need to upscale the role of pharmacists. 
The next chapter presents the general discussion of all studies in this PhD thesis, including 
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8. CHAPTER EIGHT: General discussion and conclusion  
This thesis presents multiple interconnected studies that examine medication-related factors 
and outcomes in patients with CKD, considering prescriber, medication regimen, the healthcare 
environment, and patient factors. A combination of methods, including retrospective and 
prospective cohorts and a systematic review, were applied to address the specific objectives of 
the thesis. As a starting point, a systematic review of the literature was conducted to summarise 
the evidence on inappropriateness of medication use in patients with CKD across different 
healthcare settings. Based on the gaps identified in the review, consecutive studies were 
performed to investigate medication inappropriateness and associated outcomes in patients 
with CKD. Following on from this, the relationship between medication-related factors and 
outcomes, such as hospital readmission and HRQOL, was examined. The effect of the 
healthcare environment and, the care involved, in modifying medication appropriateness was 
assessed focusing on a public hospital setting. The author also expanded on evaluating the role 
of pharmacist-led medication review in improving the quality use of medicines in older 
hospitalised patients with CKD.  
The following vignette, which is based on a patient from the research included in this thesis, 
illustrates how medication-related factors in a patient with CKD could contribute to, and be 
influenced by, hospitalisation.  
A 66-year-old adult with stage 3 CKD (eGFR 42 mL/min/1.73m2) living at home was admitted 
to a tertiary care hospital due to shortness of breath because of pre-existing congestive heart 
failure (left ventricular ejection fraction=35%). Comorbidities at admission included 
congestive heart failure, diabetes mellitus (type 2), ischaemic heart disease, dyslipidaemia and 
hypertension. Findings suggested poorly controlled hypertension (blood pressure=173/99 
mmHg), diabetes (HbA1c=9.6%), and dyslipidaemia (total cholesterol=9.8mmol and 
LDL=7.5mmol) that probably contributed to hospital readmission. On hospital admission, the 
patient was prescribed seven different medications, including oral and parenteral dosage 
forms, and medications with multiple dosing intervals (MRCI=19). The number of medications 
increased to nine at discharge after efforts to manage the patient’s conditions (MRCI=23.5). 
It was during a routine inpatient medication review that a pharmacist was able to detect long-
standing medication non-adherence, and this was verified using community pharmacy records 
(patient did not refill prescriptions from pharmacy for almost three months). Therefore, poor 
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adherence to the prescribed medications prior to admission resulted in suboptimal medication 
use, and likely contributed to hospitalisation.  
The detection of medication non-adherence by a pharmacist shows an opportunistic 
identification of a medication-related problem during hospitalisation. As noted, poor adherence 
to multiple medications, including those for congestive heart failure, was highly likely to have 
caused the hospitalisation in the abovementioned vignette. The findings also indicated long-
standing poor adherence to antihypertensive and antidiabetic medications. The need to 
prescribe additional medications during hospitalisation to manage the patient’s conditions 
resulted in a more complex regimen at discharge than admission, indicating how one 
medication problem can potentially lead to another.  
This thesis was designed with the notion that problems like the one illustrated in the vignette 
are common in patients with CKD and could be identified and prevented or corrected at 
different stages of patient care.  
8.1. Systematic Review  
The systematic review (described in Chapter 2) revealed that inappropriate medication use in 
patients with CKD is common and highly variable across different countries and healthcare 
settings.17 It was observed from the systematic review that a range of renal dosing guidelines 
has been employed to define medication inappropriateness in CKD, which may have 
contributed to the wide variation in the prevalence of inappropriate prescribing. Some of the 
discrepancies among the different renal dosing guidelines have been demonstrated in a 
previous study.164 Another probable cause for the observed differences in inappropriate 
prescribing is the varied use of renal function measures and dosing equations (CG, MDRD or 
CKD-EPI). Regardless of these variations, the results of the review indicated that medication 
inappropriateness is common in patients with CKD and there is a need for cautious use of 
renally-cleared medications in these patients. 
The systematic review also revealed that interventions in the form of pharmacist involvement 
and computerised decision support systems were effective in reducing the prescribing of 
renally-cleared and nephrotoxic medications in patients with CKD. Substantial improvement 
was particularly observed when physicians receive immediate feedback from pharmacists, 
showing the relevance of the input from clinical pharmacists in CKD care. Other reviews that 
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investigated the impact of clinical pharmacy services in the management of CKD also showed 
promising outcomes, although there was a lack of high-quality data in this area.165,166  
The systematic review identified some gaps in the literature that need further research attention. 
One of the main gaps was the limited number of studies that reported clinical outcomes 
attributed to the use of inappropriate medications. Further, most of the studies simply reported 
prevalence of inappropriate medication use, with a small number of studies performing 
regression analyses to identify predictors of medication inappropriateness. Finally, it was 
observed from the systematic review that research including patients with CKD was highly 
focussed on examining the extent of dosage adjustment of renally-cleared medications or 
avoidance of nephrotoxic medications.17 However, patients with CKD, especially those older 
than 65 years, are expected to have a higher risk of medication inappropriateness due to the 
age- and CKD-related functional decline. Therefore, the author hypothesised that older adults 
with CKD would be predisposed to additional inappropriate medications than those that can be 
determined solely based on renal function.  
8.2. Main research findings  
The different studies included in this thesis showed that adults with CKD are prone to high 
level of medication inappropriateness, regimen complexity and  medication non-adherence. 
The results also indicated that medication-related factors in patients with CKD could relate to 
clinical and patient-reported outcomes and be influenced by the healthcare service provided, 
including hospitalisation and pharmacist-led medication review. 
8.2.1. Medication inappropriateness, its predictors and medications involved 
In Chapter 3, medication inappropriateness was assessed in older patients with CKD using 
tools that are applicable in older adults, the MAI and Beers criteria. The findings revealed that 
applying such tools can identify added risks in older patients with CKD. This corroborates the 
hypothesis that these patients have a higher risk of medication inappropriateness.167 Issues 
related to medication dosing and medication-medication and medication-disease interactions 
were particularly frequent in older patients with CKD. This result shows the importance of 
integrating the use of established criteria to holistically capture MRPs in this patient group.  
The research also explored factors associated with medication inappropriateness in older 
patients with CKD. The number of medications and eGFR were identified as the main 
predictors of medication inappropriateness.167 This result is consistent with the findings from 
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the systematic review, where polypharmacy and lower eGFR values were associated with PIMs 
use.17 The use of multiple medications is not only responsible for PIMs, but increases the 
probability of adverse drug reactions occurring,168 emphasising the need to be vigilant in 
patients with many medications. The association between lower eGFR and medication 
inappropriateness is likely in part due to the need for several dosage adjustments at advanced 
stages of CKD. Identifying these factors as predictors of medication inappropriateness is 
important given their accessibility in both community and institutional settings.  
The thesis’ findings revealed that various classes of medications were inappropriately 
prescribed in older patients with CKD (shown in Chapter 3).167 Cardiovascular agents were the 
most commonly, and inappropriately, prescribed medication according to the different criteria 
the author employed.167 The reason for this could relate to the substantial cardiovascular 
disease burden in patients with CKD.114 It is important to note that cardiovascular conditions 
were also the most common comorbidities involved with hospitalisation and hospital 
readmission (Chapter 4 and 5). Therefore, improved identification of inappropriateness of 
cardiovascular medications has potential health ramifications in patients with CKD. Also, 
giving extra attention to patients with CKD and coexisting cardiovascular conditions would be 
beneficial to most adults with CKD. 
PPIs were another class of medications that were often prescribed potentially inappropriately 
with no indication or for a longer duration than recommended.45 These medications are 
associated with a range of possible adverse effects, including increased risk of infection, bone 
fracture, and deficiencies of vitamins and minerals.169 The most important potential adverse 
effects in patients with CKD, however, are renal incidents, including disease progression and 
AKI.170-172 This indicates the need for heightened attention by healthcare professionals to assess 
the appropriateness of indications and duration of therapy with PPIs in patients with CKD. It 
should also be noted that, given the mounting evidence of over-prescribing of PPIs, there are 
now restrictions in place through the PBS to reduce the use of these medications in the 
Australian context (1st May 2019).173  
The inappropriate prescribing of benzodiazepine receptor agonists and psychotropics with 
strong anticholinergic properties in older patients with CKD was another problem identified.167 
Importantly, these medications were prescribed in the context of dementia, cognitive 
impairment, history of falls and delirium, further increasing the risk of adverse effects. This 
finding should be seen in the light of recent evidence in patients with CKD that reported the 
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association between psychotropic drug use and adverse outcomes, such as altered mental status, 
falls and fractures.174 The author also found out that 1 in 10 readmissions within 30 days was 
related to falls and associated fractures (Chapter 5).175 Therefore, ensuring the judicious use of 
these medications is imperative to minimise medication-related harms, including falls and 
unplanned hospital readmission. This could include a thorough assessment of the risks and 
benefits of these medications and consideration of their deprescribing when the individual risks 
outweigh the benefits.176 
8.2.2. Medication-related factors and hospital readmission  
In Chapter 4 and 5, the association between medication-related factors and hospital readmission 
was explored. The findings indicated that patients taking RAS blockers had lowered hospital 
readmission risks within 30 and 90 days, compared with those not on these medications 
(Chapter 4).163 Yet, these medications were prescribed only to half of the patients included in 
our study, as shown in Chapter 4. Understandably, adverse effects to such medications, such 
as hyperkalaemia, AKI, and hypotension, could limit the use of these medications in highly 
sensitive older adults.177 However, the findings suggest that these medications could be 
associated with a lower risk of readmission in these patients. This finding is also supported by 
guidelines, such as the KDIGO and Kidney Health Australia-Caring for Australasians with 
Renal Impairment (KHA-CARI), on using these medications in both diabetic and non-diabetic 
patients with CKD to reduce proteinuria and thus improve outcomes.86,87  
Medication inappropriateness, although relatively higher in people with 30-day and 90-day 
hospital readmissions, was not an independent predictor of hospital readmission in older 
patients with CKD. However, as shown in Chapter 4, people with higher level of medication 
inappropriateness were likely to return to hospital relatively sooner than those with lower 
medication inappropriateness. This shows the potential importance of a thorough medication 
review using standard tools like Beers criteria and components of the MAI to identify patients 
who can benefit from interventions and post-discharge follow-up care.  
The studies presented in this thesis also explored the relationship between medication regimen 
complexity and health outcomes (presented in Chapter 5). Medication regimen complexity was 
quantified using a validated tool that considers not only the medication count but also the 
dosage forms, dosing frequency and additional instructions.18 Higher regimen complexity was 
associated with a shorter time to 12-month readmission after adjusting for covariates, including 
Charlson’s comorbidity index. The association between regimen complexity (MRCI) and 12-
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month time to readmission independent of Charlson’s comorbidity index suggests that MRCI 
may capture burden of disease in patients with CKD over and above that measured by the 
comorbidity measure. Therefore, regimen complexity measured via the MRCI could serve as 
a proxy measure of overall health status in older patients with CKD, particularly in settings 
with limited available clinical information.  
Medication regimen complexity (medication count or MRCI) may also be a source of perceived 
burden of medications. This has been explored in this thesis by examining the relationship 
between medication regimen complexity and self-reported perceived burden of medications, 
targeting pre-dialysis patients with CKD (Chapter 6). The results revealed a positive 
association between the two variables. Higher perceived medication burden, in turn, was 
associated with poor medication adherence in these patients. This highlights the importance of 
assessing patients’ medication-related perceptions and experiences as part of routine 
medication reviews to better target individuals who can benefit from interventions seeking to 
improve adherence.  
8.2.3. The effect of hospitalisation and pharmacist intervention 
This thesis indicated that medication inappropriateness, despite its significant reduction after 
hospitalisation, was still substantial at hospital discharge (Chapter 3).167 Hospitalisation brings 
an opportunity for healthcare professionals to re-evaluate and, thus, identify medications that 
no longer have benefits or identify new risk factors if the patient’s condition has changed. 
However, the substantial medication inappropriateness based on the MAI and Beers criteria at 
hospital discharge indicates that older patients with CKD have an added risk that is potentially 
being missed despite this opportunity brought by hospitalisation. This shows the continual need 
to raise the awareness of clinicians, including pharmacists, about CKD, PIMs use and the 
different criteria available to identify them. Also, evidence-based educational sessions about 
the clinical consequences of PIMs may help reinforce the prescribing of appropriate 
medications in these patients.62  
As a continuation of investigating the effect of hospitalisation, the impact of pharmacist-led 
medication review on medication inappropriateness was investigated in Chapter 7, targeting 
older patients with CKD. Overall, pharmacist-led medication review was conducted in less 
than half of patients targeted in this study, indicating the need to deliver a standardised clinical 
pharmacy service to all inpatients. The findings also revealed pharmacist-led medication 
review led to a significant reduction in medication inappropriateness, albeit this reduction was 
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not significantly better than that observed with hospitalisation alone. However, the trend was 
indicative of greater improvement with pharmacist medication review, especially upon 
implementation of pharmacists’ recommendations by physicians.  
Pharmacists were likely to recognise renal impairment, and thus suggest dosage adjustments 
of renally-cleared medications in older patients with CKD. This is important because one of 
the prescribing considerations in patients with CKD is minimising adverse events due to 
medications that need dosage adjustment in renal impairment. In contrast, assessments of 
medication adherence and medication interactions (with other medications, diseases or 
laboratory) were often overlooked by pharmacists during medication review. Therefore, 
expanding pharmacist’s involvement in these aspects would be valuable to further improve 
quality use of medicines in patients with CKD. The Standard of Practice developed by the 
Society of Hospital Pharmacists Australia for renal pharmacists can be used by pharmacists 
involved in CKD care to provide enhanced and standardised services.178 
8.2.4. Medication burden and patient-centred outcomes 
In Chapter 6, the associations between medication burden and non-adherence, and HRQOL 
were examined targeting adults with pre-dialysis CKD. This study revealed that a significant 
proportion of adults with pre-dialysis kidney disease were non-adherent to their medications. 
Interestingly, it was the perceived burden of medications, not the actual burden, that predicted 
non-adherence behaviour in these participants. This result indicates the need to integrate the 
assessment of medication-related experiences and perceptions as part of routine medication 
review to improve medication adherence in these patients.  
This study also examined the effect of medication regimen complexity and adherence on 
kidney disease-targeted and generic HRQOL measures. These measures capture both physical 
and mental health status, as self-reported by participants. The findings revealed that while 
medication regimen complexity was negatively associated with both physical and mental 
HRQOL at baseline, medication non-adherence was predictive of a decline in physical HRQOL 
over time. These results are important given the modifiable nature of medication-related factors, 
such as regimen complexity and non-adherence.  
Patient-centred outcomes, such as HRQOL, are important outcome measures with implications 
for patients, healthcare providers, and payers.132 This research is one of the few studies that 
examined patient-centred outcomes in pre-dialysis patients with CKD and therefore contributes 
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to an emerging unique evidence base in these patients. Understanding medication-related 
factors affecting patient-centred outcomes is instrumental to inform decisions in CKD 
treatment and strategies. The change in HRQOL, and how this is affected by medication-related 
factors, can offer some insight for earlier care planning in advanced CKD. For example, the 
main target of medication therapy in patients who receive supportive (conservative) CKD care 
instead of RRT is to improve the HRQOL. Therefore, planning feasible regimens and ensuring 
optimal medication adherence would play an invaluable role in symptom management and 
consequently improve HRQOL in these patients. Improving HRQOL has, in turn, broader 
clinical relevance in terms of long-term prognosis, as poorer HRQOL was linked with higher 
risk of hospitalisation and mortality in patients with CKD.179 
8.3. Strengths and limitations of the studies 
In this thesis, the author has attempted to fill the evidence gap regarding medication-related 
outcomes in patients with CKD using prospective and retrospective study designs. However, 
these studies had their own limitations. One of the limitation of the retrospective studies is the 
relatively small sample size employed (Chapter 3, 4, 5 & 7). This may partly explain the lack 
of statistically significant associations between medication-related variables (regimen 
complexity and appropriateness) and readmission within 30 and 90 days of discharge. 
The prospective cohort, as shown in Chapter 6, also consisted of a relatively small number of 
participants. However, this cohort solely included people with advanced CKD on pre-dialysis 
stage who, therefore, had multiple comorbidities. Thus, the relatively small number of 
participants was anticipated based on previous report.142 Nevertheless, the inclusion of a range 
of sociodemographic, psychosocial, medical, clinical and HRQOL information (with a follow-
up data) was the main strength of the study.  
In the medication appropriateness studies (Chapter 3, 4 and 7), the use of MAI, an implicit 
measure that requires clinical judgement, may have introduced some level of subjectivity. 
However, the assessment tool (MAI) is enriched with several explicit referential guides to be 
used during rating that somewhat minimises the subjectivity of evaluation. Another drawback 
with the use of this tool is the time it takes, which makes it less practical to implement in the 
real-world scenario. However, the author also used the Beers criteria (an explicit tool), 
alongside MAI, to identify medications that were potentially inappropriate in these patients, 
which can be considered as the strength of the research. 
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The author has used two different cohorts (retrospective and prospective) to investigate the 
effect of medication regimen complexity on medication non-adherence and hospital 
readmission. These cohorts targeted older hospitalised patients with CKD (retrospective) and 
adults with advanced pre-dialysis CKD living in the community (prospective). Therefore, 
targeting these vulnerable population groups in the studies can be considered as the strength of 
the overall research. However, the findings should be interpreted in the context of adults with 
eGFR <60mL/min/1.73m2 and not on renal replacement therapy. 
People with complex regimens, such as older patients with CKD, may not only be predisposed 
to errors of (prescribing) commission but also of omission. In this thesis the author primarily 
focused on the former. Despite the high number of medications used in these patients, it is 
possible that there may have been under-prescribing of beneficial medications. The author did 
not used structured tools, like START criteria,47 to assess prescription omissions in these 
patients. However, the author examined the association between different classes of 
medications and hospital readmission in older patients with CKD. This analysis revealed that 
users of RAS blockers had improved outcomes compared with their non-user counterparts.163 
The assessment of medication adherence was solely based on self-report by study participants. 
This method has its limitations as adherence is over-estimated when self-reported, largely 
attributed to social desirability bias.22 However, having this limitation in mind, the author 
applied two self-report measures to ascertain the magnitude of medication non-adherence in 
CKD.  
8.4. Research and practice implications, and future directions  
The high level of medication inappropriateness identified using the MAI and Beers criteria 
indicates the importance of using standard criteria to assess medication appropriateness in CKD. 
Healthcare professionals, including pharmacists, should implement the different criteria 
developed for identification of medication inappropriateness. For example, explicit measures 
like the Beers criteria can be used in combination with clinical judgment to identify PIMs in 
clinical practice. The updated Beers criteria now include a list of medications that need to be 
adjusted in CKD and include clinically important medication interactions.45 Also, the author 
found that the having higher number of Beers criteria medications was predictive of a higher 
level of medication inappropriateness measured via MAI.167 Therefore, Beers criteria, 
alongside renal dosage guidelines, can be used to ensure the quality use of medicines in CKD 
patients. The Beers criteria can be a particularly useful tool to provide a more robust medication 
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review as part of Home Medicines Reviews in an Australian community setting. Beers criteria, 
as an explicit measure, are also relatively easy to integrate into clinical decision support 
systems within an electronic medical record in a hospital setting.  
Although not statistically significant, findings in the thesis showed that people who were 
readmitted within 30 and 90 days of hospital discharge had a higher level of medication 
inappropriateness. The lack of statistical significance could be related to the relatively small 
sample size included in the study. Therefore, future work targeting larger samples of older 
patients with CKD should examine the relationship between these medication-related variables 
and hospital readmission.  
The association between the use of RAS blockers and lower readmission risk is another 
important finding that merits further research. Future studies targeting larger populations are 
important to confirm the importance of the use of these, and other renoprotective medications, 
in modifying renal and cardiovascular morbidity in older adults with CKD. Of note, emerging 
evidence has demonstrated that sodium-glucose cotransporter 2 inhibitors could be potential 
(or better) alternatives in improving outcomes in diabetic patients with CKD.180,181 Therefore, 
comparative studies between these medication classes in improving cardiovascular and renal 
outcomes have the potential to redefine clinical practice, particularly in diabetic patients with 
CKD.  
The relationship between perceived medication burden and medication non-adherence is an 
area that needs further investigation. There is a need to assess medication-related perceptions 
and experiences using detailed and more structured questionnaires that capture different 
medication aspects, such as the Living with Medicines Questionnaire,182 in patients with CKD. 
A qualitative investigation of treatment burden in patients with CKD, especially in those with 
multiple comorbidities, would also be important to better understand this problem and propose 
interventions to minimise it.  
The thesis showed the potential of pharmacist-led medication review in improving medication 
appropriateness, especially when the recommendations were acted upon by physicians. The 
vignette shown above also demonstrated the practical relevance of pharmacists’ interventions. 
This finding strengthens the evidence on the positive outcomes, including improved medication 
adherence, associated with pharmacist involvement in CKD patient care.166 However, there is 
a lack of sufficient high-quality randomised trials on pharmacist interventions in patients with 
CKD, especially in those at the pre-ESKD stage.166 Therefore, more research focusing on the 
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effect of pharmacists’ involvement on different clinical, humanistic (for example, HRQOL) 
and economic outcomes is imperative in patients with CKD not receiving RRT.  
Future studies should also investigate whether medication management interventions 
especially tailored according to therapeutic goals of patients with CKD would be more effective 
than a routine medication review in improving the quality use of medicines. Given the 
overwhelming evidence on the effect of pharmacist involvement is related to a hospital setting, 
it is important to investigate the role of pharmacists in community settings. This can be done, 
for example, by assessing the impact of Home Medicines Reviews in improving medication 
appropriateness and associated outcomes. It would also be important to investigate if 
medication review by pharmacists translates to improved clinical outcomes in patients with 
CKD.  
Finally, despite the growing body of information about the involvement of pharmacists in the 
care of patients with CKD, the quality of most of the works remains relatively poor.166 In 
addition to the lack of high-quality studies, the limited randomised controlled trials in patients 
with CKD (mainly in ESKD) also reported inconsistent outcomes regarding pharmacist-led 
interventions.166 Therefore, there is a need for further high-quality randomised trials to evaluate 
the impact of pharmacists in CKD care. Further, well-designed observational studies can also 
shed light into the role of pharmacists in a real-world scenario and thus shape their involvement 
in nephrology practice.
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9. CHAPTER NINE: Conclusions and recommendations 
Collectively, the studies included in this thesis fill an evidence gap in relation to medication-
related factors predicting health outcomes in patients with CKD. Also, it adds to the emerging 
unique body of evidence in relation to patient-centred outcomes in advanced pre-dialysis CKD. 
The findings indicated that potentially inappropriate medications use is common and can be 
better identified using robust criteria developed for use in older people. Improved identification 
of inappropriate medications can be achieved by creating a means to raise the awareness of 
healthcare professionals about the use of standard criteria in identifying problematic 
medication regimens.  
The thesis revealed that the use of RAS blockers could be particularly beneficial to older adults 
with CKD, as shown by lowered risks of readmission within 30 and 90 days of hospital 
discharge. Therefore, it is imperative that clinicians consider the use of these medications in all 
older patients with CKD unless there is a clear contraindication precluding their use.  
Medication regimen complexity is another important parameter with a potential impact on 
health outcomes in patients with CKD. This is shown by the shorter time to readmission of 
people with highly complex medication regimens within one year of hospital discharge. The 
use of medications with multiple frequencies of administration and different dosage forms is 
common in patients with CKD. Therefore, assessment of all these medication attributes, 
alongside medication count, can be important in identifying inappropriately complex regimens. 
This is crucial for targeting patients that can benefit from regimen simplification strategies.  
The other important finding in this thesis is the high prevalence of medication non-adherence 
in advanced pre-dialysis patients with CKD, and how that could relate to a change in physical 
HRQOL over time. This work can be considered as an important starting point to further 
explore the longitudinal relationship between modifiable medication-related factors and 
patient-centred outcomes. Understanding patient-centred outcomes in pre-dialysis CKD is 
particularly important in informing decisions regarding treatment options and to implement 
quality improvement strategies. This finding is, therefore, an important step forward in this 
regard and reinforces the use of patient-reported outcomes as an integral part of CKD patient 
care. 
The importance of the care received during hospitalisation, including medication review by 
pharmacists, in improving medication appropriateness is another key result of this thesis. The 
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opportunistic identification of medication non-adherence during hospitalisation (as shown in 
the vignette above) is illustrative of how the different points in the care continuum can be used 
to reassess medication-related issues in patients with CKD.  
In summary, the author believes that this thesis contributes significantly to the medication-
related outcome research in CKD. Based on the findings of this thesis, the author recommends 
for: 
• Periodic re-evaluation of patients’ medication regimens considering comorbidities and 
overall health condition using standard criteria aiming to improve the quality use of 
medicines, especially when the opportunity arises at different points of contact across 
the care continuum. 
• Assessment of patient-reported medication experiences, in addition to the number of 
medications and regimen complexity, to fully capture barriers to medication adherence 
and propose strategies to improve adherence. 
• Identification of ‘inappropriately’ complex medication regimens considering the 
dosage forms, dosing frequency or additional directions provided by physicians to 
target patients who can benefit from regimen simplification strategies. 
• Consideration of the competing tensions between reducing regimen complexity and the 
use of all beneficial medications. The use of RAS blockers, for example, should be 
routinely considered given their potential benefit in older adults with CKD. 
• Provision of standardised clinical pharmacy service using rigorous techniques by 
applying tools developed for use in older adults. 
• Optimisation of medication regimens to manage kidney disease-related symptoms and 
burden, with the ultimate goal of improving HRQOL. 
• The use of medication regimen complexity in lieu of, or in addition to, comorbidity to 
target high-risk patients in settings with limited clinical information, such as 








1. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 
countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease 
Study 2017. Lancet. 2018;392:1736-1788.10.1016/s0140-6736(18)32203-7 
2. World Health Organization Noncommunicable diseases. https://www.who.int/news-
room/fact-sheets/detail/noncommunicable-diseases; 2018. Accessed 10/02/2019 
3. Hunter DJ, Reddy KS. Noncommunicable diseases. N Engl J Med. 2013;369:1336-1343 
4. National Center for Health S. Health, United States. In: Health, United States, 2013: With 
Special Feature on Prescription Drugs. Hyattsville (MD): National Center for Health 
Statistics (US); 2014. 
5. Harvard School of Public Health The Global Economic Burden of Non-communicable 
Diseases. 
http://www3.weforum.org/docs/WEF_Harvard_HE_GlobalEconomicBurdenNonCommunica
bleDiseases_2011.pdf; 2011. Accessed 31/05/2019 
6. Morgan TK, Williamson M, Pirotta M, Stewart K, Myers SP, Barnes J. A national census of 
medicines use: a 24-hour snapshot of Australians aged 50 years and older. Med J Aust. 
2012;196:50-53 
7. Payne RA, Avery AJ. Polypharmacy: one of the greatest prescribing challenges in general 
practice. In: Br J Gen Pract; 2011. 
8. Watanabe JH, McInnis T, Hirsch JD. Cost of Prescription Drug-Related Morbidity and 
Mortality. Ann Pharmacother. 2018;52:829-837.10.1177/1060028018765159 
9. Salazar JA, Poon I, Nair M. Clinical consequences of polypharmacy in elderly: expect the 
unexpected, think the unthinkable. Expert Opin Drug Saf. 2007;6:695-704 
10. Leendertse AJ, Egberts AC, Stoker LJ, van den Bemt PM. Frequency of and risk factors for 
preventable medication-related hospital admissions in the Netherlands. Arch Intern Med. 
2008;168:1890-1896 
11. Burnier M, Pruijm M, Wuerzner G, Santschi V. Drug adherence in chronic kidney diseases 
and dialysis. Nephrol Dial Transplant. 2015;30:39-44.10.1093/ndt/gfu015 
12. Cardone KE, Bacchus S, Assimon MM, Pai AB, Manley HJ. Medication-related problems in 
CKD. Adv Chronic Kidney Dis. 2010;17:404-412.10.1053/j.ackd.2010.06.004 
13. Whittaker CF, Miklich MA, Patel RS, Fink JC. Medication Safety Principles and Practice in 
CKD. Clin J Am Soc Nephrol. 2018;13:1738-1746.10.2215/cjn.00580118 




15. Matzke GR, Aronoff GR, Atkinson Jr AJ, et al. Drug dosing consideration in patients with 
acute and chronic kidney disease—a clinical update from Kidney Disease: Improving Global 
Outcomes (KDIGO). Kidney int. 2011;80:1122-1137 
16. Long CL, Raebel MA, Price DW, Magid DJ. Compliance with dosing guidelines in patients 
with chronic kidney disease. Ann Pharmacother. 2004;38:853-858.10.1345/aph.1D399 
17. Tesfaye WH, Castelino RL, Wimmer BC, Zaidi STR. Inappropriate prescribing in chronic 
kidney disease: A systematic review of prevalence, associated clinical outcomes and impact 
of interventions. Int J Clin Pract. 2017;71:e12960.10.1111/ijcp.12960 
18. George J, Phun YT, Bailey MJ, Kong DC, Stewart K. Development and validation of the 
medication regimen complexity index.  Ann Pharmacother. 2004;38:1369-
1376.10.1345/aph.1D479 
19. Alves-Conceicao V, Rocha KSS, Silva FVN, Silva ROS, Silva DTD, Lyra-Jr DP. Medication 
Regimen Complexity Measured by MRCI: A Systematic Review to Identify Health 
Outcomes. Ann Pharmacother. 2018;52:1117-1134.10.1177/1060028018773691 
20. Wimmer BC, Cross AJ, Jokanovic N, et al. Clinical Outcomes Associated with Medication 
Regimen Complexity in Older People: A Systematic Review. J Am Geriatr Soc. 2017;65:747-
753.10.1111/jgs.14682 
21. World Health Organisation. Adherence to long-term therapies: Evidence for action. 
http://www.who.int/chp/knowledge/publications/adherence_report/en/; 2003. Accessed 
09/05/2016 
22. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-
497.10.1056/NEJMra050100 
23. Ghimire S, Castelino RL, Lioufas NM, Peterson GM, Zaidi ST. Nonadherence to Medication 
Therapy in Haemodialysis Patients: A Systematic Review. PLoS One. 
2015;10:e0144119.10.1371/journal.pone.0144119 
24. NEJM Catalyst. Engaging patients to optimize medication adherence. 
https://catalyst.nejm.org/about/; 2017. Accessed 11/06/2019 
25. Neri L, Martini A, Andreucci VE, Gallieni M, Rey LA, Brancaccio D. Regimen complexity 
and prescription adherence in dialysis patients. Am J Nephrol. 2011;34:71-
76.10.1159/000328391 
26. Department of Health. The Pharmaceutical Benefits Scheme: Australian Statistics on 
Medicines. http://www.pbs.gov.au/info/statistics/asm/australian-statistics-on-medicines. 
Accessed 23/04/2019 
27. Australian Bureau of Statistics  
REFERENCES 
 126 
National Health Survey: Use of Medications, Australia, 1995  
https://www.abs.gov.au/ausstats/abs@.nsf/PrimaryMainFeatures/4377.0?OpenDocument; 
1995. Accessed 02/06/2019 
28. Australian Department of Health and Ageing. Australian Department of Health and Ageing: 
Evaluation of the DAA/PMP Programs. 
https://www.health.gov.au/internet/main/publishing.nsf/Content/F520A0D5EDEA0172CA25
7BF0001D7B4D/$File/DAA%20PMP%20Report.pdf; 2010. Accessed 22/04/2019 
29. Australian Bureau of Statistics National Health Survey: First Results, 2017-18. 
http://www.abs.gov.au/ausstats/abs@.nsf/mf/4364.0.55.001; 2017-18. Accessed 22/04/2019 
30. Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in Prescription Drug Use 
Among Adults in the United States From 1999-2012. Jama 2015;314:1818-
1831.10.1001/jama.2015.13766 
31. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and 
quality of care for older patients with multiple comorbid diseases: implications for pay for 
performance. Jama. 2005;294:716-724.10.1001/jama.294.6.716 
32. Greene JA, Herzberg D. Hidden in plain sight marketing prescription drugs to consumers in 
the twentieth century. Am J Public Health. 2010;100:793-803.10.2105/ajph.2009.181255 
33. van Mil F. Drug-related problems: a cornerstone for pharmaceutical care. J Malta College 
Pharm Pract. 2005;10:5-8 
34. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care  Am J Hosp 
Pharm. 1990;47:533-543 
35. Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD. Drug-related problems: their 
structure and function. Dicp. 1990;24:1093-1097 
36. van Mil JW, Westerlund LO, Hersberger KE, Schaefer MA. Drug-related problem 
classification systems. Ann Pharmacother. 2004;38:859-867.10.1345/aph.1D182 
37. Lund BC, Carnahan RM, Egge JA, Chrischilles EA, Kaboli PJ. Inappropriate prescribing 
predicts adverse drug events in older adults. Ann Pharmacother. 2010;44:957-
963.10.1345/aph.1M657 
38. Hanlon JT, Schmader KE, Samsa GP, et al. A method for assessing drug therapy 
appropriateness. J Clin Epidemiol. 1992;45:1045-1051 
39. Hanlon JT, Schmader KE. The medication appropriateness index at 20: where it started, 
where it has been, and where it may be going. Drugs Aging. 2013;30:893-
900.10.1007/s40266-013-0118-4 
40. Motter FR, Fritzen JS, Hilmer SN, Paniz EV, Paniz VMV. Potentially inappropriate 




41. Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC. Explicit criteria for 
determining inappropriate medication use in nursing home residents. UCLA Division of 
Geriatric Medicine. Arch Intern Med. 1991;151:1825-1832 
42. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the 
elderly. An update. Arch Intern Med. 1997;157:1531-1536 
43. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication 
use in older adults. J Am Geriatr Soc. 2012;60:616-631.10.1111/j.1532-5415.2012.03923.x 
44. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate 
Medication Use in Older Adults. J Am Geriatr Soc. 2015;63:2227-2246.10.1111/jgs.13702 
45. American Geriatrics Society 2019 Updated AGS Beers Criteria(R) for Potentially 
Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67:674-
694.10.1111/jgs.15767 
46. O'mahony D, O'sullivan D, Byrne S, O'connor MN, Ryan C, Gallagher P. STOPP/START 
criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 
2015;44:213-218 
47. Gallagher P, Ryan C, Byrne S, Kennedy J, O'Mahony D. STOPP (Screening Tool of Older 
Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). 
Consensus validation. Int J Clin Pharmacol Ther. 2008;46:72-83 
48. Holt S, Schmiedl S, Thürmann PA. Potentially inappropriate medications in the elderly: the 
PRISCUS list. Dtsch Arztebl Int. 2010;107:543 
49. Renom-Guiteras A, Meyer G, Thürmann PA. The EU (7)-PIM list: a list of potentially 
inappropriate medications for older people consented by experts from seven European 
countries. Eur J Clin Pharmacol. 2015;71:861-875 
50. Basger BJ, Chen TF, Moles RJ. Validation of prescribing appropriateness criteria for older 
Australians using the RAND/UCLA appropriateness method. BMJ open. 2012;2:e001431 
51. Khodyakov D, Ochoa A, Olivieri‐Mui BL, et al. Screening Tool of Older Person's 
Prescriptions/Screening Tools to Alert Doctors to Right Treatment medication criteria 
modified for US nursing home setting. J Am Geriatr Soc. 2017;65:586-591 
52. Kim DS, Heo SI, Lee SH. Development of a list of potentially inappropriate drugs for the 
korean elderly using the delphi method. Healthc Inform Res. 2010;16:231-252 
53. Laroche M-L, Charmes J-P, Merle L. Potentially inappropriate medications in the elderly: a 
French consensus panel list. Eur J Clin Pharmacol. 2007;63:725-731 
54. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START 




55. Basger BJ, Chen TF, Moles RJ. Application of a prescribing indicators tool to assist in 
identifying drug-related problems in a cohort of older Australians. Int J Pharm Pract. 
2012;20:172-182.10.1111/j.2042-7174.2011.00177.x 
56. Basger BJ, Chen TF, Moles RJ. Inappropriate medication use and prescribing indicators in 
elderly Australians: development of a prescribing indicators tool. Drugs Aging. 2008;25:777-
793.10.2165/00002512-200825090-00004 
57. Morin L, Laroche ML, Texier G, Johnell K. Prevalence of Potentially Inappropriate 
Medication Use in Older Adults Living in Nursing Homes: A Systematic Review. J Am Med 
Dir Assoc. 2016;17:862.e861-869.10.1016/j.jamda.2016.06.011 
58. Gnjidic D, Agogo GO, Ramsey CM, Moga DC, Allore H. The Impact of Dementia Diagnosis 
on Patterns of Potentially Inappropriate Medication Use Among Older Adults. J Gerontol A 
Biol Sci Med Sci. 2018;73:1410-1417.10.1093/gerona/gly078 
59. Stafford AC, Alswayan MS, Tenni PC. Inappropriate prescribing in older residents of 
Australian care homes. J Clin Pharm Ther. 2011;36:33-44.10.1111/j.1365-2710.2009.01151.x 
60. Disalvo D, Luckett T, Luscombe G, et al. Potentially Inappropriate Prescribing in Australian 
Nursing Home Residents with Advanced Dementia: A Substudy of the IDEAL Study. J 
Palliat Med. 2018;21:1472-1479.10.1089/jpm.2018.0070 
61. Onatade R, Auyeung V, Scutt G, Fernando J. Potentially inappropriate prescribing in patients 
on admission and discharge from an older peoples' unit of an acute UK hospital. Drugs Aging. 
2013;30:729-737.10.1007/s40266-013-0097-5 
62. Juliano A, Lucchetti ALG, Silva J, et al. Inappropriate Prescribing in Older Hospitalized 
Adults: A Comparison of Medical Specialties. J Am Geriatr Soc. 2018;66:383-
388.10.1111/jgs.15138 
63. Ni Chroinin D, Neto HM, Xiao D, et al. Potentially inappropriate medications (PIMs) in older 
hospital in-patients: Prevalence, contribution to hospital admission and documentation of 
rationale for continuation. Australas J Ageing. 2016;35:262-265.10.1111/ajag.12312 
64. Gallagher P, Lang PO, Cherubini A, et al. Prevalence of potentially inappropriate prescribing 
in an acutely ill population of older patients admitted to six European hospitals. Eur J Clin 
Pharmacol. 2011;67:1175-1188.10.1007/s00228-011-1061-0 
65. Opondo D, Eslami S, Visscher S, et al. Inappropriateness of medication prescriptions to 
elderly patients in the primary care setting: a systematic review. PLoS One. 
2012;7:e43617.10.1371/journal.pone.0043617 
66. Tommelein E, Mehuys E, Petrovic M, Somers A, Colin P, Boussery K. Potentially 
inappropriate prescribing in community-dwelling older people across Europe: a systematic 
literature review. Eur J Clin Pharmacol. 2015;71:1415-1427.10.1007/s00228-015-1954-4 
67. Martin P, Tamblyn R, Benedetti A, Ahmed S, Tannenbaum C. Effect of a Pharmacist-Led 
Educational Intervention on Inappropriate Medication Prescriptions in Older Adults: The D-
REFERENCES 
 129 
PRESCRIBE Randomized Clinical Trial. Jama. 2018;320:1889-
1898.10.1001/jama.2018.16131 
68. Price SD, Holman CD, Sanfilippo FM, Emery JD. Association between potentially 
inappropriate medications from the Beers criteria and the risk of unplanned hospitalization in 
elderly patients. Ann Pharmacother. 2014;48:6-16.10.1177/1060028013504904 
69. Price SD, Holman CD, Sanfilippo FM, Emery JD. Impact of specific Beers Criteria 
medications on associations between drug exposure and unplanned hospitalisation in elderly 
patients taking high-risk drugs: a case-time-control study in Western Australia. Drugs Aging. 
2014;31:311-325.10.1007/s40266-014-0164-6 
70. Hagstrom K, Nailor M, Lindberg M, Hobbs L, Sobieraj DM. Association between potentially 
inappropriate medication use in elderly adults and hospital-related outcomes. J Am Geriatr 
Soc. 2015;63:185-186.10.1111/jgs.13229 
71. Wallace E, McDowell R, Bennett K, Fahey T, Smith SM. Impact of Potentially Inappropriate 
Prescribing on Adverse Drug Events, Health Related Quality of Life and Emergency Hospital 
Attendance in Older People Attending General Practice: A Prospective Cohort Study. J 
Gerontol A Biol Sci Med Sci. 2017;72:271-277.10.1093/gerona/glw140 
72. Mansur N, Weiss A, Beloosesky Y. Is there an association between inappropriate prescription 
drug use and adherence in discharged elderly patients? Ann Pharmacother. 2009;43:177-
184.10.1345/aph.1L461 
73. Hyttinen V, Jyrkka J, Valtonen H. A Systematic Review of the Impact of Potentially 
Inappropriate Medication on Health Care Utilization and Costs Among Older Adults. Medical 
care. 2016;54:950-964.10.1097/mlr.0000000000000587 
74. Rankin A, Cadogan CA, Patterson SM, et al. Interventions to improve the appropriate use of 
polypharmacy for older people. Cochrane Database Syst Rev. 
2018;9:Cd008165.10.1002/14651858.CD008165.pub4 
75. Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL. Clinical pharmacists and inpatient medical 
care: a systematic review. Arch Intern Med. 2006;166:955-964 
76. Carmichael JM, Alvarez A, Chaput R, DiMaggio J, Magallon H, Mambourg S. Establishment 
and outcomes of a model primary care pharmacy service system. Am J Health Syst Pharm. 
2004;61:472-482 
77. Mossialos E, Courtin E, Naci H, et al. From “retailers” to health care providers: transforming 
the role of community pharmacists in chronic disease management. Health policy. 
2015;119:628-639 
78. Zellmer WA. Collaborative drug therapy management. Am J Health Syst Pharm. 
1995;52:1732.10.1093/ajhp/52.15.1732 
79. Jacobi J. Clinical pharmacists: practitioners who are essential members of your clinical care 
team. Revista Médica Clínica Las Condes. 2016;27:571-577 
REFERENCES 
 130 
80. Mekonnen AB, McLachlan AJ, Brien JA. Pharmacy-led medication reconciliation 
programmes at hospital transitions: a systematic review and meta-analysis. J Clin Pharm 
Ther. 2016;41:128-144.10.1111/jcpt.12364 
81. Mekonnen AB, McLachlan AJ, Jo-anne EB. Effectiveness of pharmacist-led medication 
reconciliation programmes on clinical outcomes at hospital transitions: a systematic review 
and meta-analysis. BMJ open. 2016;6:e010003 
82. Walsh KA, O'Riordan D, Kearney PM, Timmons S, Byrne S. Improving the appropriateness 
of prescribing in older patients: a systematic review and meta-analysis of pharmacists' 
interventions in secondary care. Age Ageing. 2016;45:201-209.10.1093/ageing/afv190 
83. Riordan DO, Walsh KA, Galvin R, Sinnott C, Kearney PM, Byrne S. The effect of 
pharmacist-led interventions in optimising prescribing in older adults in primary care: A 
systematic review. SAGE Open Med. 
2016;4:2050312116652568.10.1177/2050312116652568 
84. Pai AB, Cardone KE, Manley HJ, et al. Medication reconciliation and therapy management in 
dialysis-dependent patients: need for a systematic approach. Clin J Am Soc Nephrol. 
2013;8:1988-1999.10.2215/cjn.01420213 
85. Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical 
practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 
2014;63:713-735.10.1053/j.ajkd.2014.01.416 
86. Kidney health Australia. KHA-CARI Guidelines. 
http://www.cari.org.au/CKD/ckd_guidelines.html; 2019. Accessed 22/05/2019 
87. Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the 
kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 
2013;158:825-830.10.7326/0003-4819-158-11-201306040-00007 
88. Jager KJ, Fraser SDS. The ascending rank of chronic kidney disease in the global burden of 
disease study. Nephrol Dial Transplant. 2017;32:ii121-ii128.10.1093/ndt/gfw330 
89. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and 
perspectives. Lancet. 2013;382:260-272.10.1016/s0140-6736(13)60687-x 
90. Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease–a systematic 
review and meta-analysis. PloS one. 2016;11:e0158765 
91. Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet. 
2017;389:1238-1252.10.1016/s0140-6736(16)32064-5 
92. White SL, Chadban SJ, Jan S, Chapman JR, Cass A. How can we achieve global equity in 
provision of renal replacement therapy? Bull World Health Organ. 2008;86:229-237 
93. Australia and New Zealand Dialysis and Transplan Registry. ANZDATA. 
http://www.anzdata.org.au/v1/interim_summaries.html; 2018. Accessed 26/05/2016 
REFERENCES 
 131 
94. Weiss JW, Boyd CM. Managing Complexity in Older Patients with CKD. Clin J Am Soc 
Nephrol. 2017;12:559-561.10.2215/cjn.02340317 
95. Hoy WE, White AV, Tipiloura B, et al. The influence of birthweight, past poststreptococcal 
glomerulonephritis and current body mass index on levels of albuminuria in young adults: the 
multideterminant model of renal disease in a remote Australian Aboriginal population with 
high rates of renal disease and renal failure. Nephrol Dial Transplant. 2014;31:971-
977.10.1093/ndt/gfu241 
96. National Kidney Foundation. Polycystic Kidney Disease. 
https://www.kidney.org/atoz/content/polycystic; 2019. Accessed 09/05/2019 
97. Kidney Helath Austalia Kidney Fast Facts. http://kidney.org.au/cms_uploads/docs/kidney-
fast-facts-fact-sheet.pdf; 2016. Accessed 26/05/2016 
98. Carrero JJ, Hecking M, Chesnaye NC, Jager KJ. Sex and gender disparities in the 
epidemiology and outcomes of chronic kidney disease. Nat Rev Nephrol. 2018;14:151-
164.10.1038/nrneph.2017.181 
99. Goldstein SL. Nephrotoxicities. F1000Research. 2017;6:55.10.12688/f1000research.10192.1 
100. Davis-Ajami ML, Fink JC, Wu J. Nephrotoxic Medication Exposure in U.S. Adults with 
Predialysis Chronic Kidney Disease: Health Services Utilization and Cost Outcomes. J 
Manag Care Spec Pharm. 2016;22:959-968.10.18553/jmcp.2016.22.8.959 
101. Goldstein SL, Mottes T, Simpson K, et al. A sustained quality improvement program reduces 
nephrotoxic medication-associated acute kidney injury. Kidney Int   2016;90:212-221 
102. Bowe B, Xie Y, Li T, et al. Changes in the US Burden of Chronic Kidney Disease From 2002 
to 2016: An Analysis of the Global Burden of Disease Study. JAMA Netw Open. 
2018;1:e184412.10.1001/jamanetworkopen.2018.4412 
103. Mathew AT, Strippoli GF, Ruospo M, Fishbane S. Reducing hospital readmissions in patients 
with end-stage kidney disease. Kidney Int. 2015;88:1250-1260.10.1038/ki.2015.307 
104. United States Renal Data System. Healthcare Expenditures for Persons with ESRD. 
https://www.usrds.org/2017/view/v2_09.aspx; 2015. Accessed 12/03/2019 
105. Australian Bureau of Statistics Causes of Death, Australia, 2016. 
https://www.abs.gov.au/ausstats/abs@.nsf/Lookup/by%20Subject/3303.0~2016~Main%20Fe
atures~Australia's%20leading%20causes%20of%20death,%202016~3; 2016. Accessed 
23/05/2019 
106. Australian Health Survey: Biomedical Results for Chronic Diseases, 2011-12  
http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/4364.0.55.0052011-
12?OpenDocument; 2013. Accessed 26/05/2016 
107. Australian Institute of Health and Welfare. Australian Institute of Health and Welfare. 
https://www.aihw.gov.au/reports/chronic-kidney-disease/chronic-kidney-disease-
compendium/contents/hospital-care-for-chronic-kidney-disease; 2017. Accessed 18/05/2018 
REFERENCES 
 132 
108. ANZDATA. Incidence of Renal Replacement Therapy for End Stage Kidney Disease. 
http://www.anzdata.org.au/anzdata/AnzdataReport/41streport/c01_incidence_2017_v1.0_201
81121.pdf. Accessed 08/05/2019 
109. Kidney Health Australia. Chronic kidney diease in Australia. 
https://kidney.org.au/cms_uploads/docs/state-of-the-nation-2015-web.pdf; 2015. Accessed 
12/03/2019 
110. Kidney Health Australia. Chronic Kidney Disease Hot Spots. 
https://kidney.org.au/cms_uploads/docs/state-of-the-nation--kidney-health-week-2016--
chronic-kidney-disease-hot-spots.pdf; 2016. Accessed 23/04/2019 
111. Hoy WE, Mott SA, Mc Donald SP. An expanded nationwide view of chronic kidney disease 
in Aboriginal Australians. Nephrology. 2016;21:916-922.10.1111/nep.12798 
112. Wyld ML, Lee CM, Zhuo X, et al. Cost to government and society of chronic kidney disease 
stage 1-5: a national cohort study. Intern Med J. 2015;45:741-747.10.1111/imj.12797 
113. Whaley-Connell AT, Sowers JR, Stevens LA, et al. CKD in the United States: Kidney Early 
Evaluation Program (KEEP) and National Health and Nutrition Examination Survey 
(NHANES) 1999-2004. Am J Kidney Dis. 2008;51:S13-20.10.1053/j.ajkd.2007.12.016 
114. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C-y. Chronic kidney disease and the risks 
of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305 
115. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with 
anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch 
Intern Med. 2002;162:1401-1408 
116. Kraut JA, Madias NE. Metabolic Acidosis of CKD: An Update. Am J Kidney Dis. 
2016;67:307-317.10.1053/j.ajkd.2015.08.028 
117. Doody HK, Peterson GM, Watson D, Castelino RL. Retrospective evaluation of potentially 
inappropriate prescribing in hospitalized patients with renal impairment. Curr Med Res Opin. 
2015;31:525-535 
118. National Kidney Disease Education Program. CKD and Drug Dosing: Information for 
Providers. https://www.niddk.nih.gov/health-information/health-communication-
programs/nkdep/a-z/ckd-drug-dosing/Pages/CKD-drug-dosing.aspx; 2015. Accessed 
20/02/2018 
119. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 
1976;16:31-41 
120. Jones GR. Estimating renal function for drug dosing decisions. Clin Biochem Rev. 
2011;32:81-88 
121. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to 
estimate glomerular filtration rate from serum creatinine: a new prediction equation. 
Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470 
REFERENCES 
 133 
122. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration 
rate. Ann Intern Med. 2009;150:604-612 
123. Khanal A, Peterson GM, Jose MD, Castelino RL. Comparison of equations for dosing of 
medications in renal impairment. Nephrology. 2016.10.1111/nep.12834 
124. Stevens LA, Nolin TD, Richardson MM, et al. Comparison of drug dosing recommendations 
based on measured GFR and kidney function estimating equations. Am J Kidney Dis. 
2009;54:33-42.10.1053/j.ajkd.2009.03.008 
125. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of 
blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-
level meta-analysis. Ann Intern Med. 2003;139:244-252 
126. Ward F, Holian J, Murray PT. Drug therapies to delay the progression of chronic kidney 
disease. Clin Med (Lond). 2015;15:550-557.10.7861/clinmedicine.15-6-550 
127. Maki DD, Ma JZ, Louis TA, Kasiske BL. Long-term effects of antihypertensive agents on 
proteinuria and renal function. Archives of internal medicine. 1995;155:1073-1080 
128. Samaranayaka S, Walker RJ, Samaranayaka A, Derrett S, Schollum JWB. Medication 
Exposure and Health Outcomes in Older Patients with End-Stage Kidney Disease: A 
Prospective Study Undertaken in New Zealand. Drugs Aging. 2018;35:1005-
1015.10.1007/s40266-018-0582-y 
129. Tuttle KR, Alicic RZ, Short RA, et al. Medication Therapy Management after Hospitalization 
in CKD: A Randomized Clinical Trial. Clin J Am Soc Nephrol. 2018;13:231-
241.10.2215/cjn.06790617 
130. Dawson J, Doll H, Fitzpatrick R, Jenkinson C, Carr AJ. The routine use of patient reported 
outcome measures in healthcare settings. Bmj. 2010;340:c186.10.1136/bmj.c186 
131. Ducharlet K, Sundarajan V, Philip J, et al. Patient-Reported outcome measures and their 
utility in the management of patients with advanced chronic kidney disease. Nephrology 
2018.10.1111/nep.13509 
132. Wyld MLR, Morton RL, Clayton P, et al. The impact of progressive chronic kidney disease 
on health-related quality-of-life: a 12-year community cohort study. Qual Life Res. 
2019.10.1007/s11136-019-02173-1 
133. Koria LG, Zaidi TS, Peterson G, Nishtala P, Hannah PJ, Castelino R. Impact of medication 
reviews on inappropriate prescribing in aged care. Curr Med Res Opin. 2018:1-
6.10.1080/03007995.2018.1424624 
134. Karamanidou C, Clatworthy J, Weinman J, Horne R. A systematic review of the prevalence 
and determinants of nonadherence to phosphate binding medication in patients with end-stage 
renal disease. BMC Nephrol. 2008;9:2.10.1186/1471-2369-9-2 
REFERENCES 
 134 
135. Truong VT, Moisan J, Kroger E, Langlois S, Gregoire JP. Persistence and compliance with 
newly initiated antihypertensive drug treatment in patients with chronic kidney disease. 
Patient Prefer Adherence. 2016;10:1121-1129.10.2147/ppa.s108757 
136. Hsu KL, Fink JC, Ginsberg JS, et al. Self-reported Medication Adherence and Adverse 
Patient Safety Events in CKD. Am J Kidney Dis. 2015;66:621-
629.10.1053/j.ajkd.2015.03.026 
137. Muntner P, Judd SE, Krousel-Wood M, McClellan WM, Safford MM. Low medication 
adherence and hypertension control among adults with CKD: data from the REGARDS 
(Reasons for Geographic and Racial Differences in Stroke) Study. Am J Kidney Dis. 
2010;56:447-457.10.1053/j.ajkd.2010.02.348 
138. Schmitt KE, Edie CF, Laflam P, Simbartl LA, Thakar CV. Adherence to antihypertensive 
agents and blood pressure control in chronic kidney disease. Am J Nephrol. 2010;32:541-
548.10.1159/000321688 
139. Molnar MZ, Gosmanova EO, Sumida K, et al. Predialysis Cardiovascular Disease Medication 
Adherence and Mortality After Transition to Dialysis. Am J Kidney Dis. 
2016.10.1053/j.ajkd.2016.02.051 
140. Ghimire S, Peterson GM, Castelino RL, Jose MD, Zaidi ST. Medication Regimen Complexity 
and Adherence in Haemodialysis Patients: An Exploratory Study. Am J Nephrol. 
2016;43:318-324.10.1159/000446450 
141. Wee HL, Seng BJ, Lee JJ, et al. Association of anemia and mineral and bone disorder with 
health-related quality of life in Asian pre-dialysis patients. Health Qual Life Outcomes. 
2016;14:94.10.1186/s12955-016-0477-8 
142. McKercher CM, Venn AJ, Blizzard L, et al. Psychosocial factors in adults with chronic 
kidney disease: characteristics of pilot participants in the Tasmanian Chronic Kidney Disease 
study. BMC Nephrol. 2013;14:83.10.1186/1471-2369-14-83 
143. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported 
measure of medication adherence. Med Care. 1986;24:67-74 
144. George J, Mackinnon A, Kong DC, Stewart K. Development and validation of the Beliefs and 
Behaviour Questionnaire (BBQ). Patient Educ Couns. 2006;64:50-
60.10.1016/j.pec.2005.11.010 
145. Stewart K, Mc Namara KP, George J. Challenges in measuring medication adherence: 
experiences from a controlled trial. Int J Clin Pharm. 2014;36:15-19.10.1007/s11096-013-
9877-6 
146. Australian Bureau of Statistics. Socio-Economic Indexes for Areas. 
http://www.abs.gov.au/websitedbs/censushome.nsf/home/seifa; 2011. Accessed 04/01/2019 
147. Liu J, Huang Z, Gilbertson DT, Foley RN, Collins AJ. An improved comorbidity index for 
outcome analyses among dialysis patients. Kidney Int. 2010;77:141-151.10.1038/ki.2009.413 
REFERENCES 
 135 
148. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The 
index of ADL: A standardised measure of biological and pyschosocial function. Jama. 
1963;185:914-919 
149. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental 
activities of daily living. Gerontologist. 1969;9:179-186 
150. McClellan WM, Anson C, Birkeli K, Tuttle E. Functional status and quality of life: predictors 
of early mortality among patients entering treatment for end stage renal disease. J Clin 
Epidemiol. 1991;44:83-89 
151. Hill SA, Laugharne R. Decision making and information seeking preferences among 
psychiatric patients. Journal of Mental Health. 2006;15:75-84.10.1080/09638230500512250 
152. Ende J, Kazis L, Moskowitz MA. Preferences for autonomy when patients are physicians. J 
Gen Intern Med. 1990;5:506-509 
153. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a 
brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695-
699.10.1111/j.1532-5415.2005.53221.x 
154. Watnick S, Wang PL, Demadura T, Ganzini L. Validation of 2 depression screening tools in 
dialysis patients. Am J Kidney Dis. 2005;46:919-924.10.1053/j.ajkd.2005.08.006 
155. Ware JE, Jr., Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A. Comparison 
of methods for the scoring and statistical analysis of SF-36 health profile and summary 
measures: summary of results from the Medical Outcomes Study. Med Care. 1995;33:As264-
279 
156. Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R. Pill burden, 
adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am 
Soc Nephrol. 2009;4:1089-1096.10.2215/cjn.00290109 
157. Schneider A, Wensing M, Quinzler R, Bieber C, Szecsenyi J. Higher preference for 
participation in treatment decisions is associated with lower medication adherence in asthma 
patients. Patient Educ Couns. 2007;67:57-62.10.1016/j.pec.2007.01.019 
158. Demain S, Goncalves AC, Areia C, et al. Living with, managing and minimising treatment 
burden in long term conditions: a systematic review of qualitative research. PLoS One. 
2015;10:e0125457.10.1371/journal.pone.0125457 
159. Karamanidou C, Weinman J, Horne R. A qualitative study of treatment burden among 
haemodialysis recipients. J Health Psychol. 2014;19:556-569.10.1177/1359105313475898 
160. Holt E, Joyce C, Dornelles A, et al. Sex differences in barriers to antihypertensive medication 
adherence: findings from the cohort study of medication adherence among older adults. J Am 
Geriatr Soc. 2013;61:558-564.10.1111/jgs.12171 
REFERENCES 
 136 
161. Krska J, Katusiime B, Corlett SA. Patient experiences of the burden of using medicines for 
long-term conditions and factors affecting burden: A cross-sectional survey. Health Soc Care 
Community. 2018;26:946-959.10.1111/hsc.12624 
162. Tran VT, Montori VM, Eton DT, Baruch D, Falissard B, Ravaud P. Development and 
description of measurement properties of an instrument to assess treatment burden among 
patients with multiple chronic conditions. BMC Med. 2012;10:68.10.1186/1741-7015-10-68 
163. Tesfaye WH, Peterson GM, Castelino RL, et al. Medication-Related Factors and Hospital 
Readmission in Older Adults with Chronic Kidney Disease. J Clin Med. 
2019;8.10.3390/jcm8030395 
164. Khanal A, Castelino RL, Peterson GM, Jose MD. Dose adjustment guidelines for medications 
in patients with renal impairment: how consistent are drug information sources? Intern Med J. 
2014;44:77-85.10.1111/imj.12291 
165. Salgado TM, Moles R, Benrimoj SI, Fernandez-Llimos F. Pharmacists' interventions in the 
management of patients with chronic kidney disease: a systematic review. Nephrol Dial 
Transplant. 2012;27:276-292.10.1093/ndt/gfr287 
166. Al Raiisi F, Stewart D, Fernandez-Llimos F, Salgado TM, Mohamed MF, Cunningham S. 
Clinical pharmacy practice in the care of Chronic Kidney Disease patients: a systematic 
review. Int J Clin Pharm. 2019;41:630-666.10.1007/s11096-019-00816-4 
167. Tesfaye WH, Wimmer BC, Peterson GM, et al. The effect of hospitalization on potentially 
inappropriate medication use in older adults with chronic kidney disease. Curr Med Res Opin. 
2018:1-18.10.1080/03007995.2018.1560193 
168. Onder G, Petrovic M, Tangiisuran B, et al. Development and validation of a score to assess 
risk of adverse drug reactions among in-hospital patients 65 years or older: the GerontoNet 
ADR risk score. Arch Intern Med. 2010;170:1142-1148.10.1001/archinternmed.2010.153 
169. Naunton M, Peterson GM, Deeks LS, Young H, Kosari S. We have had a gutful: The need for 
deprescribing proton pump inhibitors. J Clin Pharm Ther. 2018;43:65-72.10.1111/jcpt.12613 
170. Hart E, Dunn TE, Feuerstein S, Jacobs DM. Proton Pump Inhibitors and Risk of Acute and 
Chronic Kidney Disease: A Retrospective Cohort Study. Pharmacotherapy. 2019;39:443-
453.10.1002/phar.2235 
171. Lazarus B, Chen Y, Wilson FP, et al. Proton Pump Inhibitor Use and the Risk of Chronic 
Kidney Disease. JAMA Intern Med. 2016;176:238-246.10.1001/jamainternmed.2015.7193 
172. Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton Pump Inhibitors and 
Risk of Incident CKD and Progression to ESRD. J Am Soc Nephrol. 2016;27:3153-
3163.10.1681/asn.2015121377 
173. The Pharmaceutical Benefits Scheme .Changes to Proton Pump Inhibitor restriction level. 
http://www.pbs.gov.au/info/news/2019/05/changes-to-proton-pump-inhibitor-restriction-
level; 2019. Accessed 04/05/2019 
REFERENCES 
 137 
174. Ishida JH, McCulloch CE, Steinman MA, Grimes BA, Johansen KL. Psychoactive 
Medications and Adverse Outcomes among Older Adults Receiving Hemodialysis. J Am 
Geriatr Soc. 2019.10.1111/jgs.15740 
175. Tesfaye WH, Peterson GM, Castelino RL, et al. Medication Regimen Complexity and 
Hospital Readmission in Older Adults With Chronic Kidney Disease. Ann Pharmacother. 
2018:1060028018793419.10.1177/1060028018793419 
176. Whittaker CF, Fink JC. Deprescribing in CKD: the proof is in the process. Am J Kidney Dis. 
2017;70:596-598 
177. Turgut F, Balogun RA, Abdel-Rahman EM. Renin-angiotensin-aldosterone system blockade 
effects on the kidney in the elderly: benefits and limitations. Clin J Am Soc Nephrol. 
2010;5:1330-1339.10.2215/cjn.08611209 




179. Mapes DL, Lopes AA, Satayathum S, et al. Health-related quality of life as a predictor of 
mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS). 
Kidney international. 2003;64:339-349.10.1046/j.1523-1755.2003.00072.x 
180. Heerspink HJ, Desai M, Jardine M, Balis D, Meininger G, Perkovic V. Canagliflozin Slows 
Progression of Renal Function Decline Independently of Glycemic Effects. J Am Soc 
Nephrol. 2017;28:368-375.10.1681/asn.2016030278 
181. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes 
and Nephropathy. N Engl J Med. 2019.10.1056/NEJMoa1811744 
182. Katusiime B, Corlett SA, Krska J. Development and validation of a revised instrument to 
measure burden of long-term medicines use: the Living with Medicines Questionnaire version 













Appendix A. Electronic search strategy for systematic review (Chapter Two) 
 
Pubmed/Medline: (((dose) OR dose adjustment)) AND ((renal* impair*) OR renal* insuffic*) 
MESH terms: Renal insufficiency, chronic kidney disease, renal impairment  
Embase: 'dose'/exp OR dose AND ('kidney'/exp OR kidney) AND ('disease'/exp OR disease) 
AND practice AND guideline AND ('human'/de OR 'practice guideline'/de) AND ('cohort 
analysis'/de OR 'controlled clinical trial'/de OR 'drug dose comparison'/de OR 'meta-
analysis'/de OR 'outcomes research'/de OR 'prospective study'/de OR 'retrospective study'/de 
OR 'systematic review'/de) 
Emtree terms: Drug dose, Kidney failure 
CINAHL: Renal* impair* OR renal* insuffic* AND Dose OR Dose adjustment  
Cochrane Library: Renal impairment/ Renal insufficiency AND Dose OR Dose adjustment  
 
PsychINFO:  Renal insufficiency OR Renal impairment AND Dose OR Dose adjustment  
 
Web of Science:  Renal impairment AND Dose adjustment 
  
OVID: Dose OR dose adjustment AND kidney disease OR renal impairment OR renal 
insufficiency 
 
International Pharmaceutical Abstracts (IPA): (all(Dose) OR all (dose adjustment)) AND (all 
(renal impairment) OR all (kidney disease) OR all (renal insufficiency)) AND (all(pharmacist) 




Appendix B. Quality and risk of bias assessment used in the systematic review (Chapter Two) 
Appendix B1. An adapted appraisal checklist according to Joanna Briggs Institute (JBI) meta-analysis of statistics assessment and review instrument  
 
Experimental Studies (e.g. randomised/quasi-randomised, pre-post studies) 
















5. Are those assessing the outcomes blind to the allocation of intervention?  Y  
 N 
 U  
 NA 


















 NA  
10. Is appropriate statistical analysis used? 
Note: To score a “Y,” the studies must compare the control Vs intervention groups (e.g., 2-sample t test, Fischer test), 
and a multivariable regression must have been applied to rule out confounders. 




Cohort (with control)/Case-controlled studies 
1. Is the sample representative of patients in the population? 
Note: Answer ‘’Y’’ if the finding can be extrapolated to patients with similar stages and types of renal impairment  












4. Are confounding factors identified and strategies to deal with them stated? 
Note: To score a “Y,” confounding factors for inappropriate prescribing must have been identified and controlled 
using multivariate analysis (e.g., logistic regression). 























9. Is appropriate statistical analysis used? 
Note: To score a “Y,” multivariate analyses (e.g., logistic regression) must have been applied. 
 Y  
 N 
 U 
 NA  
Descriptive/Case series studies 
1. Is the study representative of patients with RI prescribed with medications affected by the renal system?  
 
Note: To score a “Y,” the sampling should be random or pseudo-random, patients were representative, or the demographics of 
those included and excluded reported, and were comparable. 








3. Were the confounding factors identified and strategies to rule them out stated?  
 
Note: To score a “Y,” confounding factors for inappropriate prescribing must have been identified and controlled using 
multivariate analysis (e.g., logistic regression).  





























9. Was appropriate statistical analysis used?  
Note: To score a “Y,” multivariate analyses (e.g., logistic regression) must have been applied.  
 Y  
 N 
 U 





















Appendix B2. Quality assessment of the studies included in the systematic review based on the adapted version of Joanna Briggs Institute  
Experimental Studies (e.g. randomised/quasi-randomised, pre-post studies) 
 1  2 3  4 5 6  7 8  9  10 Total Quality Score 
(Out of 10) 
Awdishu et al, 2015 Y Y Y Y Y Y Y Y Y Y 10 
Bhardwaja et al, 2009 Y Y Y N Y Y Y Y N N 7 
Erler et al, 2012 Y Y N Y N Y Y Y Y N 7 
Field et al., 2009 Y Y Y N N Y Y Y Y N 6 
Terrel et al, 2010 Y Y Y N Y Y Y Y Y N 8 
Cohort (with control)/Case-controlled studies 
 1  2   3 4 5 6 7  8  9  Total Quality Score 
(Out of 9) 
Baum et al, 2010 Y Y Y N Y Y N Y N 6 
Bertsche et al., 2009 Y Y NA N Y NA N Y Y 5 
Cabello-Muriel et al, 
2014 
Y Y Y N Y NA NA Y N 5 
Chertow et al, 2001 Y Y N Y Y NA NA Y Y 6 
Falconnier et al, 2001 Y Y Y N Y Y N Y N 6 
Hassen et al, 2009 Y Y Y N Y NA NA Y N 5 
Holm et al, 2015 Y Y NA N Y NA NA Y Y 5 
Nash et al, 2005 Y Y NA U Y NA NA Y Y 5 
Pourrat et al, 2015 Y Y NA N Y NA NA Y Y 5 
Quartarlo et al, 2007 Y Y Y N Y NA NA Y Y 6 
Sellier et al, 2009 Y Y Y Y Y NA NA Y Y 7 
Such Diaz et al., 2013 Y Y NA N Y NA NA Y Y 5 
Via-Sosa et al 2013 Y Y Y Y Y NA NA Y N 6 




















Total Quality Score 
(Out of 9) 
Alahdal et al, 2011 Y Y N Y NA NA NA U N 3 
Bilge et al, 2013 Y Y N Y NA NA NA Y N 4 
Blix et al, 2006 Y Y N Y Y NA NA Y N 5 




Cantu et al, 1992 Y Y Y Y NA NA NA U Y 5 
Chang et al, 2015 Y Y Y Y Y NA NA Y Y 7 
Decloedt et al, 2010 N Y N Y NA NA NA Y N 3 
Doody et al, 2015 Y Y Y Y NA NA NA Y Y 6 
Drenth-van et al, 2015 Y Y Y Y NA NA NA Y N 5 
Durand et al, 2013 N Y N Y NA NA NA Y N 3 
Fahimi et al, 2012 N Y N Y NA NA NA Y N 3 
Farag et al, 2014 Y Y Y Y NA NA NA Y Y 6 
Getachew et al, 2015 N Y Y Y NA NA NA Y Y 5 
Gheewala et al, 2014 Y Y N Y NA NA NA Y N 4 
Jones et al, 2013 Y Y N Y NA NA NA Y N 4 
Joosten et al, 2013 Y Y N Y NA NA NA Y N 4 
Khanal et al, 2015 Y Y Y Y NA NA NA Y Y 6 
Markota et al, 2009 N Y N Y Y NA NA Y N 4 
Nielsen et al, 2014 N Y Y Y Y NA NA Y N 5 
PapaioanNu et al, 2000 Y Y Y Y NA NA NA Y Y 6 
Pillans et al, 2003 N Y N Y NA NA NA Y N 3 
Prajapati et al, 2013 Y Y N Y NA NA NA Y N 4 
Roberts et al, 2010 Y Y N  Y Y Y NA Y N 6 
Sah et al, 2014 N Y N Y NA NA NA Y N 3 
Salomon et al, 2003 Y Y N Y NA NA NA Y N 4 
Sheen et al, 2008 Y Y N Y NA NA NA Y Y 5 
Sweileh et al, 2007 Y Y Y Y NA NA NA U Y 5 
Van et al, 2006 Y Y Y Y Y NA NA Y N 6 
Van et al, 2006 (letter) Y Y Y Y Y NA NA Y N 6 










Appendix C. Additional patient (laboratory and clinical) information by readmission status (supplementary to results in Chapter Four) 
 
        Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
  30-day readmission  90-day readmission 
Characteristics Total (n=204) Yes (n=50) No (n=154) P Yes (n=81) No (n=123) P 
Hemoglobin (g/L), median (IQR) 118 (106-134) 117 (103-133) 118 (108-134) 0.54 118 (105-131) 119 (106-135) 0.68 
Serum albumin (g/L), median (IQR) 32 (29-36) 32 (29-37) 32 (29-36) 0.66 33 (29-37) 32 (29-37) 0.34 
Elevated Ca (>2.55 mmol/L), n (%) 24 (11.2) 5 (10) 44 (28) 0.01 6 (7.4) 18 (14.6) 0.12 
Elevated PO4 (>1.50 mmol/L), n (%) 15 (18.5) 4 (8) 11 (7) 0.84 8 (10) 7 (5.7) 0.26 
Sodium (mmol/L), median (IQR) 142 (137-144) 140 (136-142) 139 (137-142) 0.42 142 (140-142) 139 (137-142) 0.92 
Potassium (mmol/L), median (IQR) 5.2 (4.6-5.6) 4.7 (4.2-5.2) 4.6 (4.2-5.2) 0.95 4.6 (4.2-5.1) 4.6 (4.2-5.2) 0.59 
ALT (IU/L), median (IQR) 16.5 (11-26) 19.5 (12-30) 16 (11-26) 0.11 16 (12-26) 17 (11-27) 0.56 
ALP (IU/L), median (IQR) 88.5 (72-114) 92.5 (67-125) 88 (73-111) 0.44 89 (68-117) 88 (74-113) 0.82 
AST (IU/L), median (IQR) 23 (16-52) 23 (16-35) 23 (15-32) 0.47 22 (16-30) 23 (16-33) 0.60 
Common comorbidities, n (%) 
Hypertension, 145 (71) 30 (60) 115 (75) 0.05 55 (68) 90 (73) 0.42 
Diabetes 70 (34) 22 (44) 48 (31) 0.10 30 (37) 40 (32.5) 0.51 
Atrial fibrillation 66 (32) 16 (32) 50 (32) 0.95 25 (31) 41 (33) 0.71 
Heart failure 49 (24) 11 (22) 38 (25) 0.70 20 (25) 29 (24) 0.85 
Length of hospitalisation, median (IQR) 4 (2-8) 4 (2-8) 4 (3-8) 0.85 4 (2-8) 4 (3-8) 0.89 




























Appendix D. Changes in different kidney-disease targeted and generic (SF-36) health-
related quality of life over time (supplementary to results in Chapter Six) 
Abbreviations: SF-36, 36-item short form survey; MCS, mental component summary; PCS, physical  
component summary 
*Paired t-test 












HRQOL scales All 
participants 
(n=101) 
Participants with follow-up 
data 
 
Kidney disease-related scales (n=63)  Baseline  Follow-up  p-value* 
     
Burden of kidney disease 75 (24) 77 (25) 70 (31) 0.01 
Symptoms 79 (16) 78 (16) 77 (15) 0.59 
Cognitive function   81 (16) 81 (15) 79 (16) 0.45 
Effect of kidney disease 88 (13) 88 (14) 86 (17) 0.19 
Sleep  64 (19) 62 (20) 62 (22) 0.80 
Social interaction 82 (15) 82 (15) 82 (15) 0.89 
Social support  83 (25) 87 (22) 82 (27) 0.18 
Work status  43 (34) 42 (33) 41 (35) 0.64 
Overall health status 63 (18) 62 (19) 59 (19) 0.08 
SF-36 scales (n=60) 
Physical function 56 (26) 56 (26) 55 (30) 0.78 
Physical role limitations  47 (42) 49 (39) 36 (38) 0.01 
Pain  60 (28)  64 (27) 60 (28) 0.13 
General health  49 (29) 46 (20) 44 (21) 0.29 
Emotional well-being 79 (22) 77 (18) 76 (19) 0.57 
Emotional role limitations 70 (40) 77 (36) 65 (38) 0.02 
Social function  77 (30) 77 (26) 68 (29) 0.004 
Vitality  55 (27) 48 (23) 45 (24) 0.22 
SF36-PCS  38 (10) 38 (11) 37 (11) 0.22 




Appendix E. Morisky-Green-Levine Medication Adherence Scale (Morisky et al., 
1986) 
It has indicated that you are taking medication for your health problems. Individuals have 
identified several issues regarding their medication-taking behaviour and we are interested in 
yours. There is no right and wrong answer. Please place a cross (X) in ONE box that best 
applies to you.  Please answer the following questions based on your personal experience. 
 Yes No 
1. Do you ever forget to take your medication?     
2. Are you careless at times about taking your medication?   
3. When you feel better, do you sometimes stop taking your 
medication? 
  
4. Sometimes, if you feel worse when you take your 






























Appendix F. Tool for Adherence Behaviour Screening (TABS) (George et al., 2006) 
Many people find a way of using medicines that suits them.  Here are some ways in which 
people have said they use their medicines.  For each statement, please place a cross (X) in ONE 

























1. I get confused about my medication 
     
2. I have strict routines for using my regular medication 
     
3. I keep my medications close to where I need to use them 
     
4. I ensure I have enough medication so that I don’t run out 
     
5. I strive to follow the instructions of my doctors 
     
6. I make changes in the recommended management to suit my 
lifestyle      
7. I vary my recommended management based on how I am 
feeling      
8. I put up with my medical problems before taking any action 
     

















Appendix G. Perceived Burden of Medication (Neri et al., 2011) 
This scale assesses to what extent you feel bothered by the medications you have to take, with 
“1” indicating, “Not at all bothered” and “5,” “Extremely bothered.” Please place a cross (X) 
in ONE box that best applies to you.   
 1 2 3 4 5 
1. Do you feel bothered by the number of 
medication(s) prescribed? 
     
2. Do you feel bothered by the size of the pill(s)? 
     
3. Do you feel bothered by the adverse effects of 
medication? 
     
4. Do you feel bothered by the number of times 
therapy should be administered during the day? 
     
5. Do you feel bothered by the need to take 
medicine(s) at work or in social contexts? 
     
6. Do you feel bothered by the need to drink in order 
to take medication(s)? 
     
1 = Not at all bothered; 2 = somewhat bothered; 3 = moderately bothered; 4 = Very bothered; 





















Appendix I. Medication Appropriateness Index (Hanlon et al., 1992) 
 
Patient ID# __________   Evaluator 
_______________________Date_____________________ 
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